

Regd. Office: 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax: 0731-2723017 Tel.: 0731-2723016, 4066216 E-mail: biofilchemicals@yahoo.com / bcplcompliance@gmail.com Factory: Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office: B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)

Tel.: 0731-2426700, 2426718, 2524003, Fax: 0731-2426726 • CIN: L24233MP1985PLC002709

Date: 3^{rd} September, 2019

To, The Secretary, Corporate Compliance Department, BSE Limited, Dalal Street, P.J. Tower, Mumbai

To, The Secretary, Corporate Compliance Department, The National Stock Exchange of India Limited, Bandra Kurla Complex, Mumbai

Sub: Submission of Annual Report 2018-19 as per Regulation 34 of SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015

Ref- Biofil Chemicals and Pharmaceuticals Limited (BSE Scrip Code: 524396; NSE Scrip Id: BIOFILCHEM; ISIN No. INE829A01014)

Dear Sir/Madam,

In compliance with the requirements of Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit copy of Annual Report for the year 2018-19 containing Notice of AGM, Board's Report, Audit Report and Financial Statements and other required attachments.

You are requested to please take on record the above Annual Report for your reference

Thanking you,

Yours Faithfully

For Biofil Chemicals Pharmaceuticals Limited

INDORE

Company Secretary Compliance Officer

ACS: 43203

34th Annual Report 2018 - 2019




BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED





CIN: L24233MP1985PLC002709





CIN: L24233MP1985PLC002709

34thAnnual Report 2018 - 2019 CORPORATE INFORMATION

Board of Directors:

Shri Ramesh Shah - Managing Director
Shri Romil Shah - Non Executive Director
Smt. Shaila Jain - Independent Director
Shri Subhash Chandra Swarnkar - Independent Director

Chief Financial Officer:

Shri Jitendra Kumar Sahu

Company Secretary & Compliance Officer:

Ms. Shikha Khilwani

Statuory Auditors:

M/s Maheshwari & Gupta

Chartered Accountants 312-314, Manas Bhawan Extn., 11/2, RNT Marg, Indore - 452001 (M.P.)

Secretarial Auditors:

M/s L.N. Joshi & Co.

Company Secretaries

306, Sterling Arcade 15/3, Race Course Road, Indore (M.P.)

, ,

Bankers:

State Bank of India,

Industrial Estate Branch, Indore.

· IDBI Bank Ltd.,

Ratlam Kothi Branch, Indore.

Listed at Stock Exchanges :

National Stock Exchange of India Ltd.

Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai

Bombay Stock Exchange, Mumbai

Phiroze Jeejeebhoy Tower, Dalal Street, Fort, Mumbai - 400 001

Registered Office:

BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

11/12, Sector "E", Sanwer Road, Industrial Area,

Indore - 452015 (M.P.)

Email: bcplcompliance@gmail.com Website: www.biofilgroup.net Phone: 0731-2723016, 2723017

Plant Location:

- Plot No. 8, Sector-4, Kheda Industrial Estate, Pithampur Dist. Dhar (M.P.)
- 11/12, Sector 'E', Sanwer Road Industrial Area, Indore - 452015 (M.P.)

Registrar & Share Transfer Agent :

Ankit Consultancy Private Limited

Plot No. 60, Electronic Complex, Pardeshipura,

Indore-452010 (M.P.) • Phone: 0731-2551745, 2551746 • Fax: 0731-4065798

• Email ID: ankit_4321@yahoo.com • Website : www.ankitonline.com

34th ANNUAL GENERAL MEETING

Day : Thursday

Date: 26th Day of September, 2019

Time: 3:00 P.M.
Venue: 11/12, Sector 'E',
Sanwer Road Industrial Area,
Indore - 452015 (M.P.)

Contents	Page
Corporate Information	3
Notice of Meeting	4
Route Map	10
Report of Board of Directors	11
Annexure's to the Report of Board of Directors	18
Management Discussion and Analysis Report	31
Corporate Governance Report	33
Independent Auditor Report	49
Balance Sheet	55
Statement of Profit & Loss account	56
Cash Flow Statement	58
Notes to the Financial Statements	59
Proxy Form	81
Attendance Slip	83



CIN: L24233MP1985PLC002709

NOTICE OF 34th ANNUAL GENERAL MEETING

NOTICE is hereby given that 34th Annual General Meeting of the members of **BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED** will be held on Thursday, 26th September, 2019 at 3.00 P.M. at the Registered office of the company situated at 11/12, Sector 'E' Sanwer Road, Industrial Area, Indore-452015 (M.P.), to transact the following businesses:-

ORDINARY BUSINESS:

- 1. To receive, consider, approve and adopt the Audited Financial Statements of the Company for the financial year ended 31st March, 2019, together with the Reports of the Board of Directors and Auditors thereon.
- 2. To appoint a Director in place of Shri Romil Shah (DIN: 00326110), who retires by rotation and being eligible offers himself for re-appointment.

SPECIAL BUSINESS:

3. RE-APPOINTMENT OF SHRI SUBHASH CHANDRA SWARNKAR (DIN: 01658151), AS AN INDEPENDENT DIRECTOR OF THE COMPANY.

To consider and if thought fit, to pass with or without modification(s), the following resolution as a Special Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 149 and 152 read with Schedule IV and other applicable provisions, if any, of the Companies Act, 2013 and the Companies (Appointment and Qualification of Directors) Rules, 2014 and the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), Shri Subhash Chandra Swarnkar (DIN: 01658151), who was appointed as an Independent Director of the Company at the 30th Annual General Meeting of the Company and who holds office of the Independent Director up to 12th August, 2020 and who is eligible for being re-appointed as an Independent Director and in respect of whom the Company has received a Notice in writing from a Member under Section 160 of the Companies Act, 2013 proposing his candidature for the office of Director, be re-appointed as an Independent Director of the Company, not liable to retire by rotation, to hold office for a second term of five consecutive years commencing from 13th August, 2020 to 12th August, 2025."

Place: Indore Date: 13/08/2019 By Order of the Board of Directors
For Biofil Chemicals and Pharmaceuticals Ltd.
Sd/-

Biofil Chemicals and Pharmaceuticals Ltd.

CIN: L24233MP1985PLC002709

Reg Off: 11/12, Sector "E", Sanwer Road Industrial Area,

Indore - 452015 (M.P.)

Shikha Khilwani

(Company Secretary) Membership No.: A43203

Notes:-

- A MEMBER ENTITLED TO ATTEND AND VOTE AT A MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE ON A POLL, INSTEAD OF HIMSELF/HERSELF AND THE PROXY NEED NOT BE A MEMBER OF THE COMPANY. A PERSON CAN ACT AS PROXY ON BEHALF OF MEMBERS UPTO AND NOT EXCEEDING FIFTY AND HOLDING IN THE AGGREGATE NOT MORE THAN TEN PERCENT OF THE TOTAL SHARE CAPITAL OF THE COMPANY. FURTHER, A MEMBER HOLDING MORE THAN TEN PERCENT OF THE TOTAL SHARE CAPITAL OF THE COMPANY CARRYING VOTING RIGHTS MAY APPOINT A SINGLE PERSON AS PROXY AND SUCH PERSON SHALL NOT ACT AS PROXY FOR ANY OTHER PERSON OR MEMBER. THE INSTRUMENT APPOINTING PROXY MUST BE DEPOSITED AT THE REGISTERED OFFICE OF THE COMPANY NOT LESS THAN 48 HOURS BEFORE THE COMMENCMENT OF ANNUAL GENERAL MEETING.
- During the period beginning 24 hours before the time fixed for the commencement of the meeting and ending with the conclusion of the meeting, members would be entitled to inspect the proxies lodged, at any time during the business hours of the Company, provided not less than 3 day's written notice is given to the Company.
- Only bonafide members of the Company whose names appear on the Register of Members/Proxy holders, in possession of valid attendance slips duly filled and signed will be permitted to attend the meeting. The Company reserves its right to take all steps as may be deemed necessary to restrict non-members from attending the meeting.
- In order to enable us to register your attendance at the venue of the Annual General meeting, we request you to please bring your folio number/demat account number/DP ID-Client ID to enable us to give a attendance slip for your signature and participation at the meeting.
- The requirement to place the matter relating to appointment of Auditors for ratification by members at every Annual General Meeting is omitted vide notification dated May 7, 2018 issued by the Ministry of Corporate Affairs, New Delhi. Accordingly, no resolution is proposed for ratification of appointment of Auditors, who were appointed in the 32nd



CIN: L24233MP1985PLC002709

Annual General Meeting, held on 25th September, 2017.

- The explanatory statement pursuant to Section 102 of the Companies Act, 2013 is annexed hereto.
- Pursuant to Provisions of Section 91 of the Companies Act, 2013, the Register of Members and Share Transfer Book of the Company will remain closed during the period from Friday, 20th Day of September, 2019 to Thursday 26th Day of September, 2019 (both days inclusive) for the purpose of 34th Annual General Meeting.
- As per Regulation 40 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended from time to time, securities of listed companies can be transferred only in dematerialized form with effect from April 1, 2019, except in case of request received for transmission or transposition of securities. In view of this and to eliminate all risks associated with physical shares and for ease of portfolio management, members holding shares in physical form are requested to consider converting their holdings to dematerialized form. Members can contact the Company or Company's Registrars and Transfer Agents, Ankit Consultancy Private Limited for assistance in this regard.
- As directed by SEBI, the Members holding shares in physical form are requested to submit particulars of their bank account along with the original cancelled cheque bearing the name of the Member to R & STA / Company to update their Bank Account details. Members holding shares in demat form are requested to update their Bank Account details with their respective Depository Participant. The Company or R & STA cannot act on any request received directly from the Members holding shares in demat form for any change of bank particulars. Such changes are to be intimated only to the Depository Participants of the Members. Further, instructions, if any, already given by them in respect of shares held in physical form will not be automatically applicable to shares held in the electronic mode.
- Additional information pursuant to Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements)
 Regulations, 2015 and Secretarial Standard of General Meeting in respect of the Directors seeking appointment/reappointment at the ensuing AGM are provided in Annexure-1 of this Notice.
- Sections 101 and 136 of the Companies Act, 2013 read together with the rules made there under, permits the listed companies to send the notice of annual general meeting and the Annual Report, including financial statements, Board's Report, etc. by electronic mode. The Company is accordingly forwarding electronic copy of the Annual Report for 2019 to all the Members whose e-mail ids are registered with the Company/Depository Participants(s) for communication purposes unless any Member has requested for a hard copy of the same. For the Members who have not registered their e-mail address, physical copies of the Annual Report for 2019 is being sent in the permitted mode. Members who have not yet register their e-mail id are requested to register the same with the Company (if shares are held in physical form) or Depository participant (if shares are held in demat mode). Members are also requested to intimate to the Company the changes, if any in their e-mail address.
- All the Documents referred to in the accompanying notice and the explanatory statement will be kept open for inspection by the members at the registered office of the Company on all working days (Monday to Friday) from 11.00 a.m. to 1.00 p.m. except holidays, up to the date of the ensuing Annual General Meeting. The aforesaid documents will be also available for inspection by members at the Meeting.
- Pursuant to Section 72 of the Companies Act, 2013, members holding shares in physical form may file nomination in the
 prescribed Form SH-13 with the Company's share transfer agent. In respect of shares held in electronic form, the
 nomination form may be filed with the respective depository participant.
- In case of joint holders attending the Meeting, only such joint holder who is higher in the order of names will be entitled
 to vote.
- The Members are requested to:
 - a) Intimate changes, if any, in their registered addresses immediately.
 - b) Quote their ledger folio/DPID number in all their correspondence.
 - c) Hand over the enclosed attendance slip, duly signed in accordance with their specimen registered with the Company for admission to the meeting place.
 - d) Bring their Annual Report and Attendance Slips with them at the AGM venue.
 - e) Send their Email address to us for prompt communication and update the same with their Depository Participants to receive softcopy of the Annual Report of the Company.
- Corporate Members are requested to forward a Certified True Copy of Board Resolution alongwith the specimen signature(s), authorizing their representatives to attend and vote on their behalf at the Annual General Meeting.
- Route map for the venue of Annual General Meeting along with prominent landmark is enclosed with this Notice.
- A member desirous of getting any information on the accounts or operations of the Company is requested to forward his/ her query to the Company at least seven working days prior to the meeting, so that the required information can be made available at the meeting.
- Members who are holding shares in identical order of names in more than one folio are requested to send to the company or Company's Registrar and Share Transfer Agent the details of such folios together with the share certificates for consolidating their holding in one folio. The share certificates will be returned to the members after making requisite changes, thereon. The members requested to use New Share Transfer Form SH-4 for this purpose.



CIN: L24233MP1985PLC002709


- The Notice of AGM along with complete Annual report shall be dispatched to the shareholders who are registered as member as on 23rd August, 2019. Further Members may also note that Notice of this Annual General Meeting and the Annual Report for financial year 2018-19 will also be available on the Company's website i.e. www.biofilgroup.net.
- Members are requested to contact the Registrar and Share Transfer Agent for all matter connected with Company's shares at Ankit Consultancy Private Limited, Plot No. 60, Electronic Complex, Pardeshipura, Indore-452010 (M.P.)
- The Company has designated an exclusive email ID: bcplcompliance@gmail.com which would enable the members to post their grievances and monitor its redressal. Any member having any grievance may post the same to the said Email address for its quick redressal.
- The voting rights of Shareholders shall be in proportion of shares held by them to the total paid up equity shares of the Company as on Thursday, 19th September, 2019, being the cut-off date.
- The businesses as set out in the Notice may be transacted through Electronic Voting system and the Company shall provide a facility for voting by electronic means. In compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended by MCA vide its notification dated March 19, 2015 and Regulation 44 of The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company is pleased to offer the facility of "remote e-voting" (e-voting from a place other than venue of the AGM) as an alternate, to all its members to enable them to cast their votes electronically instead of casting their vote at the meeting. If a member has opted for remote e-voting, then he/she should not vote by physical ballot also and vice-versa. However, in case members cast their vote both via physical ballot and remote e-voting, then voting through electronic mode shall prevail and voting done by physical ballot shall be treated as invalid. The Members who have cast their vote by remote e-voting prior to the AGM may also attend the AGM but shall not be entitled to cast their vote again. For E-voting facility, the Company has entered in to an agreement with the CDSL for facilitating remote E-voting. The Procedure and instructions for E-voting given below:

Instructions for shareholders voting through electronic means:

- (i) The e-voting period begins on Monday, 23rd September, 2019 from 9.00 A.M. and ends on Wednesday, 25th September, 2019 at 5.00 p.m. During this period shareholders' of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date (record date) of Thursday 19th September, 2019, may cast their vote electronically in proportion to their shares in the paid up equity share capital of the company. The e-voting module shall be disabled by CDSL for voting thereafter.
- (ii) The shareholders should log on to the e-voting website www.evotingindia.com during the voting period.
- (iii) Click on "Shareholders" tab.
- (iv) Now Enter your User ID
 - a. For CDSL: 16 digits beneficiary ID,
 - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
 - c. Members holding shares in Physical Form should enter Folio Number registered with the Company.
- (v) Next enter the Image Verification as displayed and Click on Login.
- (vi) If you are holding shares in demat form and had logged on to **www.evotingindia.com** and voted on an earlier voting of any company, then your existing password is to be used.
- (vii) If you are a first time user follow the steps given below:

	For Members holding shares in Demat Form and Physical Form									
PAN (Permanent Account Number)	Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) • Members who have not updated their PAN with the Company/Depository Participant are requested to use the first two letters of their name and the 8 digits of the sequence number in the PAN field. • In case the sequence number is less than 8 digits enter the applicable number of 0's before the number after the first two characters of the name in CAPITAL letters. eg. If your name is Ramesh Kumar with sequence number 1 then enter RA00000001 in the PAN field.									
Dividend Bank Details OR Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. • If both the details are not recorded with the depository or company please enter the member id / folio number in the Dividend Bank details field as mentioned in instruction (iv).									

- (viii) After entering these details appropriately, click on "SUBMIT" tab.
- (ix) Members holding shares in physical form will then directly reach the Company selection screen. However, members holding shares in demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.



BIOFIL Health for All

CIN: L24233MP1985PLC002709

- (x) For Members holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- (xi) Click on the EVSN for the relevant <BIOFIL CHEMICALS AND PHARMACEUTICALS LTD> on which you choose to vote.
- (xii) On the voting page, you will see "RESOLUTION DESCRIPTION" and against the same the option "YES/NO" for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- (xiii) Click on the "RESOLUTIONS FILE LINK" if you wish to view the entire Resolution details.
- (xiv) After selecting the resolution you have decided to vote on, click on "SUBMIT". A confirmation box will be displayed. If you wish to confirm your vote, click on "OK", else to change your vote, click on "CANCEL" and accordingly modify your vote.
- (xv) Once you "CONFIRM" your vote on the resolution, you will not be allowed to modify your vote.
- (xvi) You can also take out print of the voting done by you by clicking on "Click here to print" option on the Voting page.
- (xvii) If Demat account holder has forgotten the same password then enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- (xviii) Shareholders can also cast their vote using CDSL's mobile app m- Voting available for android based mobiles. The m-Voting app can be downloaded from Google Play Store. Apple and Windows phone users can download the app from the App Store and the Windows Phone Store respectively. Please follow the instructions as prompted by the mobile app while voting on your mobile.

(xix) Note for Non - Individual Shareholders and Custodians

- Non Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to https://www.evotingindia.com and register themselves as Corporates.
- A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
- After receiving the login details a compliance user should be created using the admin login and password. The Compliance user would be able to link the account(s) for which they wish to vote on.
- The list of accounts linked in the log in should be mailed to **helpdesk.evoting@cdslindia.com** and on approval of the accounts they would be able to cast their vote.
- A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favor of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
- (xx) In case you have any queries or issues regarding e-voting, you may refer the Frequently Asked Questions ("FAQs") and e-voting manual available at www.evotingindia.com under help section or write an email to helpdesk.evoting@cdslindia.com.
- (xxi) Mr. L.N. Joshi, Practicing Company Secretary (Membership No. FCS 5201) has been appointed as the scrutinizer to receive and scrutinize the completed ballot forms and votes casted electronically by the members in a fair and transparent manner.
- (xxii) The Scrutinizer shall after scrutinizing the vote cast at the AGM (Poll) and through Remote E-Voting not later than 48 hours from conclusion of AGM, make and submit a consolidated scrutinizers report to the Chairman. The Results declared along with the consolidated scrutinizers report shall be placed on the website of the company and CDSL. The results shall simultaneously be communicated to the Stock Exchanges where the company's shares are listed.
- (xxiii) The Resolutions shall be deemed to be passed on the date of the Meeting, i.e. Thursday, 26th September, 2019 subject to receipt of the requisite number of votes in favor of the Resolutions.

Place: Indore

Date: 13th August, 2019

By Order of the Board of Directors
For Biofil Chemicals and Pharmaceuticals Ltd.
Sd/-

Shikha Khilwani Company Secretary

Membership No.: A43203

Biofil Chemicals and Pharmaceuticals Ltd.

CIN: L24233MP1985PLC002709

Reg Off: 11/12, Sector "E", Sanwer Road Industrial Area,

Indore - 452015 (M.P.)





CIN: L24233MP1985PLC002709

EXPLANATORY STATEMENT UNDER SECTION 102 OF THE COMPANIES ACT, 2013 ITEM NO. 3:- RE-APPOINTMENT OF SHRI SUBHASH CHANDRA SWARNKAR (DIN: 01658151) AS AN INDEPENDENT DIRECTORS OF THE COMPANY.

In the 30th Annual General Meeting held on 24th September 2015, Shri Subhash Chandra Swarnkar (Din: 01658151) was appointed as an Independent Director of the Company for a term of five years.

The Board, based on the performance evaluation and as per the recommendation of the Nomination and Remuneration Committee, considers that, given his background and experience and contribution made by him during his tenure, the continued association of aforesaid Independent Director would be beneficial to the Company and it is desirable to continue to avail his services as an Independent Director. Accordingly, he is proposed to be re-appointed as Independent Director of the Company, not liable to retire by rotation, for second term of 5 (five) consecutive years on the Board of the Company.

The Proposed appointee is not disqualified from being appointed as a Director in terms of Section 164 of the Act and has given his consent to act as a Director. The Company has also received declaration from appointee that he meet the criteria of independence as prescribed both under Section 149(6) of the Act and under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Further Shri Subhash Chandra Swarnkar shall be attaining the age of 75 years during this second term and as per regulation 17(1A) of SEBI(Listing Obligations and Disclosure Requirements) Regulations 2015. Special Resolution is required to be pass by Shareholders for such appointment.

In the opinion of the Board, proposed appointee fulfils the condition for appointment as an Independent Director as specified in the Act and the Listing Regulations. He is independent of the management. Copy of draft letter of appointment of proposed appointees setting out the terms and conditions of appointment is available for inspection by the members at the registered office of the Company.

The Company has received notices in writing from a Member under section 160 of the Act, proposing the candidature of Shri Subhash Chandra Swarnkar for the office of Director of the Company.

This statement may also be regarded as an appropriate disclosure under the Act and the Listing Regulations.

The Board recommends the Special Resolution set out at Item No. 3 of the Notice for approval by the members.

Save and except the above, none of the other Directors / Key Managerial Personnel of the Company / their relatives is, in any way, concerned or interested, financially or otherwise, in this resolution.

The brief profile of the director's who are proposed to be appointed as independent director are given in the notice convening the Annual General Meeting in separate annexure.

Place : Indore

Date: 13th August, 2019

Biofil Chemicals and Pharmaceuticals Ltd.

CIN: L24233MP1985PLC002709

Reg Off: 11/12, Sector "E", Sanwer Road Industrial Area,

Indore - 452015 (M.P.)

By Order of the Board of Directors
For Biofil Chemicals and Pharmaceuticals Ltd.
Sd/-

Shikha Khilwani Company Secretary Membership No.: A43203



CIN: L24233MP1985PLC002709

Annexure-1


Additional Information of Directors seeking re-appointment/appointment at the ensuing Annual General Meeting pursuant to Regulation 36(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 and pursuant to secretarial standard of General Meeting:

Name of Directors	Shri Romil Shah (DIN: 00326110)	Shri Subhash Chandra Swarnkar (DIN: 01658151)		
Date of Birth	07/04/1985	01/07/1948		
Date of Appointment	30/07/2005	13/08/2015		
Expertise / Experience in specific functional areas	12 Year experience in the field of field of technical and administration	More than 34 years experience in the field of Pharmaceuticals & Chemicals		
Qualification	B.E., M.B.A	B.Sc. (Pharma)		
No. & % of Equity Shares held in the Company	382550 (2.35%)	Nil		
List of outside Company's directorship held	Sedate Mercantile Pvt. Ltd. Formo Plast Pvt.Ltd. MID (India) Pharmaceuticals Pvt Ltd	MPPMO Analytical and Research Centre Private Limited		
Chairman / Member of the Committee of the Board of Directors of the Company	Member of Stakeholders Relationship Committee, Audit Committee and Nomination & Remuneration Committee	Member of Audit Committees, Stakeholders Relationship Committee and Nomination & Remuneration Committee		
Salary or Sitting fees paid	Nil	Nil		
Chairman/Member of the Committees of the Board of Directors of other Companies in which he/she is director	Nil	Nil		
Relationship between directors	Shri Romil Shah is Brother's Son of Shri Ramesh Shah	No relationship with any other directors		





CIN: L24233MP1985PLC002709







CIN: L24233MP1985PLC002709

BOARD'S REPORT

Dear Shareholders

Your Directors present their Report together with the audited financial statements of your company for the year ended March 31, 2019.

1. STATE OF AFFAIRS, FINANCIAL PERFORMANCE AND FUTURE OUTLOOK:

1.1 FINANCIAL HIGHLIGHTS AND SUMMARY

The performance highlights and summarized financial results of the Company are given below:

(Rupees in Lakhs except EPS)

PARTICULARS	Year ended 31st March 2019	Year ended 31st March 2018
Total Income	2322.98	1246.07
Total Expenditure	2263.15	1187.25
Profit/(Loss) before Exceptional & Extraordinary Items & Tax	59.83	58.81
Exceptional Items	0.00	0.00
Extraordinary Items	0.00	0.00
Profit/(Loss) before tax	59.83	58.81
Provision for Tax		
Current Tax	11.51	11.30
Deferred Tax	0.00	0.00
Earlier year Tax	0.09	0.44
Profit/Loss after tax	48.23	47.07
Other comprehensive Income (Net of Tax)	0.00	0.00
Total Comprehensive Income	48.23	47.07
Paid up Equity Share Capital	1627.38	1627.38
Earning per share (Rs.10/- each) Basic & Diluted (in Rs.)	0.30	0.29

1.2 OPERATIONAL AND STATE OF COMPANY'S AFFAIR AND OUTLOOK:

During the financial year, your company has achieved total turnover of Rs.2322.98 Lacs in comparison to previous year's turnover of Rs.1246.07 Lacs and earned net profit of Rs. 48.23 lacs in comparison to previous year's net profit of Rs. 47.07 lacs.

The Company is major producer and trader of Ferrous Sulphate and Calcium (Salt) which are the main supplements of Ferrous Sulphate and Folic acid Tablets (IP) and needed by every expectant mother and during lactation period and calcium & Vit D3 Tablets which helps in strengthening the bones.

Looking into the future prospects, your company shall continue to grow its business with leading pharmaceutical Central Public Sector Enterprises, Bengal Chemicals and Pharmaceuticals Limited for providing C&F facility and HLL Lifecare Limited for providing job work facility.

1.3 CHANGE IN NATURE OF BUSINESS

During the year there was no change in business activity of the company.

1.4 SHARE CAPITAL

The Paid-Up Equity Share Capital as at 31st March 2019 stood at Rs. 16,27,38,000/-. During the year under review, the company has not issued shares with differential voting rights nor has granted any stock option or sweat equity shares. As on 31st March 2019, none of the Directors of the company hold instruments convertible into equity shares of the Company.

2. EXTRACT OF ANNUAL RETURN

The details forming part of the extract of the Annual Return in form MGT-9, as required under Section 92 of the Companies Act, 2013 is annexed as **Annexure - A** and forms an integral part of this Report and is also available on the website of the Company i.e. www.biofilgroup.net.



CIN: L24233MP1985PLC002709

3. NUMBER OF MEETINGS OF THE BOARD, ITS COMMITTEES & AGM

The details of the number of meetings of the Board and its committee held during the Financial Year 2018-19 forms part of the Corporate Governance Report. Further, Annual General Meeting of the Company for financial year 2017-18 was held on 27th September, 2018.

4. DIVIDEND

To conserve resources and plough back profits, your Directors have not recommended any dividend for the year under review

5. AMOUNTS TRANSFERRED TO RESERVES

During the financial year no amount has been transferred to any reserve.

6. DEPOSITS

The Company has not accepted any deposits, within the meaning of Section 73 of the Companies Act, 2013, read with the Companies (Acceptance of Deposits) Rules, 2014.

DISCLOSURE OF UNSECURED LOAN RECEIVED FROM DIRECTORS.

Pursuant to Section 2(31) of Companies Act, 2013 Read with Rule 2(1)(viii) of Companies (Acceptance of Deposits) Rules, 2014, (including any statutory modification or re-enactment thereof for the time being in force), the Company has not received any unsecured loan from directors during the financial year.

7. DETAILS OF SUBSIDIARY, JOINT VENTURE OR ASSOCIATES COMPANIES

During the financial year ended on 31st March 2019, the Company did not have any subsidiary, joint venture or associate company.

8. DETAILS OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

In accordance with the provisions of Section 152 of the Companies Act, 2013 and the Company's Articles of Association, Shri Romil Shah (DIN: 00326110), Non Executive Director, retires by rotation at the forthcoming Annual General Meeting and, being eligible offers himself for re-appointment. The Board recommends his re-appointment for the consideration of the Members of the Company at the ensuing Annual General Meeting.

Further term of office of Shri Subhash Chandra Swarnkar (DIN: 01658151) as an Independent Director, will expire on August, 12, 2020. The Board of Directors, on recommendation of the Nomination and Remuneration Committee has proposed re-appointment of Shri Subhash Chandra Swarnkar (DIN: 01658151) as an Independent Director of the Company for a second term of 5 (Five) consecutive years on the expiry of his current term of office, for the consideration of the Members of the Company at the ensuing Annual General Meeting. The Company has received the requisite Notice from a Member in writing proposing his appointment as Independent Director.

During the financial year under review, there was no change in the Board of Directors & KMPs of the Company. The following have been designated as the Key Managerial Personnel of the Company pursuant to Sections 2(51) and 203 of the Companies Act, 2013 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014:

- 1. Shri Ramesh Shah, Managing Director
- 2. Ms. Shikha Khilwani, Company Secretary and Compliance Officer
- 3. Shri Jitendra Kumar Sahu, Chief Financial Officer

DISQUALIFICATIONS OF DIRECTORS

During the year declarations were received from the Directors of the Company pursuant to Section 164 of the Companies Act, 2013. Board appraised the same and found that none of the director is disqualified for holding office as director.

9. DECLARATION BY INDEPENDENT DIRECTOR

The Company has received declarations from all the Independent Directors of the Company as required under Section 149(7) of the Companies Act, 2013 confirming that they fulfil the criteria of independence as prescribed under subsection (6) of Section 149 of the Companies Act, 2013 and Regulation 16(1)(b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 ('the Listing Regulations').

10. DIRECTORS RESPONSIBILITY STATEMENT

Pursuant to Section 134(5) of the Companies Act, 2013, the Board of Directors, to the best of their knowledge and ability, confirm that:

- i. in the preparation of the annual accounts, the applicable accounting standards have been followed and there are no material departures in adoption of these standards;
- ii. the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit of the Company for that year;
- iii. the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- iv. the Directors have prepared the annual accounts on a going concern basis;





CIN: L24233MP1985PLC002709

v. the Directors have laid down internal financial controls to be followed by the Company and such internal financial controls are adequate and operating effectively:

vi. the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

11. FAMILIARIZATION OF INDEPENDENT DIRECTORS

The details of familiarization programme for Independent Directors have been disclosed on website of the Company at web link: http://www.biofilgroup.net/Appointment%20letter%20Independent%20Director/Familiarization%20programme%20to%20Independent%20Directors.pdf

12. MEETING OF INDEPENDENT DIRECTORS

The Independent Directors met once during the year as on 30th March, 2019. The Meeting was conducted in an informal manner without the presence of the Chairman, the Whole Time Director, the Non-Executive Non-Independent Directors and the Chief Financial Officer.

13. COMMITTEES OF THE BOARD OF DIRECTORS

The Company has various committees which have been constituted as a part of the good corporate governance practices and the same are in compliance with the requirements of the relevant provisions of applicable laws and statutes. Your Company has an adequately qualified and experienced Audit Committee with Smt. Shaila Jain (Chairperson), Shri Romil Shah and Shri Subhash Chandra Swarnkar, as Members. The recommendations of the Audit Committee were duly approved and accepted by the Board during the year under review.

The other Committees of the Board are:

- (i) Nomination and Remuneration Committee
- (ii) Stakeholders Relationship Committee

The details with respect to the composition, powers, roles, terms of reference, Meetings held and attendance of the Directors at such Meetings of the relevant Committees are given in detail in the Report on Corporate Governance of the Company which forms part of this Report.

14. STATEMENT INDICATING THE MANNER IN WHICH FORMAL ANNUAL EVALUATION HAS BEEN MADE BY THE BOARD OF ITS OWN PERFORMANCE, ITS DIRECTORS, AND THAT OF ITS COMMITTEES

The Board of directors has carried out an annual evaluation of its own performance, board committees and individual directors pursuant to the provisions of the Act and the corporate governance requirements as prescribed by Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations 2015 ("SEBI Listing Regulations").

The performance of the board was evaluated by the board after seeking inputs from all the directors on the basis of the criteria such as the board composition and structure, effectiveness of board processes, information and functioning, etc.

The performance of the committees was evaluated by the board after seeking inputs from the committee members on the basis of the criteria such as the composition of committees, effectiveness of committee meetings, etc. The board and the nomination and remuneration committee reviewed the performance of the individual directors on the basis of the criteria such as the contribution of the individual director to the board and committee meetings like preparedness on the issues to be discussed, meaningful and constructive contribution and inputs in meetings, etc. In addition, the Chairman was also evaluated on the key aspects of his/her role. The Directors were satisfied with the evaluation results, which reflected the overall engagement of the Individual Directors, the Board as a whole and its Committees with the Company.

Performance Evaluation Criteria for Independent Directors:

The performance evaluation criteria for independent directors are determined by the Nomination and Remuneration committee. An indicative list of factors that may be evaluated include participation and contribution by a director, commitment, effective deployment of knowledge and expertise, effective management of relationship with stakeholders, integrity and maintenance of confidentiality and independence of behavior and judgments

15. PARTICULARS OF LOAN, GUARANTEES AND INVESTMENTS U/S 186

The Company has not provided any loans and guarantees or made investments pursuant to Section 186 of the Companies Act, 2013 during the financial year under review.

16. PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES

In line with the requirements of the Companies Act, 2013 and Listing Regulations, your Company has formulated a Policy on Related Party Transactions which is also available on the Company's website at web link: http://www.biofilgroup.net/Policies/Policy%20for%20Related%20party%20transaction.pdf. The Policy intends to ensure that proper reporting, approval and disclosure processes are in place for all transactions between the Company and Related Parties.

All Related Party Transactions are placed before the Audit Committee for review and approval. Prior omnibus approval is obtained for Related Party Transactions on a quarterly basis for transactions which are of repetitive nature and/or entered in the Ordinary Course of Business and are at Arm's Length. All Related Party Transactions are subjected to independent review by an Audit Committee to establish compliance with the requirements of Related Party Transactions under the Companies Act, 2013, and Listing Regulations.





CIN: L24233MP1985PLC002709

All Related Party Transactions entered during the year were in Ordinary Course of the Business and at Arm's Length basis. The Material Related Party Transactions, i.e. transactions exceeding 10% of the annual consolidated turnover as per the last audited financial statement, which were entered during the year by your Company are given separately in notes to the financial statements. Further the disclosure of Related Party Transactions as required under Section 134(3)(h) of the Companies Act, 2013, in Form AOC-2 is set out as **Annexure-B** and form part of this report.

Your Directors draw your attention to Note No. 36 to the financial statements, which set out related party disclosures.

17. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO

The particulars in respect of conservation of energy, technology absorption and foreign exchange earnings and outgo, as required under sub-section (3)(m) of Section 134 of the Companies Act, 2013 read with Rule (8)(3) of the Companies (Accounts) Rules, 2014 are given as under:

(A) Conservation of Energy

(i) The steps taken or impact on conservation of energy

The company is putting continues efforts to reduce the consumption of energy and maximum possible saving of energy.

(ii) The steps taken by the company for utilising alternate sources of energy: The

Company has used alternate source of energy, whenever and to the extent possible

(iii) The capital investment on energy conservation equipment's: Nil

(B) Technology Absorption:

- (i) The efforts made towards technology absorption: Not Applicable.
- (ii) The benefits derived like product improvement, cost reduction, product development or import substitution: Not Applicable.
- (iii) In case of imported technology (imported during the last three years reckoned from the beginning of the Financial Year): Not Applicable.
- (iv) The expendicture incurred on Research and Development: Company has not incurred any expenditure on Research and Development during the year under review.

(C) FOREIGN EXCHANGE EARNINGS AND OUTGO:

There was neither inflow nor outflow of foreign exchange during the year.

18. STATEMENT IN RESPECT OF ADEQUACY OF INTERNAL FINANCIAL CONTROL WITH REFERENCE TO THE FINANCIAL STATEMENTS

Your company has an effective internal control and risk mitigation system, which are constantly assessed and strengthened with new/revised standard operating procedures. The company's internal control system is commensurate with its size, scale and complexities of its operations; the internal and operational audit is entrusted to M/s. Sethiya Khandelwal & Co., Chartered Accountants. The main thrust of internal audit is to test and review controls, appraisal of risks and business processes, besides benchmarking controls with best practices in the industry.

The audit committee of the board of directors actively reviews the adequacy and effectiveness of the internal control systems and suggests improvements to strengthen the same. The company has a robust management information system, which is an integral part of the control mechanism.

The audit committee of the board of directors, statutory auditors and the business heads are periodically apprised of the internal audit findings and corrective actions taken. Audit plays a key role in providing assurance to the Board of Directors. Significant audit observations and corrective actions taken by the management are presented to the audit committee of the board. To maintain its objectivity and independence, the internal audit function reports to the chairperson of the audit committee. Report of Statutory Auditors for internal financial control system is part of Audit Report.

19. CORPORATE SOCIAL RESPONSIBILITY (CSR)


Provisions of Section 135 of the Companies Act, 2013 does not apply to the Company, therefore Company has not constituted Corporate Social Responsibility (CSR) committee as required under the Act.

20. REMUNERATION POLICY / DISCLOSURE RELATING TO REMUNERATION OF DIRECTORS, KEY MANAGERIAL PERSONNEL AND PARTICULARS OF EMPLOYEES:

In accordance with Section 178 and other applicable provisions if any, of the Companies Act, 2013 read with the Rules issued there under and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors formulated the Nomination and Remuneration Policy of your Company on the recommendations of the Nomination and Remuneration Committee. The Nomination and Remuneration Policy of the company is available on the website of the Company at http://www.biofilgroup.net/Policies/Policy%20for%20the%20%20Nomination %20&%20Remuneration.pdf

The Disclosure required under Section 197(12) of the Companies Act, 2013 read with the Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 as amended up to date, is annexed as **Annexure-C** and forms an integral part of this Report.

None of the employee of the company is drawing more than Rs. 1,02,00,000/- per annum or Rs. 8,50,000/- per month for the part of the year, during the year under review. Therefore, Particulars of the employees as required under Section





CIN: L24233MP1985PLC002709

197 of Companies Act, 2013 read with rule 5(2) & rule 5(3) of Companies (Appointment and Remuneration of Managerial Personnel) Rules 2014 are not applicable, during the year under review.

Further, Company did not have any holding or subsidiary company therefore receipt of the commission or remuneration from holding or subsidiary company of the company as provided under section 197(14) of Companies Act, 2013 is not applicable.

21. REPORTS ON CORPORATE GOVERNANCE & MANAGEMENT DISCUSSION ANALYSIS:

As per Regulation 34(3) read with Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a separate section on corporate governance practices followed by the Company, together with a certificate from the Practicing Chartered Accountants confirming compliance forms an integral part of this Report.

A detailed analysis of the Company's performance is discussed in the Management Discussion and Analysis Report, which forms part of this Annual Report.

22. DISCLOSURE ON ESTABLISHMENT OF A VIGIL MECHANISM/WHISTLE BLOWER POLICY:

The Company has established a Vigil Mechanism/Whistle Blower Policy to provide a framework for promoting responsible and secure whistle blowing and to provide a channel to the employee(s), Directors and other stakeholders to report to the management, concerns about unethical behavior, actual or suspected fraud or violation of the code of conduct or policy/ies of the Company. The details of said vigil mechanism is given in Corporate Governance Report, which forms part of this Annual Report.

23. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS OF THE COMPANY:

There are no significant and material orders passed by the Regulators/Courts that would impact the going concern status of the Company and its future operations.

24. SECRETARIAL AUDIT

Pursuant to the provisions of Section 204 of the Companies Act, 2013 and Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the company has appointed M/s. L. N. Joshi, Practicing Company Secretary, Indore to conduct Secretarial Audit of the company for the year ended March 31, 2019. The Secretarial Audit report given by Secretarial Auditor of the company is annexed as **ANNEXURE-D** and forms an integral part of this Report.

EXPLANATION TO SECRETARIAL AUDITOR'S REMARKS

With respect to the observations of the Secretarial Auditor, the Board replies hereunder:-

- 1. As on 31st March, 2019, 2262500 Equity Shares held by Promoter & Promoter Group were not in Demat Form. Company had re-issued 2262500 Forfeited Equity Shares in physical mode which could not be dematerialized due to pending of listing approval from stock exchanges till 31st March, 2019. However, company has received listing approval from both the stock exchanges and aforesaid shares have also been dematerialized on 4th July, 2019.
- 2. SEBI had condoned the delay w.r.t Compliance with Reg. 77(1) of SEBI (ICDR) Regulations, 2009.

At the time of listing application, National Stock Exchange of India Limited (NSE) sought clarification on the provisions of Regulation 77(1) of SEBI (Issue of Capital and Disclosure Requirement) Regulations, 2009 which states that "Full consideration of specified securities other than warrants issued shall be paid by the allottees at the time of allotment of such specified securities".

Company had reissued forfeited equity shares at Rs. 7/- each in 2011 and after that in 2015 remaining Rs. 3/- was called from respective allottees. To condone such delay company had made an application to SEBI for giving clarification/exemption for calling remaining amount of Rs. 3/- for reissue of 5712500 forfeited equity shares. It was also submitted that Company has not violated any provision of Reg. 77(1) of SEBI(ICDR) Reg., 2009 as forfeited equity shares were reissued as per erstwhile listing agreement and Companies Act, 1956.

On request of the company, SEBI has condoned the delay for calling remaining amount of Rs. 3/- each from allottee for reissue of forfeited equity shares.

3. Company had reissued 5712500 forfeited equity shares in year 2011 but still listing and trading approval pending from stock exchanges till 31st March, 2019.

Company had re-issued 5712500 Forfeited Equity Shares in 2011 for which listing and trading approvals were pending from both the Stock Exchanges till 31st March, 2019. However company has received Listing and Trading Approval from both the Stock Exchanges in July, 2019.

25. STATUTORY AUDITORS

M/s Maheshwari & Gupta, Chartered Accountants, Indore (ICAI Firm Registration No. 006179C) were appointed as Statutory Auditors of your Company in the 32nd Annual General Meeting held on 25th September, 2017, for a term of five consecutive years. Pursuant to the Notification issued by the Ministry of Corporate Affairs on 7th May, 2018, amending Section 139 of the Companies Act, 2013, the mandatory requirement for ratification of appointment of Auditors by the Members at every AGM has been omitted and hence your Company has not proposed ratification of appointment of M/s Maheshwari & Gupta, Chartered Accountants at the forthcoming AGM.

The Auditors have confirmed that they have subjected themselves to the peer review process of Institute of Chartered





CIN: L24233MP1985PLC002709

Accountants of India (ICAI) and hold valid certificate issued by the Peer Review Board of the ICAI.

EXPLANATION TO AUDITOR'S REMARKS

The Auditors in their report have referred to the notes forming part of the Accounts which are self-explanatory and does not contain any qualification, reservation or adverse remark or disclaimer.

Further, there was no fraud in the Company, which was required to report by statutory auditors of the Company under sub-section (12) of section 143 of Companies Act, 2013.

26. COST AUDIT

The company does not falls within the provisions of Section 148 of Companies Act, 2013, read with the Companies (Cost Records & Audit) Rules, 2014, therefore, no such records are required to be maintained and company is not required to appoint cost auditor for the financial year 2018-19.

27. INTERNAL AUDITOR

The Board has appointed M/s Sethiya Khandelwal & Company, Chartered Accountants Indore, as Internal Auditor of the company and takes his suggestions and recommendations to improve and strengthen the internal control systems. His scope of work includes review of operational efficiency, effectiveness of systems & processes, compliances and assessing the internal control strengths in all areas.

The Audit Committee reviews adequacy and effectiveness of the Company's internal control environment and monitors the implementation of audit recommendations including those relating to strengthening of the Company's risk management policies and systems.

28. CODE OF CONDUCT

The Board of Directors has laid down a Code of Conduct ("the Code") for all Board members and senior management personnel of your Company. The Code of conduct is available on Company's website at the web link: http://www.biofilgroup.net/Policies/Code%20of%20Conduct%20of%20BCPL.pdf

All Board members and senior management personnel have confirmed compliance with the Code. Declaration on adherence to the code of conduct is forming part of the Corporate Governance Report.

29. MD/CFO CERTIFICATION

As required under Regulation 17(8) of the Listing Regulations, the Managing Director and Chief Financial Officer of the Company have certified to the Board regarding the Financial Statements for the year ended 31st March, 2019 and same was reviewed by the Board of Directors and is annexed to the Corporate Governance Report.

30. CODE FOR PROHIBITION OF INSIDER TRADING PRACTICES:

On December 31, 2018, Securities and Exchange Board of India amended the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, prescribing various new requirements with effect from April 1, 2019. In line with the amendments, the Company has adopted an amended Code of Conduct to regulate, monitor and report trading by Designated Persons and their Immediate Relatives & Connected Persons under the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

31. STATEMENT INDICATING DEVELOPMENT & IMPLEMENTATION OF RISK MANAGEMENT POLICY:

The Board of Directors has adopted risk management policy for the Company which provides for identification, assessment and control of risks which in the opinion of the Board may threaten the existence of the Company. The Management identifies and controls risks through a properly defined framework in terms of the aforesaid policy.

32. MATERIAL CHANGES & COMMITMENTS. IF ANY AFFECTING THE FINANCIAL POSITION OF THE COMPANY

No material changes and commitments affecting the financial position of the company have occurred between the end of the financial year to which the financial statements relate and at the date of this Board's report.

33. ENVIRONMENT AND SAFETY

The Company is conscious of the importance of environmentally clean and safe operations. The Company's policy requires conduct of operations in such a manner, so as to ensure safety of all concerned, compliances environmental regulations and preservation of natural resources.

34. SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION & REDRESSAL) ACT, 2013

The Company has in place an Anti Sexual Harassment Policy in line with the requirements of The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. An Internal Complaints Committee (ICC) has been set up to redress the Complaint received regarding sexual harassment. There was no case of sexual harassment reported during the year under review.

35. LISTING OF SHARES

Company's shares listed on Bombay Stock Exchange Limited & National Stock Exchange of India Ltd. The company has paid annual listing fee for financial year 2019-20 to both the Stock Exchanges. Further please note that Bombay Stock Exchange and National Stock Exchange of India Limited in their letter dated 11th July, 2019 have granted listing and trading approval w.e.f. 12th July, 2019 for 5712500 forfeited equity shares re-issued to promoters and non promoters on preferential basis which were allotted on 31.03.2011.





CIN: L24233MP1985PLC002709

36. INSURANCE

The Company's assets are adequately insured against the loss of fire and other risk, as consider necessary by the Management from time to time. The Company has also taken insurance cover for any claims/losses arising out of its core business of Pharmaceuticals and Chemicals.

37. BUSINESS RESPONSIBILITY REPORT

The Business Responsibility Reporting as required by Regulation 34(2) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, is not applicable to your Company for the financial year ending March 31, 2019

38. COMPLIANCE OF SECRETARIAL STANDARD

The Directors state that applicable Secretarial Standards, i.e. SS-1 and SS-2, relating to 'Meetings of the Board of Directors' and 'General Meetings', respectively, have been duly followed by the Company.

39 DEPOSITORY SYSTEM

Your Company's shares are tradable compulsorily in electronic form and your Company has connectivity with both the Depositaries i.e. National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL). In view of the numerous advantage offered by the Depository System, members are requested to avail of the facility of Dematerialization of the Company's shares on either of the Depositories mentioned as aforesaid. The Company has paid the annual custodian fee to both the depositories.

40. INDUSTRIAL RELATIONS

Company's Industrial relations continued to be healthy, cordial and harmonious during the period under review.

41. ACKNOWLEDGMENT

The Board of Directors wish to place on record its appreciation for the extended co-operation and assistance rendered to the Company and acknowledge with gratitude the continued support and cooperation extended by the employee, investors, stakeholders, banks and other regulatory authorities.

On behalf of the Board of Directors Biofil Chemicals and Pharmaceuticals Ltd.

Place : Indore
Date : 13th August, 2019

Ramesh Shah
Managing Director

anaging Director Director (DIN: 00028819) (DIN: 00326110)

Romil Shah





CIN: L24233MP1985PLC002709

ANNEXURE - A Form No. MGT-9 Extract of Annual Return

As on Financial Year Ended on 31st March 2019

[Pursuant to Section 92(3) of the Companies Act, 2013 and Rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION & OTHER DETAILS:

1	CIN	L24233MP1985PLC002709
2	Registration Date	04/01/1985
3	Name of the Company	Biofil Chemicals and Pharmaceuticals Limited
4	Category / Sub-Category of the Company	Listed Public Company Limited by shares / Indian Non-government Co.
5	Address of the Registered office and contact details	11/12, Sector E, Sanwer Road, Industrial Area, Indore-452015 (M.P.) Tel. No.: 0731-2723016/17 • Email id : bcplcompliance@gmail.com Website : www.biofilgroup.net
6	Whether listed company Yes / No	Yes
7	Name, Address and Contact details of Registrar and Transfer Agent, if any	Ankit Consultancy Pvt. Ltd. (SEBI Reg. No: INR000000767) 60, Electronic Complex, Pardeshipura, Indore- 452010 (M.P.) Tel.: 0731-2551745/46 • Fax: 0731-4065798 Email: ankit_4321@yahoo.com • Web address: www.ankitonline.com

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY (All the business activities contributing 10 % or more of the total turnover of the company shall be stated)

- 1	S. Io.	Name and Description of Main Products / Services	NIC Code of the Product/ Service	% of Total Turnover of the Company	
Г	1	Wholesale of Pharmaceuticals and Medical goods	46497	84.19%	

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES

S.	Name and Address of	CIN/GLN	Holding / Subsidiary	% of Shares	Applicable	
No.	the Company		/ Asscoiate	Held	Section	
-	-	-	-	-	-	

IV. SHARE HOLDING PATTERN (EQUITY SHARE CAPITAL BREAKUP AS PERCENTAGE OF TOTAL EQUITY)

(I) CATEGORY WISE SHARE HOLDING

Category of No. of Shares Held at the beginning of the year (As on 01st April 2018) No. of Shares Held at the end of the year (As on 31st March 2019)							% Change		
	Demat	Physical	Total	% of Total Share	Demat	Physical	Total	% of Total Share	during the year
A. Promoter's									
(1) Indian									
a) Individual/ HUF	3304560	0	3304560	20.31%	3304560	0	3304560	20.31%	0.00%
b) Central Govt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
c) State Govt(s)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
d) Bodies Corp.	2051700	2262500	4314200	26.51%	2051700	2262500	4314200	26.51%	0.0%
e) Banks / FI	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
f) Any other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Sub-Total (A) (1)	5356260	2262500	7618760	46.82%	5356260	2262500	7618760	46.82%	0.00%
(2) Foreign									
a) NRI- Individual	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
b) Other- Individual	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
c) Bodies Corp.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
d) Banks / FI	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
e) Any other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Sub Total (A) (2)	0.0	0.0	0.0	0.0%	0.0	0.0	0.0	0.0	0.0%



CIN: L24233MP1985PLC002709

Category of	1			ginning of	No. of Shares Held at the end of				% Chang
Shareholders	the year (As on 01st April 2018)			the year (As on 31st March 2019)				during	
	Demat	Physical	Total	% of Total Share	Demat	Physical	Total	% of Total Share	the yea
Fotal shareholding of									
promoter									
(A) = (A)(1)+(A)(2)	5356260	2262500	7618760	46.82%	5356260	2262500	7618760	46.82%	0.00%
B. Public Shareholding									
1. Institutions									
a) Mutual Funds	0	74000	74000	0.46%	0	74000	74000	0.46%	0.00%
b) Banks / FI	20000	13300	33300	0.20%	20000	13300	33300	0.20%	0.00%
c) Central Govt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
d) State Govt(s)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
e) Venture Capital Funds	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
f) Insurance Companies	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
g) FIIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
h) Foreign Venture									
Capital Funds	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
i) Others (specify)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Sub total (B) (1)	20000	87300	107300	0.66%	20000	87300	107300	0.66%	0.009
2. Non-Institutions							101000		
a) Bodies Corp.									
i) Indian	3490340	356400	3846740	23.64%	3398692	98100	3496792	21.49%	(2.159
ii) Overseas	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
b) Individuals									
i) Individual shareholders	2319609	716110	3035719	18.65%	2397317	665110	3062427	18.82%	0.179
holding nominal share									
capital upto Rs. 1 lakh									
ii) Individual shareholders	1323074	66800	1389874	8.54%	1390979	331500	1722479	10.58%	2.049
holding nominal share									
capital in excess of									
Rs1 lakh									
c) Others									
i) NRI & OCB	115415	156000	271415	1.67%	112999	152400	265399	1.63%	(0.04°
ii) Clearing Members	3992	0	3992	0.02%	643	0	643	0.00%	(0.029
Sub-total (B)(2):-	7252430	1295310	8547740	52.52%	7300630	1247110	8547740	52.52%	0.009
Total Public Shareholding									
(B) = (B)(1) + (B)(2)	7272430	1382610	8655040	53.18%	7320630	1334410	8655040	53.18%	0.009
C. Shares held by									
Custodian for GDRs & ADRs	0.0	0.0	0.0	0.00%	0.0	0.0	0.0	0.0	0.00%
4 API 13	. 0.0	. 0.0	. v.v	. 0.00/0	. v.v	· v.u	. U.U	. 0.0	U.UU/



II)

CIN: L24233MP1985PLC002709

SHAREHOLDING OF PROMOTERS:

S. No.	Share Holder's Name		Shareholdin beginning of	•	S	Shareholding at the end of the year			
		No. of Shares	% of total shares of the company	% of Share Pledge / encumbered to total shares	No. of Shares	% of total shares of the company	% of Share Pledge / encumbered to total shares	in share holding during the year	
1	Smitesh Sanalal Shah	1082740	6.65	0	1082740	6.65	0	0	
2	Ramesh Shah	793940	4.88	0	793940	4.88	0	0	
3	Romil Shah	382550	2.35	0	382550	2.35	0	0	
4	Ketan Shah	340800	2.09	0	340800	2.09	0	0	
5	Meena Shah	140600	0.86	0	140600	0.86	0	0	
6	Sandeep Shah	106600	0.66	0	106600	0.66	0	0	
7	Trupti Shah	101750	0.63	0	101750	0.63	0	0	
8	Meet Shah	87200	0.54	0	87200	0.54	0	0	
9	Ritu Shah	87100	0.54	0	87100	0.54	0	0	
10	Rohan Shah	65500	0.40	0	65500	0.40	0	0	
11	Kiran Shah	63100	0.39	0	63100	0.39	0	0	
12	Pragnesh Shah	52680	0.32	0	52680	0.32	0	0	
13	Scope Finance Company Private Limited	2262500	13.90	0	2262500	13.90	0	0	
14	Mid (India) Pharmaceuticals Pvt Limited	1175250	7.22	0	1175250	7.22	0	0	
15	Cyano Finance and Sales Private Limited	876450	5.39	0	876450	5.39	0	0	
	Total	7618760	46.82%	0	7618760	46.82%	0	0.00%	

III) CHANGE IN PROMOTERS' SHAREHOLDING (PLEASE SPECIFY, IF THERE IS NO CHANGE)

S. No.			ding at the of the year	Cumulative Shareholding during the year		
		No. of Shares	% of total shares of the company	No. of Shares	% of total shares of the company	
1	At the beginning of the year	7618760	46.82%	7618760	46.82%	
	Date wise Increase / Decrease in Promoters Shareholding during the year specifying the reasons for increase / decrease (e.g. allotment /transfer / bonus/ sweat equity etc.):	0.0	0.0	7618760	46.82%	
	At the end of the year	7618760	46.82%	7618760	46.82%	



CIN: L24233MP1985PLC002709

(IV) SHAREHOLDING PATTERN OF TOP TEN SHAREHOLDERS

(OTHER THAN DIRECTORS, PROMOTERS AND HOLDERS OF GDRs AND ADRs):

S.	Top Ten Shareholders	Shareho		Date wise Increase	Increase / Decrease	Reason	Share	ulative cholding g the year
No.	Name	No. of Shares at the begining of the year	% of total shares of the Company	Decrease in top ten share holders	in share holding		No. of Shares	% of total shares of the Company
1	Starline Equifin Private Limited At the end of the year (31.03.2019)	1850800 1850800	11.37% 11.37%	01.04.2018	-	No Change -	1850800 1850800	11.37% 11.37%
2	Libra Healthcare Private Limited At the end of the year (31.03.2019)	850000 850000	5.22% 5.22%	01.04.2018	-	No Chnage -	850000 850000	5.22% 5.22%
3	KSL and Industries Limited At the end of the year (31.03.2019)	308065 308065	1.89% 1.89%	01.04.2018	-	No Change -	308065 308065	1.89% 1.89%
4	Tejal Keyur Shah	257721 -	1.58%	01.04.2018 13.04.2018	- -250000	Sale Removed from Top 10 w.e.f. 13.04.2018	257721 7221	1.58% 0.05%
		- -	- -	03.08.2018	107721	Purchase (Joined Top 10 w.e.f. 03.08.2018 Purchase	107721 257721	0.66% 1.58%
	At the end of the year (31.03.2019)	257721	1.58%	-	-	-	257721	1.58%
5	Vandana Gupta	0	0.00%	15.02.2019	200300	Purchase (Joined from Top 10 w.e.f. 15.02.2019		1.23%
	At the end of the year (31.03.2019)	250000	1.54%	22.03.2019	49700	Purchase	250000 250000	1.54% 1.54%
6	Kishor Himmatsinh Jhala At the end of the year (31.03.2019)	200000	1.23% 1.23%	01.04.2018	-	No change		1.23 1.23%
7	Gom Industries Ltd. At the end of the year (31.03.2019)	180800 180800	1.11% 1.11%	01.04.2018	-	No Change -	180800 180800	1.11% 1.11%
8	Rashmi Chandrakant Shah At the end of the year (31.03.2019)	99100 99100	0.61% 0.61%	01.04.2018	- -	No Change -	99100 99100	0.61% 0.61%
9	Manthan C. Shah At the end of the year (31.03.2019)	85056 85056	0.52% 0.52%	01.04.2018 -	- -	No Change -	85056 85056	0.52% 0.52%
10	Taraben C. Shah At the end of the year (31.03.2019)	80030 80030	0.49% 0.49%	01.04.2018	-	No Change -	80030 80030	0.49% 0.49%

Note : The above information is based on the weekly beneficiary position received from Depositories. As it is not feasible to provide daily changes in shareholding, consolidated changes on weekly basis during the financial year 2018-19 has been provided.





V)

CIN: L24233MP1985PLC002709

SHAREHOLDING OF DIRECTORS AND KEY MANAGERIAL PERSONNEL:

		Shareholdin beginning of	_		ative Share uring the year
S. No.		No. of Shares	% of total shares of the company	No. of Shares	% of total shares of the company
1	Domach Chab (Managing Divastor)	Snares	the company		the company
'	Ramesh Shah (Managing Director) At the beginning of the year Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase / decrease	793940 0	4.88% 0%	793940 793940	4.88% 4.88%
	(e.g. allotment /transfer / bonus/ sweat equity etc.): At the end of the year	793940	4.88%	793940	4.88%
2	Romil Shah (Non Executive Director) At the beginning of the year Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase / decrease	382550	2.35%	382550	2.35%
	(e.g. allotment /transfer / bonus/ sweat equity etc.): At the end of the year	0.0 382550	0.0% 2.35 %	382550 382550	2.35% 2.35%
3	Shaila Jain (Independent Director) At the beginning of the year Date wise Increase / Decrease in Shareholding during	0.0	0.0%	0.0	0.0%
	the year specifying the reasons for increase / decrease (e.g. allotment /transfer / bonus/ sweat equity etc.): At the end of the year	0.0 0.0	0.0% 0.0%	0.0 0.0	0.0% 0.0%
4	Subhash Chandra Swarnkar (Independent Director) At the beginning of the year Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase / decrease	0.0	0.0%	0.0	0.0%
	(e.g. allotment /transfer / bonus/ sweat equity etc.): At the end of the year	0.0 0.0	0.0% 0.0%	0.0 0.0	0.0% 0.0%
5	Jitendra Kumar Sahu (Chief Financial Officer) At the beginning of the year Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase / decrease	0.0	0.0%	0.0	0.0%
	(e.g. allotment /transfer / bonus/ sweat equity etc.): At the end of the year	0.0 0.0	0.0% 0.0%	0.0 0.0	0.0% 0.0%
6	Shikha Khilwani (Company Secretary) At the beginning of the year Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase / decrease	0.0	0.0%	0.0	0.0%
	(e.g. allotment /transfer / bonus/ sweat equity etc.): At the end of the year	0.0 0.0	0.0% 0.0%	0.0 0.0	0.0% 0.0%



CIN: L24233MP1985PLC002709

V) INDEBTEDNESS - INDEBTEDNESS OF THE COMPANY INCLUDING INTEREST OUTSTANDING/ACCRUED BUT NOT DUE FOR PAYMENT (Amount in Rs.)

BOT NOT BOET ON ATMIENT				
	Secured Loans Excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year		-		
i) Principal Amount	0	14235516	0	14235516
ii) Interest due but not paid	0	1500000	0	1500000
iii) Interest accrued but not due	0	(150000)	0	(150000)
Total (i+ii+iii)	0	15585516	0	15585516
Change in Indebtedness during the financial year				
* Addition	0	0.00	0	0.00
* Reduction	0	(605222)	0	(605222)
Net Change	0	(605222)	0	(605222)
Indebtedness at the end of the financial year				
i) Principal Amount	0	14980294	0	14980294
ii) Interest due but not paid	0	1547520	0	1547520
iii) Interest accrued but not due	0	(154752)	0	(154752)
Total (i+ii+iii)	-	16373062	0	16373062

VI) REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. REMUNERATION TO MANAGING DIRECTOR, WHOLE-TIME DIRECTORS AND/OR MANAGER:

S.	Particulars of Remuneration	Name of MD / WTD / MANAGER	TOTAL
No.	Faiticulars of Hemoneration	Ramesh Shah (Managing Director)	AMOUNT
1	Gross salary	0.0	0.0
	(a) Salary as per provisions contained in		
	section 17(1) of the Income-tax Act, 1961	0.0	0.0
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	0.0	0.0
	(c) Profits in lieu of salary under section 17(3)		
	Income- tax Act, 1961	0.0	0.0
2	Stock Option	0.0	0.0
3	Sweat Equity	0.0	0.0
4	Commission	0.0	0.0
	- as % of profit		
	- others, specify		
5	Others, please specify	0.0	0.0
	Total (A)	0.0	0.0
	Ceiling as per the Act	0.0	0.0

B. REMUNERATION TO OTHER DIRECTORS

S.No.	Particulars of Remuneration	N	Name of Director		
1	Independent Directors	Shaila Jain	Subhash Chandra Swarnkar	Amount	
	Fee for attending board committee meetings	0.0	0.0	0.0	
	Commission	0.0	0.0	0.0	
	Others, please specify	0.0	0.0	0.0	
	Total (1)	0.0	0.0	0.0	
			Romil Shah		
2	Other Non - Executive Directors				
	Fee for attending board committee meetings		0.0	0.0	
	Commission		0.0	0.0	
	Others, please specify		0.0	0.0	
	Total (2)		0.0	0.0	
	Total (B)=(1+2)		0.0	0.0	
	Total Managerial Remuneration		0.0	0.0	
	Overall Ceiling as per the Act		NA	NA	



C.

CIN: L24233MP1985PLC002709

REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD

		Key Manageria	al Personnel	Total
S. No.	Particulars of Remuneration	Company Secretary (Shikha Khilwani)	Chief Financial Officer (Jltendra Kumar Sahu)	Amount (In Rs.)
1	Gross salary			
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act,	304500/-	318000/-	622500/-
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	-	-	-
	(c) Profits in lieu of salary under section 17(3)			
	Income-tax Act, 1961	-	-	-
2	Stock Option	-	-	-
3	Sweat Equity	-	-	-
4	Commission	-	-	-
	- as % of profit	-	-	-
	others, specify	-	-	-
5	Others, please specify	-	-	-
	Total	304500/-	318000/-	622500/-

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES: NIL

For and on behalf of the Board of Directors **Biofil Chemicals and Pharmaceuticals Ltd.**

Ramesh Shah **Romil Shah** Place : Indore Managing Director Date: 13th August 2019 (DIN: 00028819)

Director (DIN: 00326110)





CIN: L24233MP1985PLC002709

ANNEXURE - B FORM NO. AOC -2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arms length transaction under third proviso thereto.

1.	Details of contracts or arrangements or transactions not at Arm's length basis.		
(a)	Name (s) of the related party & nature of relationship	Nil	
(b)	Nature of contracts/arrangements/transaction	Nil	
(c)	Duration of the contracts/arrangements/transaction	Nil	
(d)	Salient terms of the contracts or arrangements or transaction including the value, if any	Nil	
(e)	Justification for entering into such contracts or arrangements or transactions'	Nil	
(f)	Date(s) of approval by the Board	Nil	
(g)	Amount paid as advances, if any	Nil	
(h)	Date on which the special resolution was passed in General meeting as required under first proviso to Section 188	Nil	

2.	Details of Material contracts or arrangements or transactions at Arm's length basis	Details
(a)	Name (s) of the related party & nature of relationship	Cyano Pharma Private Limited. Relative of Directors are Director in the Company
(b)	Nature of contracts / arrangments / transaction	Sale/purchase of goods and services in ordinary course of business and on arms length basis
(c)	Duration of the contracts/arrangements/transaction	On going
(d)	Salient terms of the contracts or arrangements or transaction including the value, if any*	Rs. 6,53,55,057 /-
(e)	Date(s) of approval by the Board	Since all transactions are done in the ordinary course of business and are at arms length basis, approval of the board is not applicable. However, necessary omnibus approvals were granted by the Audit committee from time to time.
(f)	Amount paid as advances or refunded, if any	No advance have been paid or received against the tranactions mentioned above.

^{*} Salient terms of the contracts or arrangements or transactions, including the value, if any - All the transactions were in Ordinary Course of Business and on arms length basis.

On behalf of the Board of Directors of Biofil Chemicals and Pharmaceuticals Ltd.

Place : Indore

Date: 13th August 2019

Ramesh Shah Managing Director (DIN: 00028819) Romil Shah Director (DIN: 00326110)



CIN: L24233MP1985PLC002709

ANNEXURE - C

Information required under Section 197 of the Companies Act, 2013 read with Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

(I). The Ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the financial year:

S. No.	Name of Director	Ratio to median Remunerationan
N.A.	N.A	N.A

Note: Not applicable as none of the director receiving any remuneration from Company.

(II) The percentage increase in the remuneration of each Director, CFO & Company Secretary in the financial year 2018-19 is as follows:

S. No.	Name of Person	Designation	% Increase in Remunerationan
1	Ramesh Shah	Managing Director	Nil
2	Romil Shah	Director	Nil
3	Shaila Jain	Independent Director	Nil
4.	Subhash Chandra Swarnakar	Independent Director	Nil
5.	Jitendra Kumar Sahu	Chief Financial Officer	16.06%
6.	Shikha Khilwani	Company Secretary	15.34%

Note: None of the Director is receiving any remuneration hence comments are not required.

(IV) The Percentage increase in the median remuneration of employees in the financial year:

During the year there was increase of 3.51% in the median remuneration of all employees in comparison to previous year.

(IV) The Number of permanent employees on the rolls of the Company:

Total Number of employees: 39 (Thirty Nine)

(V) Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration:

Average percentile increase in the salaries of employees other than the managerial personnel in the last financial year is 31.69% and the average percentile increase in the remuneration of managerial personnel is 15.70%. Since no average percentile increase in managerial remuneration is made in comparison to average percentile increase in employees hence no comments are required.

(VI) Affirmation:

The Board affirms remuneration is as per remuneration policy of the Company.

(VII) Statement showing name of top ten employees in terms of remuneration drawn (as per sub rule 3 of Rule 5 Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 as amended from time to time:-

Particulars	Ketan Shah	Akshay Atri	Jitendra Kumar Sahu	Vinayak Bhopte	Shikha Khilwani
Designation of the employee	Chief Operating Officer	Marketing Manager	Chief Financial Officer	Chief Chemist	Company Secretary
Remuneration received (Amount in Rs.)	1740000	432000	318000	369000	304500
Nature of Employment, Whether Contractual or Otherwise	Otherwise	Otherwise	Otherwise	Otherwise	Otherwise
Qualifications and experience of the employee	B.Sc. 33 years	B.B.A. 4.5 Years	M.B.A.(Finance) 9 years	B.Sc. 16 Years	B.Com., C.S. 4 Years
Date of Commencement of Employment	05.02.1986	05.04.2015	30.05.2014	01.08.2012	13.02.2016
The age of such employee	58 years	28 Years	33 Years	45 Years	27 years
The last employment held by such employee before joining the company	-	-	Team Xtreme as Finance Manager	-	-
The percentage of equity shares held by the employee in the company with in the meaning of clause (iii) of sub rule (2) of Rule 5	2.09% (340800 shares)	Nil	Nil	Nil	Nil



CIN: L24233MP1985PLC002709

Particulars	Ketan Shah	Akshay Atri	Jitendra Kumar Sahu	Vinayak Bhopte	Shikha Khilwani
Whether any such employee is a relative of any director or manager of the company and if so, name of such director or manager	Yes, Shri Ketan Shah belongs to Promoter Group and is relative of Shri Ramesh Shah & Shri Romil Shah	No	No	No	No

Particulars	Rohan Shah	Meet Shah	Namrata Tiwari	Nirmal Kumar Katiyar	Joseph Chacko
Designation of the employee	Asst. Marketing Manager	Asst. Marketing Manager	Manager	Supervisior	Administration Head
Remuneration received	300000	300000	265500	265500	258000
Nature Of Employment, Whether Contractual Or Otherwise	Otherwise	Otherwise	Otherwise	Otherwise	Otherwise
Qualifications and experience of the employee	B.B.A 5.5 years	B.com, M.B.A. 5 Years	M.B.A.(Finance) 6 years	M. Sc. 6 Years	B.A. 33 Years
Date Of Commencement Of Employment	01.02.2014	09.04.2014	15.08.2013	01.04.2018	02.02.2013
The age of such employee	29 years	27 years	36 Years	40 years	58 years
The last employment held by such employee before joining the company	-	-	Man Industries India Limited	-	Man Industries India Ltd.
The percentage of equity shares held by the employee in the company with in the meaning of clause (iii) of sub rule (2) of Rule 5	0.40% 65500 shares	0.54% 87200 shares	Nil	Nil	Nil
Whether any such employee is a relative of any director or manager of the company and if so, name of such director or manager	Yes, Shri Rohan Shah belongs to promoter group and is relative of Shri Ramesh Shah and Shri Romil Shah	Yes, Shri Meet Shah belongs to promoter group and is relative of Shri Ramesh Shah and Shri Romil Shah			

BIOFIL Health for All

CIN: L24233MP1985PLC002709

ANNEXURE - D

SECRETARIAL AUDIT REPORT Form No. MR-3

For the Financial Year Ended on 31st March, 2019
[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies
(Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To.

The Members,

BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

Registered Office:


11/12, Sector E, Sanwer Road, Indore - 452015 (M.P.)

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED** (hereinafter called the company). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/ statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, the company has, during the audit period covering 1st April, 2018 to 31st March, 2019, complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by **BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED** for the financial year ended on 31st March, 2019 according to the provisions of:

- (i) The Companies Act, 2013 (the Act) and the rules made there under;
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under;
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;
- (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings; (not applicable to the company during the audit period)
- (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-
 - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations,
 - (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;
 - (d) The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014; *(not applicable to the company during the audit period);*
 - (e) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; *(not applicable to the company during the audit period);*
 - (f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
 - (g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; *(not applicable to the company during the audit period);*
 - (h) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018 (not applicable to the company during the audit period)
 - (i) The Securities and Exchange Board of India (Listing Obligations and Disclosure requirements) Regulations, 2015 as amended from time to time.
- (vi) I have relied on the representation made by the Company and its officers for systems and mechanism formed by the Company for compliances under other applicable Acts, laws and Regulations to the Company on test check basis. The laws, regulations, directions, orders applicable specifically to the Company are as follows:
 - 1. Drugs and Cosmetics Act, 1940
 - 2. The Pharmacy Act, 1948
 - 3. Drugs (Pricing Control) Order, 2013





CIN: L24233MP1985PLC002709

I have also examined compliance with the applicable clauses of Secretarial Standards on Meeting of Board of Directors(SS-1) and Secretarial Standards on General Meetings(SS-2) issued by The Institute of Company Secretaries of India.

I further report that I have not reviewed the applicable financial laws (direct and indirect tax laws), Accounting standard, since the same have been subject to review and audit by the Statutory Auditors of the Company.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above *subject to following observations:*

- 1. As on 31st March, 2019, 2262500 Equity Shares held by Promoter & Promoter Group were not in Demat Mode
- 2. SEBI had condoned the delay w.r.t Compliance with Req. 77(1) of SEBI (ICDR) Regulations, 2009.
- 3. Company had reissued 5712500 forfeited equity shares in year 2011 but still listing and trading approval were pending from stock exchanges till 31st March, 2019.

I further report that

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. During the year under review there were no changes in the composition of Board of Directors.

Adequate notice is given to all the directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All decisions at Board Meetings and Committee Meetings are carried out unanimously as recorded in the minutes of the meetings of the Board of Directors or Committee of the Board, as the case may be.

I further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

I further report that during the audit period, the company has not undertaken event/action having a major bearing in the company's affair in pursuance of the above referred laws, rules, regulations, guidelines, standards, etc. referred above.

For L.N. Joshi & Company Company Secretaries

Place : Indore

Dated: 13th August, 2019

L.N. Joshi Proprietor FCS: 5201; C P No 4216

Note: This report is to be read with our letter of even date which is annexed as Annexure herewith and forms and integral part of this report.





CIN: L24233MP1985PLC002709

ANNEXURE TO SECRETARIAL AUDIT REPORT

To.

The Members,

BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

Registered Office:

11/12, Sector E, Sanwer Road, Indore - 452015 (M.P.)

My report of even date is to be read along with this letter.

- 1. Maintenance of secretarial record is the responsibility of the management of the Company. My responsibility is to express an opinion on these secretarial records based on my audit.
- I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in Secretarial records. I believe that the processes and practices, I followed provide a reasonable basis for my opinion.
- 3. I have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
- 4. Where ever required, I have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
- 5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. My examination was limited to the verification of procedures on test basis.
- 6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For L.N. Joshi & Company Company Secretaries

Place : Indore

Dated: 13th August, 2019

L.N. Joshi Proprietor FCS: 5201; C P No 4216



CIN: L24233MP1985PLC002709

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

INDUSTRY STRUCTURE AND DEVELOPMENT

India is the largest provider of generic drugs globally. Indian pharmaceutical sector industry supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 per cent of all medicine in UK. India enjoys an important position in the global pharmaceutical sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Presently over 80 per cent of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) are supplied by Indian pharmaceutical firms.

India's pharmaceutical exports stood at US\$ 17.27 billion in FY18 and have reached US\$ 19.14 billion in FY19. Indian pharmaceuticals market will grow to USD 55 billion by 2020 driven by a steady increase in affordability and a step jump in market access. At the projected scale, this market will be comparable to all developed markets other than the US, Japan and China. Even more impressive will be its level of penetration. In terms of volumes, India will be at the top, a close second only to the US market. This combination of value and volume provides interesting opportunities for upgrading therapy and treatment levels. Pricing controls and an economic slowdown can wean away investments and significantly depress the market, allowing it to reach only USD 35 billion by 2020. On the other hand, the market has the potential to reach USD 70 billion provided industry puts in super normal efforts behind the five emerging opportunities, and enhances access and acceptability in general.

OPPORTUNITIES AND THREATS

The affordability of drugs will rise due to sustained growth in incomes and increases in insurance coverage. With real GDP growing at nearly 8 per cent over the next decade, income levels will rise steadily. Rising incomes will drive 73 million households into the middle and upper income segments. In addition to income growth, health insurance coverage will augment affordability.

The Government of India unveiled 'Pharma Vision 2020' aimed at making India a global leader in end-to-end drug manufacture. Approval time for new facilities has been reduced to boost investments. The Indian government has taken many steps to reduce costs and bring down healthcare expenses. Speedy introduction of generic drugs into the market has remained in focus and is expected to benefit the Indian pharmaceutical companies.

Your Company is major producer and trader of Ferrous Sulphate and Calcium which are the main supplements of Folic (IP) Tablets.

In addition, the thrust on rural health programmes, lifesaving drugs and preventive vaccines also augurs well for the pharmaceutical companies

Medicine spending in India is projected to grow 9-12 per cent over the next five years, leading India to become one of the top 10 countries in terms of medicine spending

Despite of the nation enjoys an important position in the global pharma sector and the future of Indian pharma industry is quite bright, but there are a few dark clouds on the horizon as well.

- Indian pharma companies are not getting proper profits, their earnings are basically very low as compared to their counterparts in other countries such as the US. Their income is not sufficient enough to invest money on research component.
- The pharma industry is dependent on China for the supply of raw material for generic medicines production.
- India needs user friendly government policy for the common man to establish small scale, raw material manufacturing units/incubators in all states of the country to improve availability of raw materials to manufacture generic drugs at affordable rates
- The government and industry should facilitate the pharmacist community to become entrepreneurs and promote incubators' establishment.
- Raw material produced from small scale units should be properly validated in the testing laboratory of the state to ascertain their quality specifications.
- There is a need for a functional testing laboratory in every state to fasten the work of specification of raw materials.
- Small scale produces may be re-processed in another industry or via a chain of industry for quality products that can be used for parenteral/tailor-made formulations.
- · Skilled manpower from academic institutions can be achieved through continuing education programmes.
- High Economic growth along with increase penetration of health insurance to push expenditure on healthcare and medicine in India.

SEGMENT WISE PERFORMANCE

Your Company is multi segment Company as it deals in Pharmaceuticals and Chemicals products. During the year under review the performances in terms of revenue of the segments were as follows:-

Pharma Unit : In the financial year 2017-18 revenue generated from Pharma Unit was Rs. 1053.13 Lacs and in the year 2018-19 the same unit generated revenue of Rs. 2110.13 Lacs.

Chemicals Unit: In the financial year 2017-18 revenue generated from Chemical Division was Rs 180.02 Lacs and in the year 2018-19 the same unit generated revenue of Rs 202.73 Lacs.

Plastic Unit: During the year, no work was carried out in the plastic unit.

OUTLOOK



CIN: L24233MP1985PLC002709

The Indian pharmaceuticals market has characteristics that make it unique. First, branded generics dominate, making up for 70 to 80 per cent of the retail market. Second, local players have enjoyed a dominant position driven by formulation development capabilities and early investments. Third, price levels are low, driven by intense competition. While India ranks tenth globally in terms of value, it is ranked third in volumes. These characteristics present their own opportunities and challenges.

RISKS AND CONCERN

The pharmaceutical industry continues to thrive, yet there are several challenges that may affect the industry's future growth in 2019 and beyond. Drug prices are at an all-time high, R&D productivity has only just begun to climb again following a shortening in 2016/2017 and the pharmaceutical landscape is constantly changing with the rapid growth of biosimilars and disruptions of health technology. Further The Indian pharma industry faces lack of research components and real time good manufacturing practices. This has always been a difficulty for the pharma industry. Pharma companies should built in such a way that they are equipped with better operational facilities and abilities

India needs user friendly government policy for the common man to establish small scale, raw material manufacturing units/ incubators in all states of the country to improve availability of raw materials to manufacture generic drugs at affordable rates. Adoption of user-friendly policies will help establish small scale industry and encourage students and middle class business owners with ambitions in this line. This will also help overcome the problem of unemployment for pharmacists and promote entrepreneurship in the nation.

INTERNAL CONTROL SYSTEM

The Company has a reasonable system of internal control comprising authority levels and powers, supervision, checks and balances, policies and procedures so as to ensure orderly and efficient conduct of business, safeguard the assets of the business, prevent and detect fraud, ensure the completeness and accuracy of accounting records, to ensure the timely preparation of financial information. Further, the system is reviewed and updated on an on-going basis on recommendations as and when made by the Statutory Auditors, Internal Auditors and Independent Audit Committee of the Board of Directors.

FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE

During the financial year your company has achieved the turnover of Rs. 2322.98 Lacs in comparison to previous year's turnover of Rs.1246.07 lacs and net profit of the company is Rs. 48.23 lacs in comparison to previous net profit of Rs. 47.07 lacs.

HUMAN RESOURCES

At Biofil we believe that "company grows when its people grow" and hence we continuously strives to emphasize creation of a conducive work environment and development of a robust and consistent approach towards talent management & leadership development. As on 31st March, 2019, Company had 39 employees.

DETAILS OF SIGNIFICANT CHANGES IN THE KEY RATIOS

As per the amendment made under Schedule V to the Listing Regulations read with Regulation 34(3) of the Listing Regulations, details key financial ratios and any changes in return on net worth of the Company are given below:

Particulars	2018-19	2017-18	Change
Debtors' turnover	1.85	1.01	82.93
Inventory turnover	1.13	0.76	48.83
Interest coverage ratio	4.70	4.86	-3.17
Current ratio	1.32	1.36	-2.89
Debt-Equity ratio	0.65	0.68	-3.86
Operating profit margin (%)	0.02	0.03	-46.23
Net profit margin (%) or sector-specific equivalent ratio as applicable	0.02	0.04	-45.24

Reason for change of 25% or more in Financial Ratios:

Debtor's turnover: Due to increase in credit sales by the company

Inventory turnover: This High inventory turnover ratio implies strong sales and ineffective buying (the company buys too often in small quantities; therefore the buying price is higher)

Operating profit margin: Due to rapid increase in sale but the increasing rate of profit is much smaller than sale; therefore, operating profit is negative

Net Profit Margin: Due to rapid increase in sale but the increasing rate of profit is much smaller than sale; hence, net profit is negative.

DETAILS OF CHANGE IN RETURN ON NET WORTH AS COMPARED TO THE IMMEDIATELY PREVIOUS FINANCIAL YEAR

There was a change of 11.34% in Return on Networth due to increase in Profit after tax and decrease in Net Worh of the Company

CAVEAT:

Some of the Statements in Management Discussion and Analysis describing company's objective may be "forward looking statement" within the meaning of applicable Securities Law and Regulations. Actual results may differ substantially or materially from those expressed or implied. Important factors that could influence companies operation include various global and domestic economic factors.



CIN: L24233MP1985PLC002709

REPORT ON CORPORATE GOVERNANCE

The Directors present the Report on compliance with the Corporate Governance provisions as prescribed under Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") for the year ended March 31, 2019 is given below:

I. COMPANY'S PHILOSOPHY ON CODE OF GOVERNANCE

Corporate Governance is the combination of voluntary practices and compliance with laws and regulations leading to effective control and management of the organization. Good corporate governance leads to long term shareholders value and enhances interest of all stakeholders. It brings into focus the fiduciary and trusteeship role of the Board of align and direct the actions of the organization towards creating wealth and shareholder value.

The company's essential character is shaped by the value of transparency, customer satisfaction, integrity, professionalism and accountability. The Company continuously endeavors to improve on these aspects. The Board views corporate governance in its widest sense. The main objective is to create and adhere to corporate culture of integrity and consciousness, transparency and openness. Corporate governance is a journey for constantly improving sustainable value creation and is an upward moving target. The Company's philosophy on corporate governance is guided by the company's philosophy of knowledge, action and care. The Company has complied with all the requirements of listing regulation and listed below is the status with regard to same.

II. BOARD OF DIRECTORS

- (i) The Company is fully compliant with the Corporate Governance norms in the terms of constitution of the Board of Directors ("the Board"). As on March 31, 2019 the Company had four directors. The Composition of the Board is in conformity with Regulation 17 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Section 149 of the Companies Act, 2013.
- (ii) Independent Directors are non-executive directors as defined under Regulation 16(1)(b) of the SEBI Listing Regulations read with Section 149(6) of the Companies Act, 2013. The maximum tenure of independent directors is in compliance with the Companies Act, 2013. All the Independent Directors have confirmed that they meet the criteria as mentioned under Regulation 16(1)(b) of the SEBI Listing Regulations read with Section 149(6) of the Companies Act, 2013.
- (iii) The Board of your Company comprises of Four Directors as on 31st March, 2019. The names and categories of Directors, the number of Directorships and Committee positions held by them in the companies are given below. None of the Director is a Director in more than 10 public limited companies (as specified in Section 165 of the Companies Act 2013) or acts as an Independent Director in more than 7 listed companies or 3 listed companies in case he/she serves as a Whole-time Director in any listed company (as specified in Regulation 25 of the Listing Regulations). Further, none of the Directors on the Board is a Member of more than 10 Committees and Chairman of more than 5 Committees (as specified in Regulation 26 of the Listing Regulations), across all the Indian public limited companies in which he/she is a Director.

A. Composition and Categories of Board

Name of Director	Category	No. of Directorship including Biofil Chemicals and Pharmaceuticals Limited		including Biofil Chemicals and Pharmaceuticals Membership includes Biofil Chemicals		ip including nicals and
		Chairperson	Member	Chairperson	Member	
Shri Ramesh Shah (DIN: 00028819)	Promoter & Managing Director	-	1	-	-	
Shri Romil Shah (DIN: 00326110)	Promoter & Non Executive Director	-	1	-	2	
Smt. Shaila Jain (DIN: 00326130)	Independent / Non Executive Director	-	1	2	2	
Shri Subhash Chandra Swarnkar (DIN: 01658151)	Independent/Non Executive Director	-	1	-	2	

- Directorship excludes Private Limited Companies, Foreign Companies and Companies registered under section 8 of the Companies Act 2013.
- Committee considered as Audit Committee and Stakeholders Relationship Committee, including that of your Company. Committee membership(s) and Chairmanship(s) are counted separately.

B. The names of other listed entities where the Directors have Directorship and their category of directorship in such listed entities:

Name of Directors & DIN	Name of Listed Entities	Category of Directorship
Shri Ramesh Shah (DIN : 00028819)	Nil	N.A.
Shri Romil Shah (DIN : 00326110)	Nil	N.A.
Smt. Shaila Jain (DIN: 00326130)	Nil	N.A.
Shri Subhash Chandra Swarnkar (DIN: 01658151)	Nil	N.A.



CIN: L24233MP1985PLC002709

C. Attendance of Directors at the Board Meetings held during 2018-19 and the last Annual General Meeting held on 27th September 2018.

During the financial year 2018-19 four Board Meetings were held. The Board met at least once in every calendar quarter and gap between two meetings did not exceed 120 days. The date on which the Board Meetings were held are given below:

May 30th 2018, August 13th 2018, November 14th 2018 & February 13th 2019.

Name of Director	Category	Meeting held during the tenure of the Director	No. of Board Meetings Attended	Attendance at the last AGM held on 27/09/2018
Shri Ramesh Shah (DIN: 00028819)	Promoter & Managing Director	4	4	Yes
Shri Romil Shah (DIN: 00326110)	Promoter & Non Executive Director	4	4	Yes
Smt. Shaila Jain (DIN: 00326130)	Independent / Non Executive Director	4	4	Yes
Shri Subhash Chandra Swarnkar (DIN: 01658151)	Independent / Non Executive Director	4	4	Yes

D. Board procedure

A detailed Agenda, setting out the business to be transacted at the Meeting(s), supported by detailed notes is sent to each Director at least seven days before the date of the Board Meeting(s) and of the Committee Meeting(s).

The Board also, inter alia, periodically reviews strategy and business plans, annual operating and capital expenditure budget(s), investment and exposure limit(s), compliance report(s) of all laws applicable to your Company, as well as steps taken by your Company to rectify instances of non compliances, review of major legal issues, minutes of the Committees of the Board, approval of quarterly/half-yearly/annual results, transactions pertaining to purchase/disposal of property(ies), major accounting provisions and write-offs, material default in financial obligations, if any and information on recruitment of Senior Officers just below the Board level etc.

The Board sets annual performance objectives, oversees the actions and results of the management, evaluates its own performance, performance of its Committees and individual Directors on an annual basis and monitors the effectiveness of the Company's governance practices for enhancing the stakeholders' value.

Apart from Board members and the Company Secretary, the Board and Committee Meetings are generally also attended by the Chief Financial Officer and wherever required the Heads of various corporate functions.

E. CONFIRMATION OF INDEPENDENT DIRECTORS

The Company has received disclosures from all independent directors that they fulfilled Conditioned specified in Section 149(6) of the Companies Act, 2013 and Regulation 16(1)(b) of the Listing Regulations and were independent of the management. After undertaking a due assessment of their disclosures, in the opinion of the Board of Directors, all the independent directors fulfilled the requirements of the Companies Act, 2013 and the Listing Regulations and were independent of the management of the Company.

III. RELATIONSHIP BETWEEN DIRECTORS

Shri Romil Shah is Brother's Son of Shri Ramesh Shah. Except for this there is no inter-se relationship among the directors.

IV. NUMBER OF SHARES AND CONVERTIBLE INSTRUMENTS HELD BY NON- EXECUTIVE DIRECTORS AS ON 31ST MARCH, 2019:

S. No.	Name of the Director	Designation	No. of Shares	Convertible Instruments
01	Shri Romil Shah (DIN : 00326110)	Non Executive Director	382550	Nil
02	Smt. Shaila Jain (DIN : 00326130)	Independent Director	Nil	Nil
03	Shri Subhash Chandra Swarnkar (DIN: 01658151)	Independent Director	Nil	Nil

The Company had not issued any Convertible instrument till date.

V. THE DETAILS OF FAMILIARISATION PROGRAMMES IMPARTED TO INDEPENDENT DIRECTORS:

Your Company has in place Familiarization Programs for Independent Directors of the Company to provide insights into the Company's Business to enable them contribute significantly to its success. The Senior Management makes presentations periodically to familiarize the Independent Directors with the strategy operations and functions of the Company. The details of the familiarization program of the independent directors are available on the website of the Company at the web link: http://www.biofilgroup.net/Appointment%20letter%20Independent%20Director/Familiarization%20programme%20to%20Independent%20Directors.pdf



CIN: L24233MP1985PLC002709

VI. MATRIX OF SKILL/EXPERTISE/COMPETENCIES OF THE BOARD OF DIRECTORS:

In terms of the requirements of the SEBI Listing Regulations, the Board has identified and approved the list of core skills/expertise/competencies as required in the context of Company's business(es) and sector(s) for it to function effectively. Broadly, the essential skills identified by the Board are categorised as under:

- Strategy & Planning
- Governance, Legal, Risk & Compliance
- Finance, Accounts & Audit
- Global Experience / International Exposure
- Contributor & collaborator
- Information Technology
- Client Engagement
- Stakeholder Engagement & Industry Advocacy
- Leadership

These skills/competencies are broad-based, encompassing several areas of expertise/experience. Each Director may possess varied combinations of skills/experience within the described set of parameters, and it is not necessary that all Directors possess all skills/experience listed therein.

VII. INDEPENDENT DIRECTORS MEETING

Pursuant to the Regulation 25(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Schedule IV of the Companies Act, 2013, the Independent Directors of the Company shall hold at least one meeting in a year without attendance of non-independent directors and members of the Management. Accordingly, meeting of the Independent Directors of the Company was held on 30th March 2019 to consider the following business as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Companies Act, 2013:-

- (a) Review the performance of Non-Independent Directors and the Board of Directors as a whole;
- (b) Review the performance of the Chairman of the Company, taking into account the views of executive directors and non-executive directors and;
- (c) Assess the quality, quantity and timelines of flow of information between the company management and the Board of Directors that is necessary for the Board of Directors to effectively and reasonably perform their duties. Attendance of Independent Directors in Independent Directors meeting

Directors	Meetings held during the Year	Meetings Attended
Smt. Shaila Jain (DIN: 00326130)	1	1
Shri Subhash Chandra Swarnkar (DIN: 01658151)	1	1

VIII. AUDIT COMMITTEE

Pursuant to the Companies Act, 2013 and Listing Regulations, the Company has an Independent Audit Committee. The Composition, Procedure, Role/Function of the committee complies with the requirements of the Companies Act, 2013 as well as those of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Audit Committee reviews all applicable mandatory information under Part C of Schedule II pursuant to Regulation 18 of SEBI (LODR) Regulations, 2015. The brief terms of reference of the Audit Committee includes the following:-

- (1) Oversight of the company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
- (2) Recommendation for appointment, remuneration and terms of appointment of Auditors of the Company;
- (3) Approval of payment to Statutory Auditors for any other services rendered by the Statutory Auditors;
- (4) Reviewing, with the management, the annual financial statements and auditor's report thereon before submission to the board for approval, with particular reference to:
 - matters required to be included in the director's responsibility statement to be included in the Board's Report in terms of clause (c) of sub-section (3) of Section 134 of the Companies Act, 2013;
 - changes, if any, in accounting policies and practices and reasons for the same;
 - major accounting entries involving estimates based on the exercise of judgment by management;
 - significant adjustments made in the financial statements arising out of audit findings;
 - compliance with listing and other legal requirements relating to financial statements;
 - disclosure of any related party transactions;
 - modified opinion(s) in the draft audit report;
- (5) Reviewing, with the management, the guarterly financial statements before submission to the Board for approval;
- (6 Reviewing and monitoring the auditor's independence and performance, and effectiveness of audit process;
- (7) Approval or any subsequent modification of transactions of the company with related parties;



CIN: L24233MP1985PLC002709

- (8) Scrutiny of inter-corporate loans and investments;
- (9) Valuation of undertakings or assets of the company, wherever it is necessary;
- (10) Evaluation of internal financial controls and risk management systems;
- (11) Reviewing, with the management, performance of statutory and internal auditors, adequacy of the internal control systems;
- (12) Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;
- (13) Discussion with internal auditors of any significant findings and follow up there on;
- (14) Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board;
- (15) Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as postaudit discussion to ascertain any area of concern:
- (16) To look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors;
- (17) To review the functioning of the whistle blower mechanism;
- (18) Approval of appointment of Chief Financial Officer after assessing the qualifications, experience and background, etc. of the candidate;
- (19) Carrying out any other function as is mentioned in the terms of reference of the audit committee.

The Audit Committee mandatorily reviews the following information:

- (1) Management Discussion and Analysis of financial condition and results of operations;
- (2) Statement of significant related party transactions (as defined by the audit committee), submitted by management;
- (3) Management letters/letters of internal control weaknesses issued by the statutory auditors;
- (4) Internal audit reports relating to internal control weaknesses; and
- (5) The appointment, removal and terms of remuneration of the chief internal auditor shall be subject to review by the audit committee.
- (6) Statement of deviations:
 - (a) quarterly statement of deviation(s) including report of monitoring agency, if applicable, submitted to stock exchange(s) in terms of Regulation 32(1) of the Listing Regulations.
 - (b) annual statement of funds utilized for purposes other than those stated in the offer document/prospectus/ notice in terms of Regulation 32(7) of the Listing Regulations.

Composition and Attendance of Members at the Meetings of the Audit Committee held during 2018-19

During the year the committee met on four occasions during the year on following dates namely:-

May 30th 2018, August 13th 2018, November 14th 2018 & February 13th 2019.

Members	Category	Meetings held during the year	Meetings Attended
Shri Romil Shah (DIN : 00326110)	Non Executive Director	4	4
Smt. Shaila Jain (DIN: 00326130)	Independent/Non Executive Director	4	4
Shri Subhash Chandra Swarnkar (DIN: 01658151)	Independent/Non Executive Director	4	4

All the members of the committee are financial literate and possess accounting and related financial management expertise. The Chairperson of the Audit Committee Smt. Shaila Jain Non executive Independent Director was present at 33rd Annual General Meeting held on 27th September, 2018 to address the shareholder's queries pertaining to Annual Accounts of the Company.

IX. NOMINATION AND REMUNERATION COMMITTEE

Pursuant to the Companies Act, 2013 and SEBI Listing Regulations, the Company has a Nomination and Remuneration Committee. The Composition, Procedure, Role/Function of the committee complies with the requirements of the Companies Act, 2013 as well as SEBI Listing Regulations are given below:

1. Brief Terms of reference:

- Formulation of the criteria for determining qualifications, positive attributes and independence of a director
 and recommend to the board of directors a policy relating to, the remuneration of the directors, key
 managerial personnel and other employees;
- Formulation of criteria for evaluation of performance of independent directors and the board of directors;
- Devising a policy on diversity of Board of Directors;



CIN: L24233MP1985PLC002709

- Identifying persons who are qualified to become directors and who may be appointed in senior management
 in accordance with the criteria laid down, and recommend to the board of directors their appointment and
 removal.
- Whether to extend or continue the term of appointment of the independent director, on the basis of the report
 of performance evaluation of independent directors.
- Recommend to the board, all remuneration, in whatever form, payable to senior management.

2. Composition and Attendance of Members at the Meeting of the Nomination and Remuneration Committee held during 2018-19.

During the year the committee met on 13th August, 2018

Members	Category	Meetings held during the year	Meetings Attended
Shri Romil Shah (DIN: 00326110)	Non Executive Director	1	1
Smt. Shaila Jain (DIN: 00326130)	Independent/Non Executive Director	1	1
Shri Subhash Chandra Swarnkar (DIN: 01658151)	Independent/Non Executive Director	1	1

As per Section 178(7) of the Act and Secretarial Standards, the Chairperson of the Committee or, in her absence, any other Member of the Committee authorised by her in this behalf shall attend the General Meetings of the Company. The Chairperson of the Committee, Smt. Shaila Jain Non executive Independent Director was present at the 33rd Annual General Meeting of the Company held on 27th September, 2018 to answer members' queries.

3. PERFORMANCE EVALUATION CRITERIA OF INDEPENDENT DIRECTORS:

The performance evaluation criterion for independent directors is determined by the Nomination and Remuneration committee. An indicative list of factors that may be evaluated include participation and contribution by a director, commitment, effective deployment of knowledge and expertise, effective management of relationship with stakeholders, integrity and maintenance of confidentiality and independence of behaviour and judgement.

The evaluation of independent directors is done by the entire board of directors which includes -

- (a) Performance of the directors; and
- (b) Fulfilment of the independence criteria as specified in these regulations and their independence from the management:

Provided that in the above evaluation, the directors who are subject to evaluation do not participate.

4. Nomination and Remuneration Policy:

In accordance with Section 178 of the Act, the Committee has framed a Nomination and Remuneration Policy and the same is available at the web-link: http://biofilgroup.net/Policies/Policy%20for%20the%20% 20Nomination% 20&%20Remuneration.pdf

5. Remuneration Paid to Directors during 2018-19

- None of the director is drawing any remuneration from the company.
- No sitting Fees was paid to any Director of the Company during the financial year
- The company has not provided any bonuses/stock options/pension etc. to its directors.
- Details of fixed component and performance linked incentives along with the performance criteria- Nil.
- The Company does not have service contract with any of its directors. Notice period of minimum 30 days has been fixed for directors. Further, the Company does not pay any severance fee.

X. STAKEHOLDERS RELATIONSHIP COMMITTEE

The Stakeholder's Relationship Committee looks into grievances of shareholders regarding transfer of Equity Shares/transmission of Equity Shares and other allied connected matters and redresses them expeditiously in accordance with Section 178 of the Companies Act, 2013 and Regulation 20 of SEBI (LODR) Regulations, 2015.

1. The role of the committee shall inter-alia include the following:-

- Resolving the grievances of the security holders of the listed entity including complaints related to transfer/ transmission of shares, non-receipt of annual report, non-receipt of declared dividends, issue of new/duplicate certificates, general meetings etc.
- Review of measures taken for effective exercise of voting rights by shareholders.
- Review of adherence to the service standards adopted by the listed entity in respect of various services being rendered by the Registrar & Share Transfer Agent.
- Review of the various measures and initiatives taken by the listed entity for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/annual reports/statutory notices by the shareholders of the company.



CIN: L24233MP1985PLC002709

Composition and Attendance of Members at the Meetings of the Stakeholders Relationship Committee held during 2018-19.

During the year the committee met on five occasions on following dates namely:-

May 30th 2018, August 13th 2018, November 14th 2018, December 05th 2018 & February 13th 2019.

Members	Category	Meetings held during the year	Meetings Attended
Shri Romil Shah (DIN: 00326110)	Non Executive Director	5	5
Smt. Shaila Jain (DIN: 00326130)	Independent/Non Executive Director	5	5
Shri Subhash Chandra Swarnkar (DIN : 01658151)	Independent/Non Executive Director	5	5

As per Section 178(7) of the Act and Secretarial Standards, the Chairperson of the Committee or, in her absence, any other Member of the Committee authorised by her in this behalf shall attend the General Meetings of the Company. The Chairperson of the Committee, Smt. Shaila Jain Non executive Independent Director was present at the 33rd Annual General Meeting of the Company held on 27th September, 2018.

3. Name, designation and address of Compliance Officer:-

Ms. Shikha Khilwani,

Company Secretary and Compliance Officer

11/12, Sector "E" Sanwer Road, Indore - 452015 (M.P.)

Email: bcplcompliance@gmail.com Telephone : 0731 - 2723016 / 17

4. Status Report of investor queries and complaints for the period from April 1, 2018 to March 31, 2019 is given below:-

S.No.	Particulars	No. of Complaints
01	Investor complaints pending at the beginning of the year	Nil
02	Investor complaints received during the year	9
03	Investor complaints disposed of during the year	9
04	Investor complaints remaining unresolved at the end of the year	Nil

XI. RISK MANAGEMENT

The Company is not required to constitute risk management committee. However the company has a well defined risk management framework in place. The risk management framework at various levels across the Company

XII. GENERAL BODY MEETINGS

(i) Location and time of last Three AGM's held:

Financial Year.	Location	Date	Time
33rd Annual General Meeting 2017-18	At Regd. Office of the Company at 11/12, Sector "E", Sanwer Road, Indore - 452015 (M.P.)	27/09/2018	03.00 P.M.
32nd Annual General Meeting 2016-17	At Regd. Office of the Company at 11/12, Sector "E", Sanwer Road, Indore - 452015 (M.P.)	25/09/2017	03.00 P.M.
31st Annual General Meeting 2015-16	At Regd. Office of the Company at 11/12, Sector "E", Sanwer Road, Indore - 452015 (M.P.)	28/09/2016	02.00 P.M.

(ii) Special resolutions were passed in last three Annual General Meetings

Following special resolutions were passed in last three Annual General Meetings:-

- Re-appointment of Shri Ramesh Shah (DIN:00028819) as Managing Director of the Company in Annual General Meeting held on 27.09.2018.
- Re-appointment of Smt. Shaila Jain (DIN:00326130) as Independent Director of the Company in Annual General Meeting held on 27.09.2018.

(iii) Special Resolution(s) passed through Postal Ballot:

No resolutions were passed by postal ballot in last three years.

None of the Businesses proposed to be transacted in the ensuing Annual General Meeting require passing of a resolution through Postal Ballot.

(iv) Extra-ordinary General Meeting

During the Financial Year 2018-19, no Extra-ordinary General Meeting was held.



CIN: L24233MP1985PLC002709

XIII. CODE FOR PREVENTION OF INSIDER TRADING PRACTICES:

On December 31, 2018, Securities and Exchange Board of India amended the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, prescribing various new requirements with effect from April 1, 2019. In line with the amendments, the Company has adopted an amended Code of Conduct to regulate, monitor and report trading by Designated Persons and their Immediate Relatives & Connected Persons under the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

This Code of Conduct also includes code of practices and procedures for fair disclosure of unpublished price sensitive information which has been made available on the Company's website at http://www.biofilgroup.net/Policies/Code%20for%20fair%20disclosure%20and%20prevention%20of%20insider%20trading%2015%20May%202015.pdf

XIV. MANAGEMENT DISCUSSION AND ANALYSIS:

The Management Discussion and Analysis is a part of the Annual report and annexed separately.

XV. DISCLOSURE REGARDING RE-APPOINTMENT OF DIRECTORS:

Brief resume(s) of the Directors proposed to be appointed / re-appointed are given in the Notice convening the Annual General Meeting in separate annexure.

XVI. MEANS OF COMMUNICATIONS:

Your Company, from time to time and as may be required, communicates with its security-holders and investors through multiple channels of communications such as dissemination of information on the website of the Stock Exchanges, Press Releases, the Annual Reports and uploading relevant information on its website:-http://www.biofilgroup.net.

The quarterly, half-yearly and annual financial results are published in widely circulated newspapers such as **Free Press (English), Indore, The Free Press Journal (English), Mumbai & Choutha Sansar (Hindi), Indore** in compliance with Regulation 47 of the Listing Regulations. These are not sent individually to the shareholders.

Your Company discloses to the Stock Exchanges, all information required to be disclosed under Regulation 30 read with Part 'A' and Part 'B' of Schedule III of the Listing Regulations including material information having a bearing on the performance/operations of the Company and other price sensitive information. All information is filed electronically on BSE's online portal - BSE Corporate Compliance & Listing Centre (Listing Centre) as well as on NSE's online portal NSE Electronic Application Processing System (NEAPS).

The Company's website: www.biofilgroup.net contains a separate dedicated section "Investors Relations" where information for shareholders is available. The Quarterly/Annual Financial Results, annual reports, analysts presentations, investor forms, stock exchange information, shareholding pattern, corporate benefits, polices, investors' contact details, etc., are posted on the website in addition to the information stipulated under Regulation 46 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The presentation, if any made to the investor/analyst are placed to the company's website.

XVII. GENERAL SHAREHOLDER INFORMATION

AGM : Date, Time and Venue	Thursday, 26th September 2019 at 3.00 P.M.	
	Venue of the meeting: 11/12, Sector "E", Sanwer Road,	
	Indore - 452015 (M.P.)	
	Last date for receipt of proxy forms: 24th September, 2019	
Financial Year	The financial year covers the period from 1st April, to 31st March	
Financial year reporting for 2019-20 :		
1st Quarter ending 30th June, 2019	Second fortnight of August, 2019	
2nd Quarter ending 30th September, 2019	Second fortnight of November, 2019	
3rd Quarter ending 31st December 2019	Second fortnight of February , 2020	
4th Quarter ending 31st March, 2020	Before 30th May, 2020	
Dividend Payment Date	No Dividend recommended by Board of Directors of the Company.	
Date of Annual Book Closure	Friday 20th September 2019 to Thursday 26th September 2019	
(Both days inclusive)	[Both days inclusive]	
Registered Office	11/12, Sector "E", Sanwer Road, Indore M.P. 452015	
Listing on Stock Exchanges	The Bombay Stock Exchange Limited	
	25th Floor, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001	
	The National Stock Exchange of India Limited	
	Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai	
Listing Fees	Annual Listing Fees for the year 2019-20 have been paid to Bombay	
	Stock Exchange Ltd. & National Stock Exchange of India Limited	
BSE Security Code -	Bombay Stock Exchange Limited (524396)	
NSE Security Code	National Stock Exchange of India Limited (BIOFILCHEM)	
ISIN Code- INE829A01014		
CIN-	L24233MP1985PLC002709	



CIN: L24233MP1985PLC002709

Market Price Data: High/Low/Close During	As per attached Table-1
each month in the last Financial Year.	
Relative Performance of Share Price V/S. BSE Sensex and NSE Index	As per attached Table-2
Suspension of Securities	N.A.
Registrar and Transfer Agents (For Physical & Demat Shares)	Ankit Consultancy Pvt. Ltd. SEBI REG. No. INR 000000767 60, Electronic Complex, Pardeshipura, Indore - 452010 (M.P.) Tel.: 0731-2551745, 2551746 • Fax: 0731-4065798 Email: ankit_4321@yahoo.com / Web Address: www.ankitonline.com
Share Transfer System	All the share transfer received are processed by the Registrar and transfer Agent
Distribution of shareholding as on 31.03.2019	As per attached Table-3
Dematerialization of Shares & liquidity	12676890 Shares are Dematerialized as on 31.03.2019 i.e. 77.89% of total Shares viz.; 1,62,73,800 equity shares (As on 31.03.2019 out of 77.89% dematerialized shares 21.20% constitute 34,50,000 reissued forfeited shares for which corporate action is pending due to listing confirmation for the same therefore same has not been credited in demate account)
Outstanding GDRs/ADRs/Warrants or any convertible instruments, Conversion date and likely impact on equity	The Company has not issued any GDRs/ADRs/Warrants or any convertible Instruments.
Commodity Price Risk or Foreign Exchange Risk and Hedging activities	Company does not deal in any commodity and hence is not directly exposed to any commodity price risk. Further, the Company has no foreign exchange exposure; hence hedging is not required.
Address for correspondence	Shareholders correspondence should be addressed to: BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED 11/12, Sector E, Sanwer Road, Industrial Area, Indore- 452015 (M.P.) Ph.: 0731-2723016/17, Mob.: +91-8889912313 Email id: bcplcompliance@gmail.com. Website: www.biofilgroup.net
Shareholding Pattern as on 31.03.2019	As per attached Table-4
Plant Locations	The Company's plant are located at :- 1) Plot No. 8 Sector 4 Kheda Industrial Estate, Pithampur (Dist. Dhar) 2) 11/12, Sector E, Sanwer Road, Industrial Area, Indore - 452015 (M.P.)
List of Credit Ratings	During the year under review your Company has not obtained any Credit Rating as the same was not applicable to the company

XVIII. DISCLOSURES:

(i) Materially Significant Related Party Transactions:

There are material related party transactions of the Company which does not have potential conflict with the interest of the Company at large. The details of related party transactions are reported in Notes to the financial statement.

Your Company has formulated a Policy on Materiality of and Dealing with Related Party Transactions which specify the manner of entering into related party transactions. This Policy has also been posted on the website of the Company and can be accessed through web link: http://www.biofilgroup.net/Policies/Policy%20for%20Related%20party%20transaction.pdf

(ii) During the last three years, there were no strictures and penalties imposed on the Company by Stock Exchange or SEBI, or any statutory authority, on any matter related to capital markets.

(iii) Vigil Mechanism/ Whistle Blower Policy

In accordance with Regulations 22 of SEBI (LODR) Regulations, 2015, Company has formulated a Whistle Blower Policy and has established a Vigil Mechanism for directors and employees to report concerns about unethical behavior, actual or suspected fraud and any wrong doing or unethical or improper practice. The Company affirms that no personnel have been denied access to the Audit Committee under Vigil Mechanism. Details of Whistle Blower Policy are provided in the Board's Report section of this Annual Report and also made available on the Company's website at web link: http://www.biofilgroup.net/Policies/Vigil%20Mechanism%20Policy%20BCPL.pdf

(iv) Commodity Price Risk or Foreign Exchange Risk and Hedging activities

Your Company does not deal in any commodity and hence is not directly exposed to any commodity price risk.



CIN: L24233MP1985PLC002709

Further, the Company has no foreign exchange exposure; hence hedging is not required.

- (v) Company had not raised funds through preferential allotment or qualified institutions placement as specified under Regulation 32 (7A)
- (vi) Mandatory and Non-mandatory requirements:

The Company has complied with all the mandatory requirements of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and The Company has fulfilled the following non-mandatory requirements as prescribed in Schedule II, PART E of Regulation 27(1) of (Listing Obligations and Disclosure Requirements) Regulations, 2015.

- 1. Chairman is elected in meeting.
- 2. During the year under review, there is no audit qualification in your company's standalone financial statement. Your company continues to adopt best practices to ensure regime of unqualified financial statements.
- 3. Shareholders' Rights: As the quarterly, half yearly, financial performance are published in the newspapers and are also posted on the Company's website, the same are not mailed to the shareholders.
- 4. Reporting of Internal Auditor: In accordance with the provisions of Section 138 of the Companies Act, 2013, the Company has appointed an Internal Auditor who reports to the Audit Committee. Quarterly internal audit reports are submitted to the Audit Committee which reviews the audit reports and suggests necessary action.
- (vii). Your Company has complied with all the applicable requirements of Regulations 17 to 27 and clause (b) to (i) of Regulation 46 (2) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015.

XIX. COMPLIANCE CERTIFICATE BY PRACTICING COMPANY SECRETARY

The Company has obtained a certificate from the Practicing Company Secretary pursuant to the provisions of Regulation 34(3) read with Schedule V Para C Clause (10)(i) of the SEBI (LODR) Regulations which is annexed herewith.

XX. SEXUAL HARASSMENT AT WORKPLACE:

The Company has formulated a Policy for Prevention of Sexual Harassment at Workplace to ensure prevention, prohibition and protection against sexual harassment. The policy provides the guidelines for reporting of such harassment and the procedure for resolution & redressal of the complaints of such nature.

Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:

S.No.	Particulars	No. of Complaints
а	Number of Complaints filed during the financial year.	Nil
b	Number of Complaints disposed during the financial year.	Nil
С	Number of Complaints pending as on end of financial year.	Nil

XXI. FEES PAID TO STATUTORY AUDITOR:

The details of total fees paid by Company to Statutory Auditor on a consolidated basis for all services rendered given below:

Type of Services	For Financial Year Ended 31.03.2019
Audit Fees	30,000
Tax Fees	-
Others	-
Total	30,000

No fee other than Audit fees has been paid to statutory auditor, as the company does not have any subsidiary company nor statutory auditor is part of any entities in the network firm/network entity.


XXII. DISCLOSURE ON ACCEPTANCE OF RECOMMENDATIONS MADE BY BOARD COMMITTEES

During the financial year under review various recommendations were made by the Committees to the Board of Directors, which were all accepted by the Board, after necessary deliberations

XXIII OTHERS INFORMATION:

- Proceeds from public issue, right issue, preferential issue : Not applicable during the period.
- The company has adopted a policy on dissemination of information on the material events to stock exchanges in accordance with the Regulation 30 of the SEBI (LODR) Regulations, 2015. The said policy is available on the website of the company at the weblink: http://www.biofilgroup.net/Policies/Policy%20on%20Disclosure %20of%20Material%20Events%20&%20Information.pdf
- The company has adopted the policy on preservation of documents in accordance with the Regulation 9 of the SEBI (LODR) Regulations, 2015. The documents preservation policy is available on the website of the company at the weblink: http://www.biofilgroup.net/Policies/POLICY%20ON%20PRESERVATION%20OF%20%20DOCUMENTS.pdf

Disclosure with respect to demat suspense account/unclaimed suspense Account.





CIN: L24233MP1985PLC002709

The Company does not have any shares in the demat suspense account/unclaimed suspense account.

Code of Conduct

The Board of Directors has laid down the Code of Conduct for all the Board Members and members of the senior management. The Code is also placed on the Company's website of the company at the weblink: http://www.biofilgroup.net/Policies/Code%20of%20Conduct%20of%20BCPL.pdf

A certificate from the Managing Director, affirming compliance of the said Code by all the Board Members and members of the senior management to whom the Code is applicable, is annexed separately to this report.

Further, the Directors and the Senior Management of the Company has submitted disclosure to the Board that they do not have any material financial and commercial transactions that may have a potential conflict with the interest of the Company at large.

MD & CFO Certification

The Managing Director and the Chief Financial Officer of the Company gives annual certification on financial reporting and internal controls to the Board in terms of Regulation 17(8) read with Schedule II of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Copy of such certificate is enclosed herewith this report. The Managing Director and the Chief Financial Officer also give quarterly certification on financial results to the Board in terms of Regulation 33(2)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Certificate on Corporate Governance

The statutory auditors have certified that the Company has complied with the conditions of Corporate Governance as stipulated in terms of Regulation 34(3) read with Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the same is annexed to this Report.

DECLARATION REGARDING COMPLIANCE BY BOARD MEMBERS AND SENIOR MANAGEMENT PERSONNEL WITH THE COMPANY'S CODE OF CONDUCT

Compliance with the Code of Business Conduct and Ethics

I, Ramesh Shah, Managing Director of Biofil Chemicals & Pharmaceuticals Limited declare that all the Members of the Board of Directors and Senior Management Personnel have affirmed compliance with the Code of Conduct for the year ended 31st March, 2019.

By Order of the Board of Directors
For Biofil Chemicals and Pharmaceuticals Limited.

(Ramesh Shah) Managing Director (DIN: 00028819)

Place : Indore

Date: 13th August 2019





Table 1- Market Price Data:

Bombay Stock Exchange Limited April, 2018 to March, 2019 at BSE

MONITU	(In Rs. Per Share)		
MONTH	High Price	Low Price	
April, 2018	16.00	13.90	
May,2018	15.40	12.35	
June, 2018	14.45	12.90	
July, 2018	14.00	11.75	
August, 2018	12.54	9.98	
September, 2018	10.92	7.75	
October, 2018	9.10	7.00	
November, 2018	9.70	7.40	
December, 2018	7.40	6.15	
January, 2019	7.70	6.80	
February, 2019	7.32	5.75	
March, 2019	7.64	6.00	

National Stock Exchange of India Limited April, 2018 to March, 2019 at NSE

MONTH	(In Rs. Per Share)		
MONTH	High Price	Low Price	
April, 2018	15.80	13.40	
May,2018	15.30	12.75	
June, 2018	14.40	11.35	
July, 2018	12.60	10.45	
August, 2018	11.70	9.60	
September, 2018	10.25	8.20	
October, 2018	8.55	6.40	
November, 2018	9.25	6.65	
December, 2018	7.95	6.60	
January, 2019	7.20	6.30	
February, 2019	6.80	5.75	
March, 2019	7.75	6.40	

• Table 2 - Relative Performance of Share Price V/S. BSE Sensex :







Table 2 - Relative Performance of Share Price V/S. NSE Index / Sensex :



• Table 3- Distribution of shareholding according to size class as on 31st March 2019

Category (Shares)	Share holders	% of Total Share holders	Shares	% of Total Shares
Upto-100	1970	34.56	158830	0.98
101-200	792	13.90	151553	0.93
201-300	620	10.88	181214	1.11
301-400	216	3.79	84072	0.52
401-500	705	12.37	350257	2.15
501-1000	661	11.60	580212	3.57
1001-2000	338	5.95	532215	3.27
2001-3000	131	2.30	332620	2.04
3001-4000	59	1.04	212104	1.30
4001-5000	61	1.07	289283	1.78
5001-10000	68	1.19	496471	3.05
10000 ABOVE	77	1.35	12904969	79.30
Total	5698	100.00%	16273800	100.00%



CIN: L24233MP1985PLC002709

Table 4-: SHAREHOLDING PATTERN AS AT 31ST MARCH 2019

S.No.	Particulars	No. of Shareholders	No. of Share	% of holding
(A)	Promoters Holding			
	(a) Individuals	12	3304560	20.31%
	(b) Bodies Corporate	03	4314200	26.51%
	Sub Total (A)	15	7618760	46.82%
(B)	Public shareholding			
	1). Institutions			
	(a) Mutual Funds/UTI	2	74000	0.46%
	(b) Financial Institutions/Banks	6	33300	0.20%
	(c) Foreign Portfolio Investor	-	-	-
	(d) Insurance Companies	-	-	-
	(e) Foreign Financial Institution	-	-	-
	(f) Foreign Mutual Fund	-	-	-
	Sub Total (B) (1)	8	107300	0.66%
	2). Non-institutions			
	(a) Bodies Corporate	108	3496792	21.49%
	(b) Individuals			
	 Individual Shareholders holding nominal share capital up to 2 lac 	5370	3449794	21.20%
	II. Individual Shareholders holding nominal share capital in excess of 2 lac	16	1335112	8.20%
	(c) Trusts	-	-	-
	(d) Foreign National	-	-	-
	(e) Hindu Undivided Family	-	-	-
	(f) Foreign Companies (g) NRI & OCB	175	- 265399	1.63%
	(h) Clearing Member	6	643	0.00%
	Sub-Total (B) (2)	5675	8547740	52.52%
(B)	Total Public Shareholding	5683	8655040	53.18%
(C)	Shares held by Custodians and against which	0	0	0
[`_[Depository Receipts have been issued			
	Grand Total (A)+(B)+(C)	5698	16273800	100.00%

Note:

- As on 31.03.2019 the Total Number of Shares included 5712500 (Demate 3450000 shares and Physical 2262500 shares) reissued of forfeited shares on 31/03/2011 but pending for corporate action and trading confirmation from stock exchange.
- Please also note that Bombay Stock Exchange Limited (BSE) and National Stock Exchange of India Limited (NSE) in their letter dated 11th July, 2019 have granted listing and trading approval w.e.f. 12th July, 2019 for 5712500 Forfeited Equity Shares issued to promoters and non promoters on preferential basis and allotted on 31st March, 2011



CIN: L24233MP1985PLC002709

MD/CFO COMPLIANCE CERTIFICATE

To
The Board of Directors
BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

Pursuant to Regulation 17(8) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

We hereby certify to the Board of Directors of BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED that:-

- A. We have reviewed financial statements prepared based on the Indian Accounting Standards for the financial year ended on 31.03.2019 and that to the best of our knowledge and belief:
 - (1) these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading:
 - (2) these statements together present a true and fair view of the Company's affairs and are in compliance with applicable Indian Accounting Standards laws and regulations.
 - (3) no transactions entered into by the Company during the year ended 31.03.2019 which are fraudulent, illegal or violative of the Company's code of conduct.
- B. We accept responsibility for establishing and maintaining internal controls for financial reporting and we have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting and we have disclosed to the auditors and the audit committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps taken or propose to be taken to rectify these deficiencies.
- C. We have indicated to the auditors and the Audit committee about:-
 - significant changes in internal control over financial reporting during the year.
 - (2) significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
 - (3) that there were no instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having a significant role in the Company's internal control system over financial reporting.

For Biofil Chemicals and Pharmaceuticals Limited

Place: Indore Date: 30.05.2019 Ramesh Shah Managing Director (DIN: 00028819)

Jitendra Kumar Sahu Chief Financial Officer

BIOFIL Health for All

CIN: L24233MP1985PLC002709

AUDITOR'S CERTIFICATE REGARDING COMPLIANCE OF CONDITIONS OF CORPORATE GOVERNANCE

To
The Members of
BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.

We have examined the compliance of conditions of Corporate Governance by **BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED** ('the Company'), for the year ended 31st March 2019, as stipulated in regulations 17 to 27, clauses (b) to (i) of sub-regulation (2) of Regulation 46 and paragraphs C, D and E of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

The compliance of conditions of Corporate Governance is the responsibility of the Management. Our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the above-mentioned Listing Regulations, as applicable.

We have examined the relevant records of the Company in accordance with the Generally Accepted Auditing Standards in India, to the extent relevant, and as per the Guidance Note on Certification of Corporate Governance issued by the Institute of the Chartered Accountants of India.

We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

For MAHESHWARI & GUPTA,

Chartered Accountants, F.R.N.: 006179C

Place: Indore

Date: 13th August, 2019

CA. SUNIL MAHESHWARI

Partner M.NO : 403346

UDIN No.: 19403346AAAADG8875



CIN: L24233MP1985PLC002709

CERTIFICATE FROM COMPANY SECRETARY IN PRACTICE

(In terms of Regulation 34(3) read with Schedule V Para C(10)(i) to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To
The Members of
BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED
11/12, Sector - E, Sanwer Road,
Indore - 452015 (M.P.)

I have examined the relevant registers, records, forms, returns and disclosures received from the Directors of **BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED** having **CIN L24233MP1985PLC002709** and having registered office at **11/12, SECTOR-E, SANWER ROAD, INDORE - 452015 (M.P.)** (hereinafter referred to as 'the Company'), produced before me by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In my opinion and to the best of my information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to me by the Company & its officers, I hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on 31st March, 2019 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India. Ministry of Corporate Affairs, or any such other Statutory Authority.

S.No	Name of Director	DIN	Date of Appointment in Company
1	Shri Ramesh Shah	00028819	04/01/1985
2	Shri Romil Shah	00326110	30/07/2005
3	Smt. Shaila Jain	00326130	31/01/2003
4	Shri Subhash Chandra Swarnkar	01658151	13/08/2015

Ensuring the eligibility of for the appointment/continuity of every Director on the Board is the responsibility of the management of the Company. My responsibility is to express an opinion on these based on my verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For L.N.Joshi & Co., Company Secretaries,

> **L.N. Joshi** Proprietor

M. No. : F5201, CP No. : 4216

Dated: 13th August, 2019

Place: Indore





INDEPENDENT AUDITOR'S REPORT

TO

THE MEMBER OF

M/S. BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.

REPORT ON THE AUDIT OF THE FINANCIAL STATEMENTS

Opinion

We have audited the financial statements of BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED ("the company"), which comprise the balance sheet as at 31st March 2019, the statement of profit and loss, and statement of cash flows for the year then ended, and notes to the Financial Statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Financial Statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2019, its profit, and of cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the Financial Statements in accordance with the Standards on Auditing (SAs), as specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Financial Statements' section of our report. We are independent of the Company in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Financial Statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Financial Statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements for the financial year ended March 31, 2019. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined that there are no key audit matters to communicate in our report. We have fulfilled the responsibilities described in the Auditor's responsibilities for the audit of the financial statements section of our report, including in relation to these matters. Accordingly, our audit included the performance of procedures designed to respond to our assessment of the risks of material misstatement of the financial statements.

Information Other than the Financial Statements and Auditor's Report Thereupon

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Annual Report 2018-19, but does not include the Financial Statements and our auditor's report thereon.

Our opinion on the Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of Financial Statements, our responsibility is to read the other information and in doing so, consider whether such other information is materially inconsistent with the Financial Statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibilities for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Financial Statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act read with the Companies (Accounting Standards) Rules, 2015, as amended. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.



CIN: L24233MP1985PLC002709

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the Audit of Financial Statements

Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Financial Statements, including the disclosures, and whether the Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

- 1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure-A" a statement on the matters specified in paragraphs 3 and 4 of the Order.
- 2. As required by Section 143(3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - (c) The Balance Sheet, the Statement of Profit and the Cash Flow Statement dealt with by this Report are in agreement with the books of account .
 - (d) In our opinion, the aforesaid Financial Statements comply with the Accounting Standards specified under Section 133 of the Act, read with Companies (Accounting Standards) Rules, 2015, as amended.
 - (e) On the basis of the written representation received from the directors as on March 31, 2019 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2019 from being appointed as a





CIN: L24233MP1985PLC002709

director in terms of Section 164(2) of the Companies Act, 2013.

- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure B". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules,2014,as amended in our opinion and to the best of our information and according to the explanations given to us:
 - The Company has no pending litigations, hence the impact of pending litigations on its financial position in its financial statements is not disclosed.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For MAHESHWARI & GUPTA, Chartered Accountants,

F.R.N.: 006179C

CA. SUNIL MAHESHWARI

Partner M.NO: 403346

Place: Indore Date: 30.05.2019



CIN: L24233MP1985PLC002709

ANNEXURE A TO THE AUDITORS' REPORT

REPORT ON THE INTERNAL FINANCIAL CONTROLS UNDER CLAUSE (I) OF SUB-SECTION 3 OF SECTION 143 OF THE COMPANIES ACT, 2013 ("THE ACT")

We have audited the internal financial control over financial reporting of **BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED** (hereinafter referred to as 'the company') comprising of the Balance Sheet as at 31st March, 2019, the Statement of Profit & Loss, the Cash Flow Statement for the period 1st April, 2018 to 31st March, 2019, and a summary of significant accounting policies & other explanatory information (hereinafter referred to as "the Financial Statements").

MANAGEMENT'S RESPONSIBILITY FOR INTERNAL FINANCIAL CONTROLS

The Respective Board of Directors of the Company are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

AUDITORS' RESPONSIBILITY

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

MEANING OF INTERNAL FINANCIAL CONTROLS OVER FINANCIAL REPORTING

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

INHERENT LIMITATIONS OF INTERNAL FINANCIAL CONTROLS OVER FINANCIAL REPORTING

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

OPINION

In our opinion, the Company have, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March, 2019, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For MAHESHWARI & GUPTA,

Chartered Accountants, F.R.N.: 006179C

CA. SUNIL MAHESHWARI

Partner M.NO: 403346

Place: Indore Date: 30.05.2019





ANNEXURE - A TO INDEPENDENT AUDITOR'S REPORT

The Annexure referred to in paragraph 1 of the Our Report of even date to the members of BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED. On the accounts of the company for the period ended 31st March, 2019.

On the basis of such checks as we considered appropriate and according to the information and explanation given to us during the course of our audit, we report that:

- (a) The company has maintained proper records showing full particulars including quantitative details and situation of its fixed assets.
 - (b) Fixed assets have been physically verified by the management during the period and no material discrepancies were identified on such verification.
 - (c) According to the information and explanations given by the management, the title deeds of immovable properties included in fixed assets of the Company are held in the name of the Company.
- 2. (a) As explained to us, inventories have been physically verified during the period by the management at reasonable intervals.
- 3. According to the information and explanations given to us and on the basis of our examination of the books of account, the Company has not granted loans, secured or unsecured, to companies, firms or other parties listed in the register maintained under Section 189 of the Companies Act, 2013. Consequently, the provisions of clause iii(a) and iii(b) of the order are not applicable to the Company.
- 4. In our opinion and according to the information and explanations given to us, the company has complied with the provisions of section 185 and 186 of the Companies Act, 2013 in respect of granting of loans, making investments and providing guarantees and securities, as applicable.
- The Company has not accepted any deposits from the public covered under section 73 to 76 of the Companies Act, 2013. No order has been passed by the Company Law Board or National Company Law Tribunal or Reserve Bank of India or any other Tribunal.
- 6. As per information & explanation given by the management, maintenance of cost records has not been prescribed by the Central Government under sub-section (1) of section 148 of the Act.
- 7. (a) According to the records of the company, undisputed statutory dues including Provident Fund, Investor Education and Protection Fund, Employees' State Insurance, Income-tax, Sales-tax, Wealth Tax, Service Tax, Custom Duty, Excise Duty, Goods & Service Tax, cess to the extent applicable and any other statutory dues have generally been regularly deposited with the appropriate authorities. According to the information and explanations given to us there were no outstanding statutory dues as on 31st March, 2019 for a period of more than six months from the date they became payable.
 - (b) According to the information and explanations given to us, there are no amounts payable in respect of income tax, wealth tax, service tax, sales tax, goods & service tax, customs duty and excise duty which have not been deposited on account of any disputes.
- 8. Based on our audit procedures and on the information and explanations given by the management, we are of the opinion that, the Company has not defaulted in repayment of dues to a financial institution, bank or debenture holders.
- 9. Paragraph 3 (ix) of the order is not applicable as the company has not raised any money by way of initial public offer or further public offer during the year.
- 10. Based upon the audit procedures performed for the purpose of reporting the true and fair view of the financial statements and according to the information and explanations given by the management, we report that no material fraud by the Company or on the Company by the officers and employees of the Company has been noticed or reported during the period.
- 11. According to the information and explanations given to us and based on the our examination of the records of the company, the company has paid/provided for managerial remuneration in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Act.
- 12. In our opinion, the Company is not a nidhi company. Therefore, the provisions of clause 3(xii) of the Order are not applicable to the Company and hence not commented upon.
- 13. According to the information and explanations given by the management, transactions with the related parties are in compliance with section 177 and 188 of the Act where applicable and the details have been disclosed in the notes to the financial statements, as required by the applicable accounting standards.
- 14. According to the information and explanations given to us and on an overall examination of the balance sheet, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year and hence, reporting requirements under clause 3(xiv) are not applicable to the Company and, not commented upon.



BIOFIL Health for All

CIN: L24233MP1985PLC002709

15.	According to the information and explanations given by the management, the Company has not entered into any non-
	cash transactions with directors or persons connected with him. Accordingly, paragraph 3(XV) of the order is not
	applicable.

16. According to the information and explanations given to us, we report that the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934.

For MAHESHWARI & GUPTA,

Chartered Accountants, F.R.N.: 006179C

Place: Indore Date: 30.05.2019 CA. SUNIL MAHESHWARI
Partner
M.NO: 403346





			AS AT MARCH 31, 2019	(Amount in Lac
	PARTICULARS	NOTE	As at March 31. 2019	As at March 31, 2018
AS	SETS			
(1)	Non-current assets Property, plant and equipment	4	1029.42	924.68
	Total Non-current assets		1029.42	924.68
(2)	Current Assets			
` ,	Inventories Financial Assets	5	119.09	102.48
	Trade Receivables	6	1202.50	1298.08
	Cash and cash equivalents	7(i)	13.62	37.45
	Other Bank balances	7(ii)		-
	Other current assets	8	56.67	52.77
	Total Current assets		1391.88	1490.79
	TOTAL ASSETS		2421.30	2415.47
EQ	UITY AND LIABILITIES			
(1)	Equity			
	Equity Share Capital Other Equity	9	1,627.38	1,627.38
	Securities premium	9C	172.82	172.82
	Retained earnings		(3,624.75)	(3,672.98)
	Other reserves		3,189.52	3,189.52
	Total equity		1,364.97	1316.74
(2)	Current liabilities			
	Financial liabilities	10	100.70	155.00
	Borrowings Trade Payables	10 11	163.73	155.86
	i. Total outstanding dues to micro &	" "		
	small enterprises		-	-
	ii. Total outstanding dues to creditors			
	other than micro & small enterprise		858.34	914.17
	Other financial liabilities	12	22.75	17.41
	Provisions	13	11.51	11.30
	Total Current liabilities		1056.33	1098.74
	TOTAL EQUITY AND LIABILITIES		2,421.30	2,415.47
_	Summary of significant accounting policies	3		

The accompanying summary of significant accounting policies and other explanatory information are as an integral part of the financial statements.

As per our Report of even date

For & on behalf of board of Directors of

For MAHESHWARI & GUPTA CHARTERED ACCOUNTANTS ICAI Registration No. 006179C	Ramesh Shah Managing Director DIN: 00028819	Romil Shah Director DIN: 00326110
CA. SUNIL MAHESWARI, Partner Membership No. 403346	Shikha Khilwani Company Secretary Meb. No.: A43203	Jitendra Kumar Sahu Chief Financial Officer
Diago , Indore	Place : Indore	

Place : Indore
Date : 30.05.2019

Place : Indore
Date : 30.05.2019





STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31st MARCH, 2019

(Amount in Lacs Except EPS)

				•	unt in Lacs Except EPS
PAF	RTICULARS	NOTE	For	the Year Ended March 31, 2019	For the Year Ended March 31, 2018
	Income				
l	Revenue from operations	14		2312.85	1236.00
П	Other income	15		10.12	10.07
Ш	Total Income (I+II)			2322.98	1246.07
IV	Expenses				
	Cost of Material Consumed	16		77.27	77.75
	Purchases of Goods Traded	17		1904.95	991.06
	Changes in inventories of finished goods,				
	goods traded and work in progress	18		17.04	(91.70)
	Employee benefits expense	19		89.22	`72.93́
	Finance costs	20		16.03	15.06
	Depreciation and amortisation expenses	21		36.51	29.63
	Other expenses	22		122.12	92.53
	Total Expenses			2263.15	1187.25
٧	Profit/(loss) before tax (V-VI)			59.83	58.82
۷I	Exceptional Items			-	-
VII	Profit/(loss) after tax (V-VI)			48.23	47.07
VIII	Tax Expenses				
	Current tax	23		11.51	11.30
	Deferred tax			-	-
	Adjustment of tax relating to earlier periods			0.09	0.45
	Income Tax Expense			11.60	11.75
IX	Profit/(loss) for the period (VII-VIII)			48.23	47.07
X	Other comprehensive income Other comprehensive income to be reclassified to profit or loss in subsequent periods Other comprehensive income not to be reclassified to profit or loss in subsequent period	e.		-	-
	Re-measurement gains/(losses) on defined benefit Income tax effect Net other comprehensive income not to be reclas profit or loss in subsequent periods	olans		0.00	0.00
	Other comprehensive income for the year, net of t	ах		0.00	0.00
ΧI	Total comprehensive income for the year, net of t	ax		48.23	47.07
	Earnings per share (computed on the basis of profit	for the v	ear)		
XII			,	0.00	0.00
XII	Basic (Face Value Rs. 10 each)	24		(),30	() 29
XII	Basic (Face Value Rs. 10 each) Diluted (Face Value Rs. 10 each)	24 24		0.30 0.30	0.29 0.29

The accompanying summary of significant accounting policies and other explanatory information are as an integral part of the financial statements.

As per our Report of even date For MAHESHWARI & GUPTA CHARTERED ACCOUNTANTS

ICAI Registration No. 006179C

Ramesh Shah Managing Director DIN: 00028819

Romil Shah Director

Shikha Khilwani Company Secretary DIN: 00326110 Meb. No.: A43203

For & on behalf of board of Directors of

Jitendra Kumar Sahu Chief Financial Officer

CA. SUNIL MAHESWARI,

Partner

Membership No. 403346

Place: Indore Date: 30.05.2019 Place: Indore Date: 30.05.2019





Statement of changes in Equity for the year ended March 31, 2019

(Amount in Lacs)

PARTICULARS	As at March 31, 2019	As at March 31,2018
a) Equity Share Capital:		
Equity shares of INR 10 each issued,		
subscribed and fully paid		
At the beginning of the year	1,627.38	1,627.38
Decrease during the year	-	-
Increase during the year	-	-
At the end of the year	1,627.38	1,627.38

(b) Other Equity Retained earnings

	As at	March 31,	2019	As at	March 31,	2018
Particular	Retained earnings	Other Reserves		Retained earnings	Other Reserves	Share Premium
Profit / (Loss) at the beginning of the year	(3,672.98)	3189.52	172.82	(3,720.06)	3,189.52	172.82
Loss for the year	48.23	-	-	47.07	-	-
Other comprehensive income / (loss) for the year		-	-	-	-	
Profit / (Loss) at the end of the year	(3624.75)	3189.52	172.82	(3,672.98)	3,189.52	172.82

The accompanying summary of significant accounting policies and other explanatory information are as an integral part of the financial statements.

As per our Report of even date

For & on behalf of board of Directors

For MAHESHWARI & GUPTA CHARTERED ACCOUNTANTS ICAI Registration No. 006179C

CA. SUNIL MAHESWARI, Partner

Membership No. 403346

Place: Indore Date: 30.05.2019

Romil Shah Ramesh Shah Managing Director Director DIN: 00326110 DIN: 00028819

Shikha Khilwani Company Secretary Meb. No.: A43203

Date: 30.05.2019

Place: Indore

Jitendra Kumar Sahu Chief Financial Officer



CIN: L24233MP1985PLC002709

FOR THE YEAR ENDED 31st Ma PARTICULARS F	or the Year Ended	For the Year Ended
	March 31, 2019	March 31, 2018
Cash flow from operating activities		
Profit before tax	59.83	58.82
Adjustments to reconcile profit before tax to net cash		
used in operating activities		
Depreciation of property, plant and equipment	36.51	29.60
Finance cost	16.03	15.00
	112.38	103.5
Working capital adjustments		
Increase/ (Decrease) in Inventory	(16.61)	(85.85
(Increase)/ Decrease in Trade Receiable	95.58	(151.64
(Increase)/ Decrease in other current assets	(3.90)	20.79
Increase/ (Decrease) in trade payables	(55.83)	204.6
Increase/ (Decrease) in other financial liabilities	5.34	5.30
Increase/ (Decrease) in other liabilities	0.00	0.00
Cash generated from operations	136.96	96.8
Current tax assets	(11.39)	(50.45
Net cash flows from operating activities	125.57	46.3
Cash flow from investing activities		
Payment for purchase and construction of property, plant and equipment	ent 141.25	37.86
Proceeds from sale of property, plant and equipment	0.00	0.0
Net cash flows from investing activities	141.25	37.80
Cash flow from financing activities		
Increase/(decrease) in Borrowings	7.88	13.09
Finance cost	(16.03)	(15.06
Net cash flows from financing activities	(8.16)	(2.01
Net increase / (decrease) in cash and cash equivalents	(23.83)	6.48
Cash and cash equivalents at the beginning of the year	37.45	30.9
Cash and cash equivalents at the end of the year	13.62	37.4
Increase /(Decrease) in cash and cash equivalnts	(23.83)	6.4

The accompanying summary of significant accounting policies and other explanatory information are as an integral part of the financial statements.

As per our Report of even date

For & on behalf of board of Directors

For MAHESHWARI & GUPTA CHARTERED ACCOUNTANTS ICAI Registration No. 006179C **CA. SUNIL MAHESWARI,**

Ramesh Shah Managing Director DIN: 00028819

Romil Shah Director

Shikha Khilwani Company Secretary DIN: 00326110 Meb. No.: A43203

Jitendra Kumar Sahu Chief Financial Officer

Partner

Membership No. 403346

Place: Indore Date: 30.05.2019 Place: Indore Date: 30.05.2019



CIN: L24233MP1985PLC002709

NOTES FORMING PART OF FINANCIAL STATEMENT FOR THE YEAR ENDED 31st MARCH, 2019

Notes to financial statements for the year ended March 31, 2019

1 Corporate Information

Biofil chemicals and Pharmaceuticals Limited is public limited Company in India with its registered office at Indore Madhya Pradesh India. The Company is listed on Bomaby Stock Exchange (BSE) and National Stock Exchange of India Limited.(NSE)

The Company deals in manufacturing and trading of Pharmaceuticals, and manufacturing of plastic. Further the company also deals in providing job work facility in respect of manufacturing of pharmaceuticals drug. The company runs its business via three unit viz Pharmaceutical Division chemicals Division and Plastic Division the Company has a separate factory unit for plastic Division at Pithampur (Dhar)

"The functional and presentation currency of the Company is Indian Rupee ("`") which is the currency of the primary economic environment in which the Company operates."

"The financial statements for the year ended March 31, 2019 were approved by the Board of Directors and authorised for issue on May 30,2019."

2 Basis of preparation

a Statement of Compliance

The financial statements of the company have been prepared in accordance with and comply in all material aspects with Indian Accounting Standards ("Ind AS") as notified under section 133 of the Companies Act, 2013 ('Act') read with Companies (Indian Accounting Standards) Rules, 2015 and the relevant provisions of the Act.

b Functional and presentation currency

These financial statements are presented in Indian rupees (in lakhs), which is the Company's functional currency. All amounts have been amount in Lakhs, unless otherwise indicated.

c Use of Estimates and Judgement

The preparation of financial statements in accordance with Ind AS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amount of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods if affected. The most significant estimates and assumptions are described below:

(i) Recognistion and measurement of Provisions and Contingencies

The Company's Management estimates Key assumptions about the likelihood and maginitude of an outflow of resources; based on available information and the assumptions and methods deemed appropriate. Wherever required, these estimates are primarily prepared with the assistance of legal counsel. As additional information becomes available to the Company, estimates are revised and adjusted periodically.

(ii) Recognistion of Deferred Tax Assets

The Management makes estimates as regards to availablity of future taxable profits against which unabsorbed depreciation/ tax losses carried forrward can be used.

(iii) The financial statements are presented in Indian Rupee ('INR') which is also the Company's functional currency and all values are rounded to the nearest lakhs, except when otherwise indicated. Wherever the amount represented '0' (zero) construes value less than Rupees five thousands.

3 Summary of significant accounting policies

3.01 Current versus non-current classification

The Company presents assets and liabilities in the balance sheet based on current/ non-current classification. An asset is treated as current when it is:

- Expected to be realised or intended to be sold or consumed in normal operating cycle
- Held primarily for the purpose of trading
- Expected to be realised within twelve months after the reporting period, or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

All other assets are classified as non-current.

A liability is current when:

It is expected to be settled in normal operating cycle



CIN: L24233MP1985PLC002709

- It is held primarily for the purpose of trading
- It is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash

3.02 Foreign currencies

The Company's financial statements are presented in INR, which is also the company's functional currency

3.03 Transactions and balances

Transactions in foreign currencies are initially recorded by the Company at their functional currency spot rates at the date the transaction first qualifies for recognition.

3.04 Fair value measurement

The company has elected to measure items of property, plant and equipment and intangible assets at its carrying value at the transition date except for certain class of assets which are measured at fair value as deemed cost.

3.05 Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, regardless of when the payment is being made. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duties collected on behalf of the government.

The specific recognition criteria described below must also be met before revenue is recognised.

3.06 Interest income

For all debt instruments measured either at amortised cost or at fair value through other comprehensive income, interest income is recorded using the effective interest rate (EIR). EIR is the rate that exactly discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the gross carrying amount of the financial asset or to the amortised cost of a financial liability. When calculating the effective interest rate, the company estimates the expected cash flows by considering all the contractual terms of the financial instrument (for example, prepayment, extension, call and similar options) but does not consider the expected credit losses. Interest income is included in finance income in the statement of profit and loss.

3.07 Dividends

Revenue is recognised when the Company's right to receive the payment is established, which is generally when shareholders approve the dividend.

3.08 Taxes

Current income tax

Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date in the country where the Company operates and generates taxable income.

"Current income tax relating to items recognised outside profit or loss is recognised outside profit or loss (either in other comprehensive income or in equity). "Current tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate."

3.09 Deferred tax

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities are recognised for all taxable temporary differences, except when the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss.

Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilised, except when the deferred tax asset relating to the



CIN: L24233MP1985PLC002709

deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax relating to items recognised outside profit or loss is recognised outside profit or loss (either in other comprehensive income or in equity). Deferred tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax as sets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

3.10 Minimum Alternate Tax (MAT)

Minimum Alternate Tax (MAT) paid as per Indian Income Tax Act, 1961 is in the nature of unused tax credit which can be carried forward and utilised when the Company will pay normal income tax during the specified period. MAT paid in a year is charged to the statement of profit and loss as current tax for the year. The deferred tax asset is recognised for MAT credit available only to the extent that it is probable that the concerned company will pay normal income tax during the specified period, i.e., the period for which MAT credit is allowed to be carried forward. In the year in which the company recognizes MAT credit as an asset, it is created by way of credit to the statement of profit and loss and shown as part of deferred tax asset. The company reviews the "MAT credit entitlement" asset at each reporting date and writes down the asset to the extent that it is no longer probable that it will pay normal tax during the specified period.

3.11 Property, plant and equipment

The Company has elected to continue with the carrying value for all of its property, plant and equipment as recognised in the financial statements as at the date of transition to Ind AS, measured as per the previous GAAP and use that as its deemed cost in accordance with the exemption provided under IND AS 101.

Plant and equipment is stated at cost, net of accumulated depreciation and accumulated impairment losses, if any such cost includes the cost of replacing part of the plant and equipment and borrowing its for long-term construction projects if the recognition criteria are met. When significant parts of plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives. Likewise, when a major inspection is performed, its cost is recognised in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognised in profit or loss as incurred.

Depreciation on property, plant and equipment is calculated on a WDV basis using the rates arrived at based on the useful lives estimated by the management which coincides with the rates as per Schedule II of the Companies Act, 2013. The useful life of major assets are as under:

Asset class	Useful lives
Building	30 years
Plant & Machinery	20 years
Office equipment	5 years
Other Assets	15 years
Furniture & fixtures	10 years

An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the income statement when the asset is derecognised.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

3.12 Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalised as part of the cost of



CIN: L24233MP1985PLC002709

the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs.

3.13 Leases

The determination of whether an arrangement is (or contains) a lease is based on the substance of the arrangement at the inception of the lease. The arrangement is, or contains, a lease if fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset or assets, even if that right is not explicitly specified in an arrangement.

For arrangements entered into prior to 1 April 2015, the Company has determined whether the arrangement contain lease on the basis of facts and circumstances existing on the date of transition.

3.14 Company as a lessee

A lease is classified at the inception date as a finance lease or an operating lease. A lease that transfers substantially all the risks and rewards incidental to ownership to the Company is classified as a finance lease.

A leased asset is depreciated over the useful life of the asset. However, if there is no reasonable certainty that the Company will obtain ownership by the end of the lease term, the asset is depreciated over the shorter of the estimated useful life of the asset and the lease term.

Operating lease payments are recognised as an expense in the statement of profit and loss on a straight-line basis over the lease term.

3.15 Inventories

Inventories are valued at the lower of cost and net realisable value.

Costs incurred in bringing each product to its present location and condition are accounted for as follows:

- Raw materials and components, stores and spares: COST includes COST of purchase and other costs incurred in bringing the inventories to its present location and condition. Cost is determined on moving wieghted average basis.
- Finished goods and work in progress: cost includes cost of direct materials and labour and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs. Cost is determined on moving weighted average basis.

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

3.16 Impairment of Financial assets (other than at fair value)

The Company assesses at each date of balance sheet whether a financial asset or a group of financial assets is impaired. Ind AS 109 ('Financial Instruments') requires expected credit losses to be measured through a loss allowance. The Company follows 'simplified approach' for recognition of impairment loss allowances. All financial assets, expected credit losses are measured at an amount equal to the 12-month expected credit losses or at an amount equal to the life time expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. The Company provides for impairment upon the occurrence of the triggering event.

3.17 Impairment of non-financial assets

TThe Company assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) fair value less costs of disposal and its value in use. Recoverable amount is determined for an individual asset. unless the asset does not generate cash inflows that are largely independent of those from other assets or group of assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for publicly traded companies or other available fair value indicators

For assets excluding goodwill, an assessment is made at each reporting date to determine whether there is an indication that previously recognised impairment losses no longer exist or have decreased. If such indication exists, the Company estimates the asset's or CGU's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. Such reversal is recognised in the statement of profit or loss.



CIN: L24233MP1985PLC002709

3.18 Contingent liabilities & Contingent Assets

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by occurrence or non-occurrence of one or more uncertain future events beyond the control of the company or a present obligation that is not recognised because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognised because it cannot be measured reliably. The Company does not recognise a contingent liability but discloses its existence in the financial statements.

A contingent assets is not recognised unless it becomes virtually certain that an inflow of economic benefits will arise. When an inflow of economic benefits is probable, contingent assets are disclosed in the financial statements.

Contingent liabilities and contingent assets are reviewed at each balance sheet date.

3.19 Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognised as a separate asset, but only when the reimbursement is virtually certain. The expense relating to a provision is presented in the statement of profit and loss net of any reimbursement.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost. Provisions are reviewed at each balance sheet and adjusted to reflect the current best estimates.

3.20 Retirement and other employee benefits

i. Defined contribution plan

Retirement benefits in the form of provident fund, Pension Fund and Employees state Insurance Fund are a defined contribution scheme and the contributions are charged to the Statement of profit and loss of the period when the employee renders related services. There are no other obligations other than the contribution payable to the respective authorities.

ii. Defined benefit plan

Gratuity liability for eligible employees are defined benefit obligation and are provided for on the basis of an actuarial valuation on projected unit credit method made at the end of each financial year. Obligation is measured at the present value of estimated future cash flows using discounted rate that is determined by reference to market yields at the balance sheet date on Government Securities where the currency and terms of the Government Securities are consistent with the currency and estimated terms of the defined benefit obligation.

Remeasurements, comprising of actuarial gains and losses excluding amounts included in net interest on the net defined benefit liability are recognised immediately in the balance sheet with a corresponding debit or credit to retained earnings through OCI in the period in which they occur. Remeasurements are not reclassified to profit or loss in subsequent periods.

"Past service costs are recognised in profit or loss on the earlier of:"

- The date of the plan amendment or curtailment, and "
- The date that the Company recognises related restructuring costs"

Net interest is calculated by applying the discount rate to the net defined benefit liability or asset. The Company recognises the following changes in the net defined benefit obligation as an expense in the statement of profit and loss:"

- Service costs comprising current service costs, past-service costs, gains and losses on curtailments and non-routine settlements; and "
- Net interest expense or income"

3.21 Financial instruments

Financial instruments are recognised when the Company becomes a party to the contract that gives rise to financial assets and financial liabilities.

Financial Assets

Initial recognition and measurement

All financial assets and liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value measured on initial recognition of financial asset or financial liability.



CIN: L24233MP1985PLC002709

Subsequent measurement

Financial assets at amortised cost

Financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method if these financial assets are held within a business whose objective is to hold these assets to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance income in the profit or loss. The losses arising from impairment are recognised in the profit or loss. This category generally applies to trade and other receivables.

Financial assets at fair value through other comprehensive income

Financial assets are measured at fair value through other comprehensive income if these financial assets are held within a business whose objective is achieved by both collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. Fair value movements are recognised in Other Comprehensive Income (OCI).

Financial assets at fair value through profit or loss

Financial assets are measured at fair value through profit or loss unless it is measured at amortised cost or at fair value through other comprehensive income on initial recognition. The transaction costs directly attributable to the acquisition of financial assets at fair value through profit or loss are immediately recognised in statement of profit and loss.

Derecognition

The Company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire or it transfers the financial asset and the transfer qualifies for derecognition under Ind AS 109. A financial liability (or a part of a financial liability) is derecognised when the obligation specified in the contract is discharged or cancelled or expires.

Financial liabilities

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate. All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Company's financial liabilities include trade and other payables and borrowings.

Loans and Borrowings

Financial liabilities are subsequently measured at amortised cost using the effective interest method. Gains and losses are recognised in profit or loss when the liabilities are derecognised as well as through the EIR amortisation process. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance cost in the statement of profit and loss. For trade and other payables maturing within one year from the balance sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

Derecognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit or loss.

Fair value of financial instruments

In determining the fair value of its financial instruments, the Company uses following hierarchy and assumptions that are based on market conditions and risks existing at each reporting date.

Fair value hierarchy

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities.

Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable.

Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.





CIN: L24233MP1985PLC002709

For assets and liabilities that are recognised in the financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by reassessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

Reclassification of financial assets

The Company determines classification of financial assets and liabilities on initial recognition. After initial recognition, no reclassification is made for financial assets which are equity instruments and financial liabilities. For financial assets which are debt instruments, a reclassification is made only if there is a change in the business model for managing those assets. Changes to the business model are expected to be infrequent. If the Company reclassifies financial assets, it applies the reclassification prospectively from the reclassification date which is the first day of the immediately next reporting period following the change in business model. The Company does not restate any previously recognised gains, losses (including impairment gains or losses) or interest.

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realize the assets and settle the liabilities simultaneously.

3.22 Cash and cash equivalents

Cash and cash equivalent in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above, net of outstanding bank overdrafts as they are considered an integral part of the Company's cash management.

3.23 Segment Reporting

"Based on ""Management Approach"" as defined in Ind AS 108 -Operating Segments, the management evaluates the Company's performance and allocates the resources based on an analysis of various performance indicators by business segments. Inter segment sales and transfers are reflected at market prices. "Unallocable items includes general corporate income and expense items which are not allocated to any business segment. "Segment Policies: "The Company prepares its segment information in conformity with the accounting policies adopted for preparing and presenting the financial statements of the Company as a whole. Common allocable costs are allocated to each segment on an appropriate basis."

3.24 Earnings Per Share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

BIOFIL Health for All

CIN: L24233MP1985PLC002709

NOTE: 04 FIXED ASSETS

Property Plant and equipment

		Deemed Cost	d Cost		Ϋ́	ccumulated	Accumulated Depreciation		Net Block	lock
Particulars	As on March 31 2018	Additions	Deletions	As on March 31 2019	As on March 31 2018	Additions	Deletions	As on March 31 2019	As on March 31 2019	As on March 31 2018
(i) TANGIBLE ASSETS										
Lease Hold Land	449.59	,		449.59	•		ı		449.59	449.59
Work in progress	33.76	3.85		37.62	•		ı		37.62	33.76
Building	257.98	0.95		258.93	22.94	11.72		34.65	224.28	235.04
Plant and Machinery	212.36	128.72		341.08	24.17	18.14	ı	42.30	298.78	188.19
Eelectric Installations	14.90	7.30		22.19	6.19	3.90	ı	10.09	12.10	8.70
Cycle	0.02			0.02	0.01	00.00		0.01	0.01	0.01
Office Equipments	9.86	0.43		10.29	4.89	2.47	ı	7.36	2.92	4.97
Vehicles	4.71	ı	ı	4.71	0.29	0.29	ı	0.58	4.13	4.41
TOTAL	983.18	141.25		1,124.43	58.49	36.51		95.01	1,029.42	924.68

		Deemed Cost	d Cost		Ā	ccumulated	Accumulated Depreciation		Net B	Net Block
Particulars	As on April 1 2017	Additions	Deletions	As on March 31 2018	As on April 01 2017	Additions	Deletions	As on March 31 2018	As on March 31 2018	As on April 1 2017
(i) TANGIBLE ASSETS										
Own Assets:										
Lease Hold Land	449.59	ı	ı	449.59	•	•	ı	,	449.59	449.59
Work in progress	30.08	3.68		33.76	,	ı	ı	,	33.76	30.08
Building	256.89	1.09	ı	257.98	11.24	11.70	ı	22.94	235.04	245.65
Plant and Machinery	184.14	28.22	ı	212.36	11.48	12.69	ı	24.17	188.19	172.66
Eelectric Installations	14.90		ı	14.90	3.69	2.50	ı	6.19	8.70	11.21
Cycle	0.02		ı	0.05	0.01	0.00	ı	0.01	0.01	0.02
Office Equipments	9.52	0.33		98.6	2.44	2.45	ı	4.89	4.97	7.08
Vehicles	0.17	4.53		4.71		0.29		0.29	4.41	0.17
TOTAL	945.31	37.86	-	983.17	28.86	29.63	-	58.49	924.68	916.45





PARTICULARS		Δe at Me	arch 31, 2019	(Amount in La	
Note 5 : Inventories		A3 at Inc			
Note 5 :	Inventories Raw Material Stores and Spares Finished Goods Work in process		37.94 0.30 79.89 0.96	4.44 0.15 97.39 0.51	
		Total	119.09	102.48	
Note 6 :	Trade Receivables				
	Trade recievables				
	- Others		1202.50	1298.08	
		Total	1202.50	1298.08	
	Break-up for security details:			-	
	Secured, considered good		_	_	
	Unsecured, considered good Doubtful		1202.50	1298.08	
		Total	1202.50	1298.08	
	Ageing analysis of the age of trade payal		1202.00		
	that are past due as at the end of reportin				
	Less than 90 days		1202.50	1298.08	
	Over 120 days		-		
		Total	1202.50	1298.08	
	(a) Balances with banks:				
	(a) Balances with banks: - On current accounts - On escrow accounts		7.98	26.74 -	
	On current accountsOn escrow accountsDeposits with original maturity of I	ess than three months	-	- -	
	 On current accounts On escrow accounts Deposits with original maturity of I (b) Cash on hand 		5.64	- - 10.71	
Note 7 (i	On current accounts On escrow accounts Deposits with original maturity of I (b) Cash on hand Total cash and cash equivalents as per		-	- -	
Note 7 (i	 On current accounts On escrow accounts Deposits with original maturity of I (b) Cash on hand 	cash flow statments	5.64	- - 10.71	
Note 7 (i	On current accounts On escrow accounts Deposits with original maturity of I (b) Cash on hand Total cash and cash equivalents as peril): Other Bank Balances In Unclaimed Dividend Accounts In fix deposits accounts (with original three months and maturing within the counts)	cash flow statments	5.64	- - 10.71	
	- On current accounts - On escrow accounts - Deposits with original maturity of I (b) Cash on hand Total cash and cash equivalents as per i): Other Bank Balances - In Unclaimed Dividend Accounts - In fix deposits accounts (with orig three months and maturing within to balance sheet date) Total other Bank Balances Other assets Current	r cash flow statments inal maturtity of more than welve months from the	5.64	- - 10.71	
	- On current accounts - On escrow accounts - Deposits with original maturity of I (b) Cash on hand Total cash and cash equivalents as per i): Other Bank Balances - In Unclaimed Dividend Accounts - In fix deposits accounts (with original three months and maturing within the balance sheet date) Total other Bank Balances Other assets Current (Unsecured, considered good unless of	r cash flow statments inal maturtity of more than welve months from the	5.64	10.71	
	- On current accounts - On escrow accounts - Deposits with original maturity of I (b) Cash on hand Total cash and cash equivalents as per i): Other Bank Balances - In Unclaimed Dividend Accounts - In fix deposits accounts (with original three months and maturing within the balance sheet date) Total other Bank Balances Other assets Current (Unsecured, considered good unless of Loans and advances against material Duties and taxes receivable)	r cash flow statments inal maturtity of more than welve months from the	5.64	- - 10.71	
	- On current accounts - On escrow accounts - Deposits with original maturity of I (b) Cash on hand Total cash and cash equivalents as per i): Other Bank Balances - In Unclaimed Dividend Accounts - In fix deposits accounts (with orig three months and maturing within to balance sheet date) Total other Bank Balances Other assets Current (Unsecured, considered good unless of Loans and advances against material Duties and taxes receivable Prepaid expenses	r cash flow statments inal maturtity of more than welve months from the	5.64 13.62 - - - - - - - - - - - - - - - - - - -	9.16 8.15 1.53	
	- On current accounts - On escrow accounts - Deposits with original maturity of I (b) Cash on hand Total cash and cash equivalents as per i): Other Bank Balances - In Unclaimed Dividend Accounts - In fix deposits accounts (with original three months and maturing within the balance sheet date) Total other Bank Balances Other assets Current (Unsecured, considered good unless of Loans and advances against material Duties and taxes receivable)	r cash flow statments inal maturtity of more than welve months from the	5.64 13.62 - - - - - - - - - - - - - - - - - - -	9.16 8.15 1.53 33.94	
Note 8 :	- On current accounts - On escrow accounts - Deposits with original maturity of I (b) Cash on hand Total cash and cash equivalents as per i): Other Bank Balances - In Unclaimed Dividend Accounts - In fix deposits accounts (with original three months and maturing within the balance sheet date) Total other Bank Balances Other assets Current (Unsecured, considered good unless of Loans and advances against material Duties and taxes receivable Prepaid expenses Security Deposits Equity	r cash flow statments inal maturtity of more than welve months from the	5.64 13.62 - - - - - - - - - - - - - - - - - - -	9.16 8.15 1.53	
Note 8 :	- On current accounts - On escrow accounts - Deposits with original maturity of I (b) Cash on hand Total cash and cash equivalents as per i): Other Bank Balances - In Unclaimed Dividend Accounts - In fix deposits accounts (with original three months and maturing within the balance sheet date) Total other Bank Balances Other assets Current (Unsecured, considered good unless of Loans and advances against material Duties and taxes receivable Prepaid expenses Security Deposits Equity Equity Equity share capital	r cash flow statments inal maturtity of more than welve months from the therwise stated)	5.64 13.62 - - - - - - - - - - - - - - - - - - -	9.16 8.15 1.53 33.94	
Note 8 :	- On current accounts - On escrow accounts - Deposits with original maturity of I (b) Cash on hand Total cash and cash equivalents as per i): Other Bank Balances - In Unclaimed Dividend Accounts - In fix deposits accounts (with original three months and maturing within the balance sheet date) Total other Bank Balances Other assets Current (Unsecured, considered good unless of Loans and advances against material Duties and taxes receivable Prepaid expenses Security Deposits Equity Equity share capital Authorised share capital	r cash flow statments inal maturtity of more than welve months from the therwise stated)	5.64 13.62 - - - - - - - - - - - - - - - - - - -	9.16 8.15 1.53 33.94	
Note 8 :	- On current accounts - On escrow accounts - Deposits with original maturity of I (b) Cash on hand Total cash and cash equivalents as per i): Other Bank Balances - In Unclaimed Dividend Accounts - In fix deposits accounts (with original three months and maturing within the balance sheet date) Total other Bank Balances Other assets Current (Unsecured, considered good unless of Loans and advances against material Duties and taxes receivable Prepaid expenses Security Deposits Equity Equity Equity share capital	r cash flow statments inal maturtity of more than welve months from the therwise stated)	5.64 13.62 - - - - - - - - - - - - - - - - - - -	9.16 8.15 1.53 33.94	



CIN: L24233MP1985PLC002709

	As at March 31, 2019		As at March 31, 2018	
	No. of Shares	Rs. in Lakhs	No. of Shares	Rs. in Lakhs
Issued Share Capital Equity shares of INR 10/- each issued, subscribed and fully paid.	16,273,800	1627.38	16,273,800	1627.38
a) Reconciliation of the number of shares outstand	ing and the amou	nt of share capi	tal:	
	As at Marc	h 31, 2019	As at March	31, 2019
	No. of Shares	Rs. in Lakhs	No. of Shares	Rs. in Lakhs

At the end of the year

b) Terms / rights attached to equity shares

or other distributions paid to shareholders.

The company has one class of equity shares having par value of Rs. 10/- per share per share. Each holder of equity shares is entitled to one vote per share.

16,273,800

1627.38

16,273,800

1627.38

In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

B) Details of shareholders holding more than 5% shares and held by the holding company:

	As at M	larch 31, 2019	As at March 31, 2018	
Particular	No. of Shares	% holding in the class	No. of Shares	% holding in the class
Scope Finance Company Pvt. Ltd.	2,262,500	13.90%	2,262,500	13.90%
Smitesh Sanalal Shah	1,082,740	6.65%	1,082,740	6.65%
Mid India Pharmaceuticals Pvt. Ltd.	1,175,250	7.22%	1,175,250	7.22%
Cyano Finance and Sales Pvt. Ltd.	876,450	5.39%	876,450	5.39%
Starline Equifin Pvt. Ltd.	1,850,800	11.37%	1,850,800	11.37%
Libra Healthcare Pvt. Ltd.	850,000	5.22%	850,000	5.22%
PARTICULARS	As at M	arch 31, 2019	As at Ma	rch 31, 2018
		(Rs. in Lacs)		(Rs. in Lacs)
C) Other Equity				
Security premium				
As at April 01, 2018		172.82		172.82
Addition/Deletion		-		-
As at March 31 , 2019		172.82	-	172.82
Other reserves			_	
As at April 01, 2018		3189.52		3189.52
Addition/Deletion		-		-
As at March 31 , 2019		3189.52	-	3189.52
Retained earnings				
As at April 01, 2018		(3672.98)		(3720.06)
Profit for the year		48.23		47.07
Other comprehensive income/(loss) for the year		0.00		0.00
As at March 31 , 2019		(3624.75)	_	(3672.98)



CIN: L24233MP1985PLC002709

PAF	RTICL	JLARS	As at	March 31, 2019	As at March 31, 2018
Note 10 :	Bori	rowings		,	<u> </u>
10.0		rent Borrowings			
		Corporate Deposits		163.73	155.86
			Total	163.73	155.86
			lotai		
Note 11 :	Trac	de Payables			
	Micr	l outstanding dues to o and eneterprises (Refer Note No. 28)		-	-
		Il outstanding dues to creditors other thar o and small enterprises	1	858.34	914.17
			Total	858.34	914.17
	∆nei	ing analysis of the age of trade payable			
	•	ounts that are past due as at the end of re	norting year :		
		s than 90 days	porting your .	858.34	914.17
		r 120 days		-	-
	0.0.	120 dayo	Total	858.34	914.17
	lafor	mation as required to be furnished as per			
		2006 (MSMED Act) for the year ended Male extent such parties have been identified Principal amopunt and interest due the reamining unpaid to any supplier cover MSMED Act: Principa Interest	ed on the basis of in ereon		with the company.
	to th	ne extent such parties have been identifie Principal amopunt and interest due the reamining unpaid to any supplier cover MSMED Act: Principa Interest The amount of interest paid by the buyer of Secction 16, of the MSMED Act, 2000 the amounts of the payment made to the beyond the appointed day during each. The amount of interest due and payable delay in making payment (which have be beyond the appointed day during the year) without adding the interest specified ur. The amount of interest accrued and rer the end of each accounting year. The amount of further interest remaining even in the succeeding years, until succeeding years actually paid enterprise for the purpose of disalloward.	ed on the basis of increon red under er in terms 6 along with the supplier accounting year. e for the period of been paid but ear) but beyond inder MSMED Act. maining unpaid at the g due and payable the date when the d to the small ince as a deductible	nformation available	with the company.
Note 12 -	to th i) ii) iv) v)	ne extent such parties have been identified. Principal amopunt and interest due the reamining unpaid to any supplier cover MSMED Act: Principa Interest The amount of interest paid by the buyer of Section 16, of the MSMED Act, 2000 the amounts of the payment made to the beyond the appointed day during each. The amount of interest due and payable delay in making payment (which have beyond the appointed day during the year without adding the interest specified ur. The amount of interest accrued and rerethe end of each accounting year. The amount of further interest remaining even in the succeeding years, until succeeding years actually paid enterprise for the purpose of disalloware expenditure under section 23 of the MS	ed on the basis of increon red under er in terms 6 along with the supplier accounting year. e for the period of been paid but ear) but beyond inder MSMED Act. maining unpaid at the g due and payable the date when the d to the small ince as a deductible	nformation available	with the company.
Note 12 :	to th i) ii) iii) v) v)	re extent such parties have been identified. Principal amopunt and interest due the reamining unpaid to any supplier cover MSMED Act: Principa Interest. The amount of interest paid by the buyer of Section 16, of the MSMED Act, 2000 the amounts of the payment made to the beyond the appointed day during each. The amount of interest due and payable delay in making payment (which have beyond the appointed day during the year without adding the interest specified under the end of each accounting year. The amount of further interest remaining even in the succeeding years, until succenterest dues as above are actually paid enterprise for the purpose of disallower expenditure under section 23 of the MS er financial liabilities.	ed on the basis of increon red under er in terms 6 along with the supplier accounting year. e for the period of been paid but ear) but beyond inder MSMED Act. maining unpaid at the g due and payable the date when the d to the small ince as a deductible	nformation available	-
Note 12 :	ii) iii) iv) v) Cother Emp	ne extent such parties have been identified. Principal amopunt and interest due the reamining unpaid to any supplier cover MSMED Act: Principa Interest The amount of interest paid by the buyer of Secction 16, of the MSMED Act, 2000 the amounts of the payment made to the beyond the appointed day during each. The amount of interest due and payable delay in making payment (which have be beyond the appointed day during the year) without adding the interest specified under the end of each accounting year. The amount of further interest remaining even in the succeeding years, until succeeding years actually paid enterprise for the purpose of disalloware expenditure under section 23 of the MS er financial liabilities.	ed on the basis of increon red under er in terms 6 along with the supplier accounting year. e for the period of been paid but ear) but beyond inder MSMED Act. maining unpaid at the g due and payable the date when the d to the small ince as a deductible	nformation available 2.29	3.57
Note 12 :	ii) iii) iv) v) Cother Emp	re extent such parties have been identified. Principal amopunt and interest due the reamining unpaid to any supplier cover MSMED Act: Principa Interest. The amount of interest paid by the buyer of Section 16, of the MSMED Act, 2000 the amounts of the payment made to the beyond the appointed day during each. The amount of interest due and payable delay in making payment (which have beyond the appointed day during the year without adding the interest specified under the end of each accounting year. The amount of further interest remaining even in the succeeding years, until succenterest dues as above are actually paid enterprise for the purpose of disallower expenditure under section 23 of the MS er financial liabilities.	ed on the basis of increon ared under ared under accounting year. The formal been paid but ear but beyond ander MSMED Act. In all the did to the small acce as a deductible access.	2.29 20.46	3.57 13.85
Note 12 :	ii) iii) iv) v) Cother Emp	ne extent such parties have been identified. Principal amopunt and interest due the reamining unpaid to any supplier cover MSMED Act: Principa Interest The amount of interest paid by the buyer of Secction 16, of the MSMED Act, 2000 the amounts of the payment made to the beyond the appointed day during each. The amount of interest due and payable delay in making payment (which have be beyond the appointed day during the year) without adding the interest specified under the end of each accounting year. The amount of further interest remaining even in the succeeding years, until succeeding years actually paid enterprise for the purpose of disalloware expenditure under section 23 of the MS er financial liabilities.	ed on the basis of increon red under er in terms 6 along with the supplier accounting year. e for the period of been paid but ear) but beyond inder MSMED Act. maining unpaid at the g due and payable the date when the d to the small ince as a deductible	nformation available 2.29	3.57
	ii) iii) iv) v) Cother Emp	the extent such parties have been identified. Principal amopunt and interest due the reamining unpaid to any supplier cover MSMED Act: Principa Interest. The amount of interest paid by the buyer of Section 16, of the MSMED Act, 2000 the amounts of the payment made to the beyond the appointed day during each. The amount of interest due and payable delay in making payment (which have beyond the appointed day during the year without adding the interest specified under the end of each accounting year. The amount of further interest remaining even in the succeeding years, until succeeding years, until succenterest dues as above are actually paid enterprise for the purpose of disallower expenditure under section 23 of the MS of the material liabilities.	ed on the basis of increon ared under ared under accounting year. The formal been paid but ear but beyond ander MSMED Act. In all the did to the small acce as a deductible access.	2.29 20.46	3.57 13.85
	ii) iii) iv) v) Cother Emp	the extent such parties have been identified. Principal amopunt and interest due the reamining unpaid to any supplier cover MSMED Act: Principa Interest. The amount of interest paid by the buyer of Secction 16, of the MSMED Act, 2000 the amounts of the payment made to the beyond the appointed day during each. The amount of interest due and payable delay in making payment (which have beyond the appointed day during the year without adding the interest specified under the end of each accounting year. The amount of further interest remaining even in the succeeding years, until succeeding years, until succenterest dues as above are actually paid enterprise for the purpose of disallower expenditure under section 23 of the MS er financial liabilities. Principal Interest payable of the payable of Payable.	ed on the basis of increon ared under ared under accounting year. The formal been paid but ear but beyond ander MSMED Act. In all the did to the small acce as a deductible access.	2.29 20.46	3.57 13.85
Note 12 :	ii) iii) iv) v) Current to the current representation of the current to the current iv)	the extent such parties have been identified. Principal amopunt and interest due the reamining unpaid to any supplier cover MSMED Act: Principa Interest. The amount of interest paid by the buyer of Secction 16, of the MSMED Act, 2000 the amounts of the payment made to the beyond the appointed day during each. The amount of interest due and payable delay in making payment (which have beyond the appointed day during the year without adding the interest specified under the end of each accounting year. The amount of further interest remaining even in the succeeding years, until succeeding years, until succenterest dues as above are actually paid enterprise for the purpose of disallower expenditure under section 23 of the MS er financial liabilities. Principal Interest payable of the payable of Payable.	ed on the basis of increon ared under ared under accounting year. The formal been paid but ear but beyond ander MSMED Act. In all the did to the small acce as a deductible access.	2.29 20.46	3.57 13.85

Trade payables are non-interest bearing and are normally settled on 90 day terms.

For terms and conditions with related parties,

For explanations on the Company's credit risk management processes





Notes forming Part of the financial statements as at March 31, 2019

(Amount in Lacs)

PARTICULARS		As at March 31, 2019	As at March 31, 2018
Note 14 : Revenue Fromm Operations			
Sale of goods Traded Goods		1947.13	916.13
Sale of manufactured goods		202.73	182.86
Other operating revenue			
- Conversion Charges		163.00	137.00
	Total	2312.85	1236.00
Note 15 : Other Income			
Lease Rent		4.20	4.20
Misc income		3.79	2.84
Interest on others		2.14	3.03
	Total	10.12	10.07
Note 16 : Cost of Material Consumed			
Cost of Material Consumed		77.27	77.75
	Total	77.27	77.75
Note 17: Purchases of Goods Traded			
Purchases of Goods Traded		1904.95	991.06
	Total	1904.95	991.06
Note 18 : Changes in inventories of work in progress,			
stock in trade and finished goods.			
Opening Balance			
- Work in progress		0.51	0.81
- Finished Goods		97.39	5.38
		97.89	6.19
Closing Balance			
- Work in progress		0.96	0.51
- Finished Goods		79.89	97.39
		80.85	97.89
Total changes in inventory of work in	Total	17.04	(91.70)
progress, stock in trade and finished goods			
Note 19 : Employee benefits expenses		00.00	00.00
Salaries, wages and bonus Contribution to provident and other funds		80.92 5.93	66.26 5.27
Staff welfare expenses		2.37	1.39
Leave encashment		0.00	0.00
Esars shousimism	Total	89.22	72.93
Note 20 : Finance Cost	· Otal		
Interest on			
- loans from banks and financial institutions		0.00	0.00
- on loan from others		16.03	15.06
	Total	16.03	15.06
Note 21 : Depreciation and amortisation expenses			
Depreciation on plant and equipment		36.51	29.63
	Total	36.51	29.63





Notes forming Part of the financial statements as at March 31, 2019

(Amount in Lacs)

	JLARS	As at March 31, 2019	As at March 31, 2018
22 :	Other Income		
	Repair and Maintenance	9.46	3.60
	Laboratory Charges	1.18	0.46
	Labour Charges	0.51	0.22
	Legal Professional & Consultancy	6.75	9.71
	Printing & Stationary	2.83	1.49
	Power and Fuel	37.48	33.20
	Freight & Cartage	9.00	10.19
	Listing Expenses	7.40	7.19
	Bank Charges	0.12	0.18
	Payment to Auditor (including service tax / GST)	0.30	0.30
	Sales Commission	37.94	3.00
	Insurance	1.44	15.50
	Travelling & Conveyance	4.10	4.04
	Communication Cost	1.11	0.79
	Advertisement & Publicity	0.85	0.77
	Miscellaneous Expenses	1.67	1.89
	Total	122.12	92.53
	Payment to Auditor		
	As auditors:		
	- Statutory Audit Fees	0.25	0.13
	- Limited Review Fees	0.05	0.03
	Total	0.30	0.15
	Income tax Reconciliation		
. 23 .	The major components of income tax expense for the y	vears ended March 31, 2019	and March Of Ooto area
	, ,		i and March 31, 2018 are:
	Current income tax :	25.75%	25.75%
	Current income tax : Current income tax charges Adjustment of tax relating to earlier periods	25.75%	25.75%
	Current income tax charges	25.75% 11.51	25.75% 11.30
	Current income tax charges Adjustment of tax relating to earlier periods	25.75% 11.51	25.75% 11.30
	Current income tax charges Adjustment of tax relating to earlier periods Deferred tax:	25.75% 11.51 0.09 31.88	25.75% 11.30 0.45
	Current income tax charges Adjustment of tax relating to earlier periods Deferred tax: Unused tax credit Income tax expense reported in the statement of professions. Reconciliation of tax expenses and the accounting of professions.	25.75% 11.51 0.09 31.88 it or loss 31.88	25.75% 11.30 0.45 32.44 32.44
	Current income tax charges Adjustment of tax relating to earlier periods Deferred tax: Unused tax credit Income tax expense reported in the statement of prof Reconciliation of tax expenses and the accounting of prof March 31, 2019 and March 31, 2018 are:	25.75% 11.51 0.09 31.88 fit or loss 31.88 ofit multiplied by Indian Dor	25.75% 11.30 0.45 32.44 32.44 nestic tax rate for
	Current income tax charges Adjustment of tax relating to earlier periods Deferred tax: Unused tax credit Income tax expense reported in the statement of professions. Reconciliation of tax expenses and the accounting of professions.	25.75% 11.51 0.09 31.88 it or loss 31.88	25.75% 11.30 0.45 32.44 32.44
	Current income tax charges Adjustment of tax relating to earlier periods Deferred tax: Unused tax credit Income tax expense reported in the statement of prof Reconciliation of tax expenses and the accounting of prof March 31, 2019 and March 31, 2018 are: Accounting profit before tax	25.75% 11.51 0.09 31.88 fit or loss 31.88 ofit multiplied by Indian Dor 59.83	25.75% 11.30 0.45 32.44 32.44 nestic tax rate for 58.82
	Current income tax charges Adjustment of tax relating to earlier periods Deferred tax: Unused tax credit Income tax expense reported in the statement of prof Reconciliation of tax expenses and the accounting of pr March 31, 2019 and March 31, 2018 are: Accounting profit before tax Tax rate under Normal / MAT Accounting profit before tax Tax rate under Normal rate/MAT	25.75% 11.51 0.09 31.88 fit or loss 31.88 ofit multiplied by Indian Dor 59.83 25.75%	25.75% 11.30 0.45 32.44 32.44 nestic tax rate for 58.82 25.75%
	Current income tax charges Adjustment of tax relating to earlier periods Deferred tax: Unused tax credit Income tax expense reported in the statement of prof Reconciliation of tax expenses and the accounting of pr March 31, 2019 and March 31, 2018 are: Accounting profit before tax Tax rate under Normal / MAT Accounting profit before tax Tax rate under Normal rate/MAT At India's Statutory income tax rate	25.75% 11.51 0.09 31.88 fit or loss 31.88 ofit multiplied by Indian Dor 59.83 25.75% 59.83 25.75%	25.75% 11.30 0.45 32.44 32.44 32.5.75% 58.82 25.75%
	Current income tax charges Adjustment of tax relating to earlier periods Deferred tax: Unused tax credit Income tax expense reported in the statement of prof Reconciliation of tax expenses and the accounting of pr March 31, 2019 and March 31, 2018 are: Accounting profit before tax Tax rate under Normal / MAT Accounting profit before tax Tax rate under Normal rate/MAT At India's Statutory income tax rate Expenses disallowed not deductible	25.75% 11.51 0.09 31.88 fit or loss 31.88 ofit multiplied by Indian Dor 59.83 25.75% 59.83 25.75% 7.52	25.75% 11.30 0.45 32.44 32.44 32.44 58.82 25.75% 58.82 25.75% 7.52
	Current income tax charges Adjustment of tax relating to earlier periods Deferred tax: Unused tax credit Income tax expense reported in the statement of prof Reconciliation of tax expenses and the accounting of pr March 31, 2019 and March 31, 2018 are: Accounting profit before tax Tax rate under Normal / MAT Accounting profit before tax Tax rate under Normal rate/MAT At India's Statutory income tax rate Expenses disallowed not deductible Income not chargeable to tax / Expenses allowed	25.75% 11.51 0.09 31.88 fit or loss 31.88 ofit multiplied by Indian Dor 59.83 25.75% 59.83 25.75% 7.52 (10.53)	25.75% 11.30 0.45 32.44 32.44 32.44 158.82 25.75% 58.82 25.75% 7.52 (10.53)
	Current income tax charges Adjustment of tax relating to earlier periods Deferred tax: Unused tax credit Income tax expense reported in the statement of prof Reconciliation of tax expenses and the accounting of pr March 31, 2019 and March 31, 2018 are: Accounting profit before tax Tax rate under Normal / MAT Accounting profit before tax Tax rate under Normal rate/MAT At India's Statutory income tax rate Expenses disallowed not deductible Income not chargeable to tax / Expenses allowed Unutilsed tax credits	25.75% 11.51 0.09 31.88 fit or loss 31.88 ofit multiplied by Indian Dor 59.83 25.75% 59.83 25.75% 7.52 (10.53) (0.81)	25.75% 11.30 0.45 32.44 32.44 32.45 nestic tax rate for 58.82 25.75% 58.82 25.75% 7.52 (10.53) (0.81)
	Current income tax charges Adjustment of tax relating to earlier periods Deferred tax: Unused tax credit Income tax expense reported in the statement of prof Reconciliation of tax expenses and the accounting of pr March 31, 2019 and March 31, 2018 are: Accounting profit before tax Tax rate under Normal / MAT Accounting profit before tax Tax rate under Normal rate/MAT At India's Statutory income tax rate Expenses disallowed not deductible Income not chargeable to tax / Expenses allowed	25.75% 11.51 0.09 31.88 fit or loss 31.88 ofit multiplied by Indian Dor 59.83 25.75% 59.83 25.75% 7.52 (10.53) (0.81) 0.00	25.75% 11.30 0.45 32.44 32.44 32.44 158.82 25.75% 58.82 25.75% 7.52 (10.53)





CIN: L24233MP1985PLC002709

Notes forming Part of the financial statements as at March 31, 2019

(Amount in Lacs expect EPS)

PARTIC	CULARS	For the year ended March 31, 2019	For the year ended March 31, 2018
Note 24 :	Earnings per share (EPS) Basic EPS amounts are calculated by dividing the profit / (loss) for the year attributable to equity holders of the		
	parent by the weighted average number of equity shares outstanding during the year.		
	The following reflects the income and share data used in the basic and diluted EPS computations:		4- 0-
	Profit/(loss) for the year	48.23	47.07
	Weighted average number of equity shares in calculating basic EPS and diluted EPS	16,273,800	16,273,800
	Face value per share (in Rupees)	10.00	10.00
	Basic earning per share (in Rupees)	0.30	0.29
	Diluted earning per share (in Rupees)	0.30	0.29
		Retained Earnings	Total
	During the year ended 31st March 2019		-
	Re-measurement gains (losses) on defined benefit plans	0.00	0.00
		0.00	0.00
	During the year ended 31st March 2018		
	Re-measurement gains (losses) on defined benefit plans	0.00	0.00
		0.00	0.00
N-1- 0F			

Note 25: Commitments and Contingencies

i) Contingent liabilities

The company's pending litigations comprise of claims against the Company primarily by the commuters and regulators except to the mentioned in below Note 1 . The company has reviewed all its pending litigations and proceedings and has adequately provided for where provisions are required. The Company has not provided for or disclosed contingent liabilities for matters considered as remote for pending litigations/public litigations(PIL)/ claims wherein the management is confident, based on the internal legal assessment and advice of its lawyers that these litigations would not result into any liabilities. The Company does not expect the outcome of these proceedings to have a material adverse effect on the financial statements.

Note 1 ·

A writ petition filed in year 2012 before hon'ble court M.P. Bench at Indore against Madhya Pradesh Adyogik Kendra Vikas Nigam (Indore) Limited, (MPAKVN Ltd) Indore and other parties with respect to vacant land admeasuring 94462 Sq. Mts. Situated at Kheda Industrial Area, Pithampur (M.P.)

Note 26: Details of dues to micro and small enterprises as per MSMED Act, 2006

There are no Micro and Small Enterprises as defined in the Micro and Small Enterprises Development Act, 2006 to whom the Company owes dues on account of principal amount together with interest and accordingly no additional disclosures have been made. The above information regarding Micro and Small Enterprises has been determined to the extent such parties has been identified on the basis of information available with the Company.

Note 27: Fair Values

Financial assets and liabilities

The accounting classification of each category of financial instruments, their carrying amounts and the categories of financial assets and liabilities measured at fair value, are set out below:



CIN: L24233MP1985PLC002709

(Amount in Lacs)

		Carry	ing Amount			Fair Value		
	FVTPL*	FVTOCL**	Amortised Cost	Total	Level 1	Level 2	Level 3	
As at 31 March, 2019								
Financial assets	1		'	1				
Trade recievables	-	- '	1202.50	1202.50	-	-	-	
Cash and Cash equivalents			13.62	13.62	-	-	-	
Total	-	-	1216.12	1216.12		-	†	
Financial liabilities								
Borrowings	-	-	163.73	163.73	-	-	-	
Trade Payable	1		858.34	858.34	-	-	-	
Other financial liabilities		'	22.75	22.75			l	
Total		-	1044.82	1044.82	-	<u></u>	-	
As at 31 March, 2018								
Financial assets	1		'	1				
Trade recievables	-	-	1298.08	1298.08	-	-	-	
Cash and Cash	1		37.45	37.45	-	-		
equivalents				l				
Total	-	-	1335.53	1335.53	-	-	<u>-</u>	
Financial liabilities								
Borrowings	-	-	155.86	155.86	-	-		
Trade Payable	1		914.17	914.17	-	-		
Other financial liabilities			17.41	17.41				
Total	-		1087.44	1087.44		T -	<u> </u>	

^{* -} Fair value through profit and loss

The company uses the following hierarchy for determining and/or disclosing the fair value of financial instruments by valuation techniques:

Level 1: Fair value measurement are those derived from quoted prices (unadjusted) in active markets for identical assets and liabilities.

Level 2: Fair value measurements are those derived from inputs other than quoted prices that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices)

Level 3: Fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs)

There were no transfers between Level 1 and Level 2 during the year. No financial assets/ liabilities that are measured at fair value were Level 3 fair value measured.

Note 28: Financial risk management objectives and policies

The Company's risk management policies are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities.

The Board of Directors has overall responsibility for the establishment and oversight of the Company's risk management framework.

In performing its operating, investing and financing activities, the Company is exposed to the Market risk, Liquidity risk.

a) Market Risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises of: interest rate risk and commodity risk. Financial instruments affected by market risk include loans and borrowings, deposits, and derivative financial instruments.

^{** -} Fair value through other comprehensive income



CIN: L24233MP1985PLC002709

(i) Interest Rate Risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to the Company's long-term debt obligations with floating interest rates. "The Company manages its interest rate risk by having a balanced portfolio of fixed and variable rate loans and borrowings."

(ii) Interest rate sensitivity

The following table demonstrates the sensitivity to a reasonably possible change in interest rates on that portion of loans and borrowings affected, after the impact of hedge accounting. With all other variables held constant, the Company's profit before tax is affected through the impact on floating rate borrowings, as follows:

(Amount in Lacs)

	For the year ended March 31, 2019	For the year ended March 31, 2018
Increase in basis points - INR Effect on profit before tax	50.00	50.00
- INR Decrease in basis points	(0.82)	(0.78)
- INR Effect on profit before tax	50.00	50.00
- INR	0.82	0.78

(iii) Commodity Price Risk

The company purchases raw materials (sulphiric acid and iron waste) on ongoing basis which is required for manufacturing of Ferrous sulphate powder and company involves trading in pharmaceatical products.

(b) Liquidity risk

Liquidity risk is the risk that the Company may not be able to meet its present and future cash and collateral obligations without incurring unacceptable losses. The Company's objective is to, at all times maintain optimum levels of liquidity to meet its cash and collateral requirements. The Company closely monitors its liquidity position and deploys a robust cash management system. It maintains adequate sources of financing including debt and overdraft from banks at an optimised cost.

The Company is maximum exposure to credit risk for the components of the balance sheet at March 31, 2019 and March 31, 2018 is the carrying amounts as illustrated in Note 10, Note 11 and Note 12 The Company's maximum exposure relating to financial guarantees.

(Amount in Lacs)

	<1 years	1 to 5 years	> 5 years	Total
As at March 31,2019				
Borrowings	163.73	-	-	163.73
Trade payable	858.34	-	-	858.34
Other financial liabilities	22.75	-	-	22.75
	1044.82		-	1044.82
As at March 31,2018				
Borrowings	155.86	-	-	155.86
Trade payable	914.17	-	-	914.17
Other financial liabilities	17.41	-	-	17.41
	1087.44			1087.44

At present, Company does expect to repay all liabilities at their contractual maturity. In order to meet such cash commitments, operating activity is expected to generate sufficient cash inflows.



CIN: L24233MP1985PLC002709

Note 29: Capital management

For the purpose of the Company's capital management, capital includes issued equity share capital and all other equity reserves attributable to the equity holders of the Company. The primary objective of the Company's capital management is to maximise the shareholder value.

The Company manages its capital so as to safeguard its ability to continue as a going concern and to optimise returns to shareholders. The capital structure of the Company is based on management's judgement of its strategic and day-to-day needs with a focus on total equity so as to maintain investor, creditors and market confidence. The Company monitors capital using a gearing ratio, which is net debt divided by total capital plus net debt is calculated as borrowing less cash and cash equivalent and other bank balances and mutual funds investments.

(Amount in Lacs)

PARTICULARS	As at March 31, 2019	As at March 31, 2018
Borrowings	163.73	155.86
Less: Cash and cash equivalent	(13.62)	(37.45)
Adjusted net debt	150.11	118.40
Total Equity	1364.97	1,316.74
Capital and net debt	1364.97	1,316.74
Gearing ratio	0.11	0.09

In order to achieve this overall objective, the Company's capital management, amongst other things, aims to ensure that it meets financial covenants attached to the interest-bearing loans and borrowings that define capital structure requirements. Breaches in meeting the financial covenants would permit the bank to immediately call loans and borrowings. There have been no breaches in the financial covenants of any interest-bearing loans and borrowing in the current period.

No changes were made in the objectives, policies or processes for managing capital during the year ended March 31, 2018 and March 31, 2017.

Note 30: Significant accounting judgement, estimates and assumptions

The preparation of the Company's financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenue, expenses, assets and liabilities, and the accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.

Estimates and assumptions

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and future periods are affected.

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. The Company based on its assumptions and estimates on parameters available when the financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Company. Such changes are reflected in the assumptions when they occur.

Taxes

Tax expense comprises of current and deferred tax. Current income tax is measured at the amount expected to be paid to the tax authorities in accordance with the Income Tax Act, 1961. Deferred income taxes reflects the impact of timing differences between taxable income and accounting income originating during the current year and reversal of timing differences of earlier years.

Deferred tax is measured based on the tax rates and the tax laws enacted or substantively enacted at the balance sheet date. Deferred tax assets and deferred tax liabilities are offset, if legally enforceable right exists to set-off current tax assets against current tax liabilities and the deferred tax assets and deferred tax liabilities related to the taxes on income levied by same governing taxation laws. Deferred tax assets are recognised only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realised. In situations where the Company has unabsorbed depreciation or carry forward tax losses, all deferred tax assets are recognized only if there is virtual certainty supported by convincing evidence that they can be realized against future taxable profits.

At each balance sheet date the Company re-assesses unrecognised deferred tax assets. It recognises unrecognised deferred tax assets to the extent that it has become reasonably certain that sufficient future taxable income will be available against which such deferred tax assets can be realised or virtually certain as the case may be.

The carrying amount of deferred tax assets are reviewed at each balance sheet date. The Company writes-down the carrying amount of a deferred tax asset to the extent that it is no longer reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which deferred tax asset can be realised. Any such write-down is reversed to the extent that it becomes reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available.



CIN: L24233MP1985PLC002709

Minimum alternative tax (MAT) credit is recognised as an asset only when and to the extent there is convincing evidence that the Company will pay income tax higher than that computed under MAT, during the period that MAT is permitted to be set off under the Income Tax Act, 1961 (specified period). In the year, in which the MAT credit becomes eligible to be recognised as an asset in accordance with the recommendations contained in the guidance note issued by the Institute of Chartered Accountants of India (ICAI), the said asset is created by way of a credit to the Statement of profit and loss and shown as MAT credit entitlement. The Company reviews the same at each balance sheet date and writes down the carrying amount of MAT credit entitlement to the extent there is no longer convincing evidence to the effect that the Company will pay income tax higher than MAT during the specified period.

There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. Where the final tax outcome of these matters is different from the amounts initially recorded, such differences will impact the current and deferred tax provisions in the period in which the tax determination is made. The assessment of probability involves estimation of a number of factors including future taxable income.

Defined benefit plans (gratuity benefits)

A liability in respect of defined benefit plans is recognised in the balance sheet, and is measured as the present value of the defined benefit obligation at the reporting date less the fair value of the plan's assets. The present value of the defined benefit obligation is based on expected future payments which arise from the fund at the reporting date, calculated annually by independent actuaries. Consideration is given to expected future salary levels, experience of employee departures and periods of service.

Further details about gratuity obligations are given in Note 31

As per our Report of even date

For & on behalf of board of Directors

For MAHESHWARI & GUPTA CHARTERED ACCOUNTANTS ICAI Registration No. 006179C Ramesh Shah Managing Director DIN: 00028819 Romil Shah
Director
DIN: 00326110

Company Secretary
Meb. No.: A43203

Jitendra Kumar Sahu Chief Financial Officer

CA. SUNIL MAHESWARI,

Partner

Membership No. 403346

Place: Indore Date: 30.05.2019 Place: Indore Date: 30.05.2019



CIN: L24233MP1985PLC002709

Note 31: Gratuity and other post employment benefit plans

(Amount in Lacs)

		For the year ended March 31, 2019	For the year ended March 31, 2018
(a)	Employee Data : Summery Statistics		
	Total Number of Employees	28.00	32.00
	Average Age	42.11	40.56
	Total Montyly Salary	3.92	3.67
	Average Salary	0.14	0.11
	Average Past Service	9.93	9.00
(b)	Gratuity Fund and Payout Information		
` ,	Opening Balance	31.35	15.15
	Contributions	-	15.15
	Benefits Paid	-	-
	Interest Credited	2.19	1.06
	Closing Balance	33.55	31.35
	Benefits paid directly by company	-	-

(c) Information about Gratuity Benefit

Gratuity Benefit if payable to employess as per the provisions of payment of Gratuity Act 1972 and its later amendments.

All employees are entitled to Gratuity benefits on exit from service due to retirement resignation or death tthere is a vesting period of 5 Year on exits due to retirement of resignation.

(e) Valuation Methos

Projected unit credit method has been used for valuation of the plans liabilities as requried under Ind As 19

(f) Assumption - Economics

Discount Rate 7.70% 7.70%

based on yields (as on valuation date) of Government bonds with/a tenure similar to the expected working lifetime of the employees.

(g) Salary Escalation rate

1.00%

based on inflation, seniority promotion and other relevant factors such as demand and supply in the employment market. This assumption has been determined in consultation with the company

(h) Assumption - Demograhics

58 year	58 year
5 % to 1 %	5 % to 1 %
Indian Assured Lives	Indian Assured Lives
Mortality (2006-08)	Mortality (2006-08)
Ult.	Ult.
33.64	31.6
3.02	3.11
(2.93)	1.37
	5 % to 1 % Indian Assured Lives Mortality (2006-08) Ult. 33.64 3.02

[&]quot;Complete disclosure required for reporting under

Indian Accounting "Standard-19 are given in the Annexture to this report."

(i) Defined Benefit Plan

The Company has an unfunded defined benefit gratuity plan. Every employee who has completed five years or more of service gets a gratuity on departure at 15 days salary (last drawn salary) for each completed year of service as per the provision of the Payment of Gratuity Act, 1972 with total ceiling on gratuity of Rs. 2,000,000/-

The following tables summaries the components of net benefit expense recognised in the statement of profit and loss and the funded status and amounts recognised in the balance sheet for the Gratuity plans.



CIN: L24233MP1985PLC002709

Statement of Profit and Loss	For the year ended March 31, 2019	
Revenue Fromm Operations	, , , , , , , , , , , , , , , , , , ,	·
Changes in the present value of the defined benefit obligation are a	s follows: 31.36	25.81
Current service cost	3.02	2.87
nterest cost on benefit obligation	2.41	
expected return on plan assets	-	-
Actuarial losses / (gains) arising from change in financial assumptions	(0.47)	(0.67)
Actuarial losses / (gains) recognised during the period	` · ·	· · · · · · · · · · · · · · · · · · ·
Actuarial losses /(gains) arising from experience adjustments	(2.69)	1.35
Past service cost	-	-
Net benefit expenses	33.64	31.36
Bifurcation of Present value of Benefit Obligation	47.04	45.04
Current-Amount due with one year	17.34	
Non-current Amount due after one year	16.30	16.02
Cotal	33.64	31.36
Expected Benefit Payment in Future Year		
Year 1	17.34	
Year 2	0.59	
Year 3	1.34	
Year 4	0.31	
Year 5	1.41	
Year 6 to Year 10	2.23	6.06
Sensitivity Analysis		
Effects of Key Assumption on defined Benefit Obligations	0.4.00	
Discount Rate -1 Percent Increse	31.99	
Discount Rate -1 Percent decraese	36.69	
Salary Escalation Rate-1 Percent increase	36.58 32.03	
Salary Escalation Rate-1 Percent decraese Withdrawal Rate 1 Percent increse	33.83	
Withdrawal Rate 1 Percent decraese		
	34.41	31.60
Changes in Fair Value of Plan Assets	04.05	45.45
Opening Fair Value of plan assets	31.35	
Expectd return on plan assets	2.41	
company contributioins	-	15.15
Benefits paid	(O 00)	(0.69)
Actuarial losses (gains) Closing Fair value of plan assets on	(0.22) 33.55	
·	33.33	31.30
Balance Sheet- Amount to be recongnised	25.5	2: 2
Present Value of Benefit Obligation on 31-03-2019	33.64	
Fair Value of Plan Assets on 31-03-2018	33.55	
Net Liability /(Asset) recognised in Balance sheet	0.09	•
Profit and Loss Statement	2.00	0.00
Current Service coast Net Interest on net Defined Liability /(Assets)	3.02 0.00	
Expenses recognised in stataement of profit and loss	3.02	
Other Comprehensive Income		
Actuarial (Gains) /Losses on Liability	(3.16)	0.00
Return of Plan Assets excluding amount included in Net interest on	(3.10)	0.00
net defined liability / (Asset) above	0.22	0.00
Total	(2.93)	0.00

The estimates of future salary increases, considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.

The overall expected rate of return on assets is determined based on the market prices prevailing on that date, applicable to the period over which the obligation is to be settled. There has been significant change in expected rate of return on assets due to change in the market scenario.

CIN: L24233MP1985PLC002709

34th Annual Report **2018-2019**

Note 32: Segment Reporting

(Amount in Lacs)

Particulars	Pharma	Chemicals Unit	Plastice Div.	Unallocable Div.	Total
Income					
External Sales/ Revenue	1,947.13	202.73			2,149.85
Job Work	163.00				163.00
Total Revenue	2,110.13	202.73	-		2,312.85
Expenditure					
Consumption of Material	1,904.95	77.27			1,982.22
Expenditure	118.16	85.29	15.48	8.45	227.37
Depreciation	11.84	20.42	4.25		36.51
(Increse)/Decrese in stock	19.21	(2.17)			17.04
Total Expenditure	2,054.16	180.81	19.73	8.45	2,263.15
Segment Results	55.97	21.92	(19.73)	(8.45)	49.71
Other Income	9.68	0.44			10.12
Profit before tax	65.65	22.36	(19.73)	(8.45)	59.83
Tax Expenses	0.00	-		`	0.00
Net Profit for the year	65.65	22.36	(19.73)	(8.45)	59.83
Segment Assets	1,411.32	958.88	51.11		2,421.30
Segment Liabilities	792.75	98.00	165.58		1,056.33
Capital Expenditure	78.38	62.87			141.25
Depreciation and Amortisation	11.84	20.42	4.25		36.51

Note 34: Events after reporting period

No subsequent event has been observed which may require an adjustment to the balance sheet.

Note 35: Standard issued but not effective

The amendments to standards that are issued, but not yet effective, up to the date of issuance of the Company's financial statements are disclosed below. The Company intends to adopt these standards, if applicable, when they become effective.

The Ministry of Corporate Affairs (MCA) has issued the Companies (Indian Accounting Standards) Amendment Rules, 2017 and Companies (Indian Accounting Standards) Amendment Rules, 2018 amending the following standard:

Ind AS 115 Revenue from Contracts with Customers

This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

Effective 1st April 2018 the company adopted Ind As 115 "Revenue from Contracts with Customers" using the cumulative retrospective transition method. The effect on adoption of Ind AS 115 was insignificant on the financial result

Amendments to Ind AS 12 Recognition of Deferred Tax Assets for Unrealised Losses

The amendments clarify that an entity needs to consider whether tax law restricts the sources of taxable profits against which it may make deductions on the reversal of that deductible temporary difference. Furthermore, the amendments provide guidance on how an entity should determine future taxable profits and explain the circumstances in which taxable profit may include the recovery of some assets for more than their carrying amount. No subsequent event has been observed which may required an adjustment to the balance sheet.

Previous period's figures have been regrouped / reclassified, wherever necessary, to confirm to current period's classification.

Note 36: Related Party disclosures

i) Holding company

Company neither have holding Company nor have subsidiary Company.

ii) Other related parties

"Fellow subsidiaries (only with whom there have been transaction during the period / there was balance outstanding at "the period end)"

During the year Company entered related party transaactions with following related paerties:

1. Cyano Pharma Private Limited



CIN: L24233MP1985PLC002709

- 2. MID (India) Pharmaceuticals Private Limited
- 3. Formoplast Private Limited

iii) Key management personnel

The following have been designated as the Key Managerial Personnel of the Company pursuant to sections 2(51) and 203 of the Companies Act, 2013 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014:

- 1. Mr. Ramesh Shah, Managing Director
- 2. Ms. Shikha Khilwani, Company Secretary and Compliance Officer
- 3.. Mr. Jitendra Kumar Sahu, Chief Financial Officer

iii) Statement of Related Party Transactions for the period ended March 31,2019

(Amount in Lacs)

			2019			2018	
S. No.	Particulars	Group Concern	Key Managrial Personnel	Relative of Key managrial	Group Concern	Key Managrial Personnel	Relative of Key managrial Personnel
1	Sale :-	004.04			07.05		
2	Cyano Pharma Private Ltd. Purchase:-	264.91			97.35		
-	Cyano Pharma Private LTd.	196.30			376.67		
3	Job Works :-						
_	Cyano Pharma Private Ltd.	192.34			158.96		
4	Salary To relative of KMP Ketan Shah			17.40			15.10
	Meet Shah			3.00			2.20
	Rohan Shah			3.00			2.20
5	Salary To KMP						
	Shikha Khilwani		3.05			2.64	
	Jitendra Kumar Sahu		3.18			2.74	
6	Borrowings repaid Formoplast Private Limited				1.02		
	MID (India) Pharmaceuticals	6.05			0.93		
	Private Limited	0.00			0.00		
7	Interest on borrowings						
	Formoplast Private Limited	6.16			5.68		
	MID (India) Pharmaceuticals Private Limited	9.32			9.32		

iii) Statement of Related Party Balances as at March 31,2019

(Amount in Lacs)

			2019			2018	
S. No.	Particulars	Group Concern	Key Managrial Personnel	Relative of Key managrial	Group Concern	Key Managrial Personnel	Relative of Key managrial Personnel
1 2 3	Cyano Pharma Private Limited- Formoplast Private Limited MID (India) Pharmaceuticals Private Limited	185.99 72.12 91.61			2.04 66.58 89.28		
1 2 3	Salary To relative of KMP Ketan Shah Meet Shah Rohan Shah			1.11 0.22 0.22			0.95 0.08 0.08
1 2	Salary To KMP Shikha Khilwani Jitendra Kumar Sahu		0.26 0.26			0.22 0.26	

PROXY FORM FORM MGT- 11

[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]

BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED

CIN: 124233MP1985PLC002709

Regd. Office: 11/12, Sector	or 'E', Sanwer Road, Industrial Area, Indore - 15 (M.P.)
Name of the member (s)	

Registered address	:
E-mail Id	:Mobile No.

PP ID : DP Name :

I/we being the member(s) of shares of Biofil Chemicals and Pharmaceuticals Limited, herby appoint:

-	••
1 Nan	0.
i.ivaii	G

- 2. Address:....
- 1. Name :
- 2. Address:.....
- 3. E-mail Id :
 or failing him
- 1. Name :
- 2. Address:
- aas my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 34th Annual General Meeting of the company, to be held on the Thursday, 26th September, 2019 at the Registered Office of the company situated at 11/12, Sector 'E' Sanwer Road, Industrial Area, Indore (M.P.)-452015, at 3.00 P.M. and at any adjournment thereof in respect of

Resolutions

	RESOLUTIONS	For	Against
Γ	ORDINARY BUSINESSES		
1	. To receive, consider, approve and adopt the Audited Financial Statements of the Company for the		
	financial year ended 31st March, 2019, together with the Reports of the Board of Directors and		
	Auditors thereon.		
2	. To appoint a Director in place of Shri Romil Shah (DIN: 00326110), who retires by rotation and		
	being eligible offers himself for re-appointment.		
	SPECIAL BUSINESSES		
3	Re-appointment of Shri Subhash Chandra Swarnkar (DIN: 01658151), As an Independent		
	Director of the Company.		
1		l	

such resolutions as are indicated below:

Signature of shareholder: Signature of Proxy holder(s)

Notes:

- 1. This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.
- 2. A proxy need not to be member of the company



BLANK

(CIN: L24233MP1985PLC002709)

Regd. Office: 11/12, Sector 'E', Sanwer Road, Industrial Area, Indore - 15 (M.P.)

ATTENDANCE SLIP

34th ANNUAL GENERAL MEETING ON THURSDAY, 26th SEPTEMBER, 2019

Folio No. / DP ID- Client ID	:	
Name of the Shareholder (In block letters)	:	
No. of Shares Held	:	
Full name of the Proxy if any (In block letters)	:	
Signature of the Shareholder/ Proxy :		

NOTE

- 1. Shareholders / proxy holders are requested to bring the attendance Slips with them when they come to the meeting and hand over them at the entrance after affixing their signatures on them.
- 2. If it is intended to appoint a proxy, the form of proxy should be completed and deposited at the Registered Office of the Company at least 48 hours before the Meeting.

BLANK



E-MAIL REGISTRATION FORM

To,
The Company Secretary
Biofil Chemicals and Pharmaceuticals Limited
11/12 Sector E, Sanwer Road,
Industrial Area, Indore 452015 (M.P.)

Dear Sir / Madam,

RE: Registration of E-mail ID for receiving communications in Electronic form. (Green Initiative in Corporate Governance)

I agree to receive all communication from the Company in electronic mode. Please register my e-mail id in your records for sending communication through e-mail. Folio No DP ID Client ID :..... PAN . Name of the 1st Registered Holder Name of the Joint Holders Registered Address Email Id • Mobile no. Date Signature of the 1st Holder

Important Notes:

- 1) On registration, all the communication will be sent to the e-mail ID registered in the folio/DP ID & Client ID.
- 2) Shareholders are requested to keep company informed as and when there is any change in the e-mail address. Unless the email Id given above is changed by you by sending another communication in writing, the company will continue to send the notices/documents to you on the above mentioned email ID.

BLANK

Book - Post

PRINTED MATTER

To,

if undelivered please return to:



CIN: L24233MP1985PLC002709

Regd. Off.: 11/12, Sector - E, Sanwer Road, Industrial Area, Indore. 452 003 INDIA